

Please, search fully a compound of formula (I) of claim 1 (in the attached file)
When:
Z= oxygen,
Q= bond,
W= 5-membered aromatic heterocycle

Also, please do a species search on the elected species attached.

Thank you very much.

Valerie
Valerie Rodriguez-Garcia, Ph.D.
Patent Examiner
U.S. Patent and Trademark Office
TEL: 571-270-6865
FAX: 571-270-6865

10/1/2008

```
=> d que l2
L1             2 SEA FILE=HCAPLUS ABB=ON  PLU=ON  US2006-563708/APPS
L2             1 SEA FILE=HCAPLUS ABB=ON  PLU=ON  L1 NOT PIXEL/TI


=> d ibib ed abs ind l2
YOU HAVE REQUESTED DATA FROM FILE 'HCAPLUS' - CONTINUE? (Y)/N:y



L2   ANSWER 1 OF 1  HCAPLUS  COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER:         2005:58199  HCAPLUS  Full-text
DOCUMENT NUMBER:          142:134592
TITLE:                    Preparation of N-pyrazolylbenzenesulfonylamide
                          derivatives as activators of PPARs
INVENTOR(S):              Vedananda, Thalaththani Ralalage
PATENT ASSIGNEE(S):       Novartis AG, Switz.; Novartis Pharma GmbH
SOURCE:                   PCT Int. Appl., 61 pp.
                          CODEN: PIXXD2
DOCUMENT TYPE:            Patent
LANGUAGE:                 English
FAMILY ACC. NUM. COUNT:   1
PATENT INFORMATION:

     PATENT NO.           KIND   DATE        APPLICATION NO.         DATE
     ---------------      ----   --------    --------------------    --------
     WO 2005005421         A1    20050120    WO 2004-EP7442          20040707
         W:  AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH,
             CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD,
             GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC,
             LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI,
             NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY,
             TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
         RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM,
             AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK,
             EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE,
             SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE,
             SN, TD, TG
     AU 2004255342         A1    20050120    AU 2004-255342          20040707
     CA 2531418            A1    20050120    CA 2004-2531418         20040707
     EP 1646628            A1    20060419    EP 2004-740754          20040707
         R:  AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
             IE, SI, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK
     CN 1816546            A     20060809    CN 2004-80019234        20040707
     BR 2004012380         A     20060919    BR 2004-12380           20040707
     MX 2006PA00118        A     20060427    MX 2006-PA118           20060105
     IN 2006CN00071        A     20070629    IN 2006-CN71            20060105
     US 20070043020        A1    20070222    US 2006-563708          20060619 <--
PRIORITY APPLN. INFO.:                        US 2003-485870P     P   20030708
                                              WO 2004-EP7442      W   20040707
OTHER SOURCE(S):          MARPAT 142:134592
ED   Entered STN:  21 Jan 2005
GI
```



I



II

AB Title compds. represented by the formula I [wherein R1, R2= independently H, halo, OH, (un)substituted alkyl(thio), alkoxy, (hetero)aralkyl; R1R2 = (un)substituted (hetero)aromatic ring, alkylene; R3 = H or (un)substituted alkyl; X = Z(CH2)pQW; Z = a bond, O, S, CO, etc.; p = 1-8, Q = a bond, O(alkylene), S(alkylene), CO, etc.; W = cycloalkyl, aryl, (hetero)aralkyl, etc.; L = heteroarom. ring; and pharmaceutically acceptable salts thereof, or prodrug derivs. thereof] were prepared as activators of PPARs (Peroxisome Proliferator-Activated Receptors). For example, II was given in a multi-step synthesis starting from 4-hydroxybenzenesulfonic acid sodium salt dihydrate. II showed an EC50 of about 5 nM in the PPARα receptor binding assay, and an EC50 of about 3 nM in the PPARγ receptor binding assay. Thus, I and their pharmaceutical compns. are useful for the treatment of conditions mediated by the PPAR receptor activity in mammals, such as dyslipidemia, hyperlipidemia, hypercholesteremia, atherosclerosis, hypertriglyceridemia, heart failure, myocardial infarction, vascular diseases, cardiovascular diseases, hypertension, obesity, inflammation, arthritis, cancer, Alzheimer's disease, skin disorders, respiratory diseases, opthalmic disorders, inflammatory bowel diseases (IBDs) ulcerative colitis and Crohn's disease, and conditions in which impaired glucose tolerance, hyperglycemia and insulin resistance are implicated, such as type-1 and type-2 diabetes, and Syndrome X (no data).

IC ICM C07D413-12
ICS A61K031-422; A61P003-10

CC 28-8 (Heterocyclic Compounds (More Than One Hetero Atom))
Section cross-reference(s): 1, 63

ST oxazolylmethoxy pyrazolyl benzenesulfonylamide prepn PPAR activator

IT Inflammation
(Crohn's disease; preparation of N-pyrazolylbenzenesulfonylamide derivs. as activators of PPAR receptors)

IT Intestine, disease
(Crohn's; preparation of N-pyrazolylbenzenesulfonylamide derivs. as activators of PPAR receptors)

IT Nuclear receptors
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(FXR (farnesoid X receptor), combination therapy agent; preparation of N-pyrazolylbenzenesulfonylamide derivs. as activators of PPAR receptors)

IT Steroid receptors
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(LXR (liver X receptor), combination therapy agent; preparation of N-pyrazolylbenzenesulfonylamide derivs. as activators of PPAR receptors)

IT Antiarteriosclerotics
(antiatherosclerotics; preparation of N-pyrazolylbenzenesulfonylamide

derivs. as activators of PPAR receptors)
IT Heart, disease
(failure; preparation of N-pyrazolylbenzenesulfonylamide derivs. as activators of PPAR receptors)
IT Heart, disease
(infarction; preparation of N-pyrazolylbenzenesulfonylamide derivs. as activators of PPAR receptors)
IT Intestine, disease
(inflammatory; preparation of N-pyrazolylbenzenesulfonylamide derivs. as activators of PPAR receptors)
IT Autoimmune disease
(insulin-dependent diabetes mellitus; preparation of N-pyrazolylbenzenesulfonylamide derivs. as activators of PPAR receptors)
IT Diabetes mellitus
(insulin-dependent; preparation of N-pyrazolylbenzenesulfonylamide derivs. as activators of PPAR receptors)
IT Sulfonylureas
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(insulinotropic, combination therapy agent; preparation of N-pyrazolylbenzenesulfonylamide derivs. as activators of PPAR receptors)
IT Metabolic disorders
(metabolic syndrome X; preparation of N-pyrazolylbenzenesulfonylamide derivs. as activators of PPAR receptors)
IT Diabetes mellitus
(non-insulin-dependent; preparation of N-pyrazolylbenzenesulfonylamide derivs. as activators of PPAR receptors)
IT Alzheimer's disease
Anti-Alzheimer's agents
Anti-inflammatory agents
Antiarthritics
Antidiabetic agents
Antihypertensives
Antiobesity agents
Antitumor agents
Arthritis
Atherosclerosis
Blood vessel, disease
Cardiovascular agents
Cardiovascular system, disease
Combination chemotherapy
Eye, disease
Hypercholesterolemia
Hypertension
Hypertriglyceridemia
Hypolipemic agents
Infectious bursal disease virus
Inflammation
Neoplasm
Obesity
Respiratory system, disease
Skin, disease
(preparation of N-pyrazolylbenzenesulfonylamide derivs. as activators of PPAR receptors)
IT Dyslipidemia
Hyperlipidemia
Peroxisome proliferator-activated receptors
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(preparation of N-pyrazolylbenzenesulfonylamide derivs. as activators of PPAR receptors)

IT Proteins
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(saposin C, combination therapy agent, inhibitors of; preparation of N-pyrazolylbenzenesulfonylamide derivs. as activators of PPAR receptors)

IT Inflammation
Intestine, disease
(ulcerative colitis; preparation of N-pyrazolylbenzenesulfonylamide derivs. as activators of PPAR receptors)

IT Peroxisome proliferator-activated receptors
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(α; preparation of N-pyrazolylbenzenesulfonylamide derivs. as activators of PPAR receptors)

IT Peroxisome proliferator-activated receptors
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(γ; preparation of N-pyrazolylbenzenesulfonylamide derivs. as activators of PPAR receptors)

IT 9028-35-7, HMG-CoA reductase 9077-14-9, Squalene synthase 54249-88-6, DPPIV
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(combination therapy agent, inhibitors of; preparation of N-pyrazolylbenzenesulfonylamide derivs. as activators of PPAR receptors)

IT 50-78-2, Aspirin 56-03-1, Biguanide 59-67-6, Nicotinic acid, biological studies 943-45-3D, Fibric acid, derivs. 9004-10-8D, Insulin, derivative or mimetic, secretagogue 11041-12-6, Cholestyramine 89750-14-1D, GLP-1, analog or mimetic
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(combination therapy agent; preparation of N-pyrazolylbenzenesulfonylamide derivs. as activators of PPAR receptors)

IT 827018-08-6P 827018-09-7P
RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(preparation of N-pyrazolylbenzenesulfonylamide derivs. as activators of PPAR receptors)

IT 827018-10-0P 827018-11-1P 827018-12-2P 827018-13-3P 827018-14-4P 827018-15-5P 827018-16-6P 827018-17-7P 827018-18-8P 827018-19-9P 827018-20-2P 827018-21-3P 827018-22-4P 827018-23-5P 827018-24-6P 827018-25-7P 827018-26-8P 827018-27-9P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of N-pyrazolylbenzenesulfonylamide derivs. as activators of PPAR receptors)

IT 6994-25-8, 3-Amino-1H-pyrazole-4-carboxylic acid ethyl ester 10580-19-5, 4-Hydroxybenzenesulfonic acid sodium salt dihydrate 52887-29-3, (3-Amino-1H-pyrazol-4-yl)phenylmethanone 174258-39-0, 4-Chloromethyl-5-methyl-2-(4-trifluoromethylphenyl)oxazole 532958-73-9, 4-(5-Methyl-2-phenyloxazol-4-ylmethoxy)benzenesulfonyl chloride
RL: RCT (Reactant); RACT (Reactant or reagent)
(preparation of N-pyrazolylbenzenesulfonylamide derivs. as activators of PPAR receptors)

IT 827018-28-0P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of N-pyrazolylbenzenesulfonylamide derivs. as activators of PPAR receptors)

IT 827018-07-5P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU

(Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of N-pyrazolylbenzenesulfonylamide derivs. as activators of PPARs)
REFERENCE COUNT: 9 THERE ARE 9 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> d que l4
L3 2 SEA FILE=WPIX ABB=ON PLU=ON US2006-563708/APPS
L4 1 SEA FILE=WPIX ABB=ON PLU=ON L3 NOT PIXEL/TI

=> d iall code l4
YOU HAVE REQUESTED DATA FROM FILE 'WPIX' - CONTINUE? (Y)/N:y

L4 ANSWER 1 OF 1 WPIX COPYRIGHT 2008 THOMSON REUTERS on STN
ACCESSION NUMBER: 2005-112619 [12] WPIX
DOC. NO. CPI: C2005-037717 [12]
TITLE: New benzenesulfonylamino compounds, useful for the treatment of e.g. dyslipidemia, hyperlipidemia, myocardial infarction, hypercholesterolemia and atherosclerosis
DERWENT CLASS: B02; B03
INVENTOR: THALATHTHANI R V; VEDANANDA T R
PATENT ASSIGNEE: (NOVS-C) NOVARTIS AG; (NOVS-C) NOVARTIS PHARMA GMBH; (VEDA-I) VEDANANDA T R
COUNTRY COUNT: 107

PATENT INFORMATION:

PATENT NO	KIND	DATE	WEEK	LA	PG	MAIN IPC
WO 2005005421	A1	20050120	(200512)*	EN	61[0]	
EP 1646628	A1	20060419	(200627)	EN		
AU 2004255342	A1	20050120	(200655)	EN		
BR 2004012380	A	20060919	(200663)	PT		
MX 2006000118	A1	20060501	(200680)	ES		
CN 1816546	A	20060809	(200682)	ZH		
US 20070043020	A1	20070222	(200717)	EN		
IN 2006CN00071	P4	20070629	(200768)	EN		

APPLICATION DETAILS:

PATENT NO	KIND	APPLICATION	DATE
WO 2005005421	A1	WO 2004-EP7442	20040707
US 20070043020	A1 Provisional	US 2003-485870P	20030708
AU 2004255342	A1	AU 2004-255342	20040707
BR 2004012380	A	BR 2004-12380	20040707
CN 1816546	A	CN 2004-80019234	20040707
EP 1646628	A1	EP 2004-740754	20040707
EP 1646628	A1	WO 2004-EP7442	20040707
BR 2004012380	A	WO 2004-EP7442	20040707
MX 2006000118	A1	WO 2004-EP7442	20040707
US 20070043020	A1	WO 2004-EP7442	20040707
IN 2006CN00071	P4	WO 2004-EP7442	20040707

IN 2006CN00071 P4 IN 2006-CN71 20060105
MX 2006000118 A1 MX 2006-118 20060105
US 20070043020 A1 US 2006-563708 20060619

FILING DETAILS:

PATENT NO	KIND		PATENT NO	
EP 1646628	A1	Based on	WO 2005005421	A
AU 2004255342	A1	Based on	WO 2005005421	A
BR 2004012380	A	Based on	WO 2005005421	A
MX 2006000118	A1	Based on	WO 2005005421	A

PRIORITY APPLN. INFO: US 2003-485870P 20030708
US 2006-563708 20060619
INT. PATENT CLASSIF.:
MAIN: C07C219-06; C07D413-12
IPC ORIGINAL: A61K0031-422 [I,A]; A61K0031-422 [I,A]; A61K0031-422 [I,A]; A61K0031-422 [I,C]; A61K0031-422 [I,C]; A61K0031-422 [I,C]; A61K0031-4523 [I,C]; A61K0031-454 [I,A]; A61K0031-4709 [I,A]; A61K0031-4709 [I,C]; A61K0031-5375 [I,C]; A61K0031-538 [I,A]; A61K0031-5415 [I,A]; A61K0031-5415 [I,C]; A61K0031-55 [I,A]; A61K0031-55 [I,C]; A61K0031-553 [I,A]; A61K0031-553 [I,C] ; A61P0003-00 [I,C]; A61P0003-00 [I,C]; A61P0003-10 [I,A] ; A61P0003-10 [I,A]; C07D0413-00 [I,C]; C07D0413-00 [I,C] ; C07D0413-00 [I,C]; C07D0413-00 [I,C]; C07D0413-02 [I,A] ; C07D0413-12 [I,A]; C07D0413-12 [I,A]; C07D0413-12 [I,A]
IPC RECLASSIF.: A61P0003-00 [I,C]; A61P0003-10 [I,A]; C07D0413-00 [I,C]; C07D0413-12 [I,A]
ECLA: C07D0413-12+263B+231
USCLASS NCLM: 514/211.100
NCLS: 514/215.000; 514/217.000; 514/224.800; 514/229.800; 514/230.500; 514/314.000; 514/374.000; 514/378.000; 540/544.000; 540/586.000; 544/044.000; 544/101.000; 544/105.000; 546/157.000; 546/211.000; 548/215.000

BASIC ABSTRACT:

WO 2005005421 A1 UPAB: 20071024

NOVELTY - Benzenesulfonylamino compounds are new.

DETAILED DESCRIPTION - Benzenesulfonylamino compounds of formula (I), their salts or prodrug derivatives are new.

R1,R2 = alkyl, alkoxy, alkylthio or (hetero)aralkyl (optionally substituted), H, halogen or OH;

R1+R2 = optionally substituted fused 5- to 6-membered aromatic or heteroaromatic ring or alkylene to form fused 5- to 7-membered ring;

R3 = H or optionally substituted lower alkyl;

X = -Z-(CH2)p-Q-W;

Z = bond, O, S, S(O), S(O)2, -C(O) or C(O)NR4-;

R4 = H, alkyl or aralkyl;

p = 1 - 8;

Q = U1, U2, U3 or U4;

U1 = a bond;

U2 = -O(CH2)r- or -S(CH2)r-;

r = 0 - 8;

U3 = -C(O)- or -C(O)NR5-;

R5,R6 = (cyclo)alkyl, (hetero)aryl, or (hetero)aralkyl (all optionally substituted) or H;

U4 = -NR6-, -NR6C(O)-, NR6C(O)NR7- or -NR6C(O)O-;

R7 = H, alkyl or aralkyl;

W = cycloalkyl, aryl, heterocyclyl or (hetero)aralkyl;

NWR5 = 3- to 7-membered monocyclic or 8- to 12-membered bicyclic ring (optionally substituted or optionally containing heteroatom selected from O, N or S);

NWR7 = a 3- to 7-membered monocyclic or 8- to 12-membered bicyclic ring (optionally substituted or optionally containing heteroatom selected from O, N or S);

L = a 5-membered aromatic heterocycle.

Provided that:

(1) when R1+R2 is optionally substituted fused 5- to 6-membered aromatic or heteroaromatic ring, then R1+R2 are attached to carbon atoms adjacent to each other;

(2) when R1+R2 is alkylene to form fused 5- to 7-membered ring, then R1+R2 is attached to carbon atoms adjacent to each other; and

(3) R1-C and R2-C may independently be replaced by nitrogen.

An INDEPENDENT CLAIM is also included for a composition comprising (I) in combination with at least one carrier and additionally insulin, its derivative or mimetic; insulin secretagogue; insulinotropic sulfonylurea receptor ligand; insulin sensitizer; biguanide; alpha-glucosidase inhibitor; GLP-1 or its analog or mimetic; dipeptidyl peptidase (IV) (DPP-IV) inhibitor; HMG-CoA reductase inhibitor; squalene synthase inhibitor; FXR or LXR ligand; cholestyramine; fibrate; nicotinic acid; or aspirin.

ACTIVITY - Antilipemic; Antiarteriosclerotic; Antidiabetic; Cardiant; Vasotropic; Hypotensive; Anorectic; Antiinflammatory; Antiarthritic; Cytostatic; Neuroprotective; Dermatological; Respiratory-Gen.; Ophthalmological; Gastrointestinal-Gen.; Antiulcer; Analgesic; Antianginal.

MECHANISM OF ACTION - Peroxisome proliferator-activated Receptors (PPAR)alpha and PPARgamma receptors agonist and antagonists. An in vitro functional binding to the PPARalpha and PPARgamma receptors was determined as follows: The functional binding assays for the PPARapproximately, and PPARgamma receptors were a variation of the coactivator-dependent receptor ligand assay (CARLA). Both assays included glutathione-S-transferase (GST) fusion proteins (3 nM). The GST fusion proteins were purified on glutathione sepharose affinity columns. The assay buffer contained Tris (50 mM) pH 7.4, KCl (50 mM), BSA (0.1%) and DTT (dithiothreitol) (1 mM).

The assay was carried out using 1-ethyl-3-(4-(5-methyl-2-)4-trifluoromethyl-phenyl)-oxazol-4-ylmethoxy)-benzene-sulfonylamino)-1H-pyrazole-4-carboxylic acid ethyl ester (Ia) in black half area 96-well plates in a final volume of 25 mul. After mixing all components, the reaction mixture stands for 3 hours at room temperature before reading the TR-FRET (Time-Resolved Fluorescence Resonance Energy Transfer) signal on a Wallac Victor 2 plate reader. The EC50 value of (Ia) was found to be 5 nm in the PPARalpha receptor binding assay and 3 nM in the PPARgamma receptor binding assay.

USE - Compounds (I) are useful for the activation of Peroxisome proliferator-activated Receptors (PPARs); for the treatment of conditions mediated by PPARs; for treatment of dyslipidemia, hyperlipidemia, hypercholesterolemia, atherosclerosis, hypertriglyceridemia, heart failure, myocardial infarction, vascular diseases, cardiovascular diseases, hypertension, obesity, inflammation, arthritis, cancer, Alzheimer's disease, skin disorders, respiratory diseases, ophthalmic disorders, inflammatory bowel diseases (IBDs), ulcerative colitis, Crohn's disease, type-1 and type-2 diabetes, and Syndrome-X; for the preparation of a medicament or pharmaceutical composition for the treatment of conditions associated with PPAR activity (all claimed).

ADVANTAGE - Compounds (I) bind or activate (PPARs). MANUAL CODE: CPI: B06-H; B07-H; B10-A08; B14-C03; B14-C09; B14-D01E; B14-D02A2; B14-D05D; B14-D07; B14-D10; B14-E08; B14-E10C1; B14-E12; B14-F01; B14-F02; B14-F06; B14-F07; B14-H01; B14-J01A4; B14-K01; B14-L01; B14-L06; B14-N03; B14-N17; B14-S04; B14-S16

AN 2005-112619 [12] WPIX

```
DC   B02; B03
IC   ICM C07C219-06; C07D413-12
IPCI A61K0031-422 [I,A]; A61K0031-422 [I,A]; A61K0031-422 [I,A]; A61K0031-422
     [I,C]; A61K0031-422 [I,C]; A61K0031-422 [I,C]; A61K0031-4523 [I,C];
     A61K0031-454 [I,A]; A61K0031-4709 [I,A]; A61K0031-4709 [I,C];
     A61K0031-5375 [I,C]; A61K0031-538 [I,A]; A61K0031-5415 [I,A];
     A61K0031-5415 [I,C]; A61K0031-55 [I,A]; A61K0031-55 [I,C]; A61K0031-553
     [I,A]; A61K0031-553 [I,C]; A61P0003-00 [I,C]; A61P0003-00 [I,C];
     A61P0003-10 [I,A]; A61P0003-10 [I,A]; C07D0413-00 [I,C]; C07D0413-00
     [I,C]; C07D0413-00 [I,C]; C07D0413-00 [I,C]; C07D0413-02 [I,A];
     C07D0413-12 [I,A]; C07D0413-12 [I,A]; C07D0413-12 [I,A]
IPCR A61P0003-00 [I,C]; A61P0003-10 [I,A]; C07D0413-00 [I,C]; C07D0413-12 [I,A]
EPC  C07D0413-12+263B+231
NCL  NCLM  514/211.100
     NCLS  514/215.000; 514/217.000; 514/224.800; 514/229.800; 514/230.500;
           514/314.000; 514/374.000; 514/378.000; 540/544.000; 540/586.000;
           544/044.000; 544/101.000; 544/105.000; 546/157.000; 546/211.000;
           548/215.000
IT   UPIT 20071024
     1022227-CL 1022227-NEW; 1022228-CL 1022228-NEW; 1022229-CL 1022229-NEW;
     1022230-CL 1022230-NEW; 1022231-CL 1022231-NEW; 1022232-CL 1022232-NEW;
     1022234-CL 1022234-NEW; 1022235-CL 1022235-NEW; 1022236-CL 1022236-NEW;
     1022237-CL 1022237-NEW; 1022238-CL 1022238-NEW; 1022239-CL 1022239-NEW;
     1022240-CL 1022240-NEW; 1022241-CL 1022241-NEW; 1022242-CL 1022242-NEW;
     1022243-CL 1022243-NEW; 1022244-CL 1022244-NEW; 1022245-CL 1022245-NEW;
     1022246-CL 1022246-NEW; 1022247-CL 1022247-NEW; 0148-98901-CL
     0148-98901-NEW; 97834-CL; 96186-CL; 8534-CL; 91469-CL; 6756-CL; 87874-CL
MC   CPI: B06-H; B07-H; B10-A08; B14-C03; B14-C09; B14-D01E; B14-D02A2;
           B14-D05D; B14-D07; B14-D10; B14-E08; B14-E10C1; B14-E12; B14-F01;
           B14-F02; B14-F06; B14-F07; B14-H01; B14-J01A4; B14-K01; B14-L01;
           B14-L06; B14-N03; B14-N17; B14-S04; B14-S16
CMC  UPB   20071024
     DRN: 0034-U 0190-U
     DCR: 130269-U 138321-U 6756-U 87874-U 87878-U
     M1 *22*   M423 M431 M782 P420 P421 P446 P520 P522 P523 P526 P617 P625 P633
               P714 P731 P738 P814 P816 P820 P922 P943  M905
               DCN: R01851-K R01851-M R01851-T R06675-K R06675-M R06675-T
               DCR: 97834-K 97834-M 97834-T
     M1 *23*   D011 D601 F014 F019 F521 F599 G010 G013 G019 G100 H1 H101 H183
               H4 H405 H441 H484 H8 J0 J014 J1 J173 J3 J373 K0 L2 L250 L299
               M280 M311 M312 M313 M314 M315 M322 M323 M331 M332 M333 M340 M342
               M343 M349 M371 M381 M393 M423 M431 M511 M522 M533 M540 M782 P420
               P421 P446 P520 P522 P523 P526 P617 P625 P633 P714 P731 P738 P814
               P816 P820 P922 P943  M905 M904
               DCN: RA0B8N-K RA0B8N-M RA0B8N-T
               DCR: 96186-K 96186-M 96186-T
     M2 *01*   C316 F011 F012 F013 F014 F015 F019 F511 F610 G013 G019 G100 H2
               H211 H5 H541 H6 H685 H8 J0 J011 J2 J211 K0 K3 K353 L943 M1 M113
               M123 M147 M210 M211 M212 M240 M272 M273 M281 M311 M322 M342 M344
               M353 M373 M391 M413 M510 M522 M532 M540 M710 P420 P421 P446 P520
               P522 P523 P526 P617 P625 P633 P714 P731 P738 P814 P816 P820 P922
               P943  M905 M904
               DCN: RAGQML-N RAGQML-T
               DCR: 1022227-N 1022227-T
     M2 *02*   C316 F011 F012 F013 F014 F015 F019 F511 F610 G010 G013 G100 H2
               H211 H5 H541 H8 J0 J011 J2 J211 K0 K3 K353 L943 M1 M113 M123
               M147 M210 M211 M212 M240 M272 M273 M281 M311 M321 M342 M373 M391
               M413 M510 M522 M532 M540 M710 P420 P421 P446 P520 P522 P523 P526
               P617 P625 P633 P714 P731 P738 P814 P816 P820 P922 P943  M905
               M904
```

DCN: RAGQMM-N RAGQMM-T
DCR: 1022228-N 1022228-T
M2 *03* C316 F011 F012 F013 F014 F015 F019 F511 F610 G010 G013 G100 H2 H211 H5 H541 H8 J0 J011 J1 J111 K0 K3 K353 L943 M1 M113 M123 M147 M210 M211 M212 M240 M273 M281 M311 M321 M342 M373 M391 M413 M510 M522 M532 M540 M710 P420 P421 P446 P520 P522 P523 P526 P617 P625 P633 P714 P731 P738 P814 P816 P820 P922 P943 M905 M904
DCN: RAGQMN-N RAGQMN-T
DCR: 1022229-N 1022229-T
M2 *04* C316 F011 F012 F013 F014 F015 F019 F511 F610 G010 G013 G100 H2 H211 H5 H541 H8 J0 J011 J3 J311 K0 K3 K353 L943 M1 M113 M123 M147 M210 M211 M212 M240 M273 M281 M311 M321 M342 M373 M391 M413 M510 M522 M532 M540 M710 P420 P421 P446 P520 P522 P523 P526 P617 P625 P633 P714 P731 P738 P814 P816 P820 P922 P943 M905 M904
DCN: RAGQMO-N RAGQMO-T
DCR: 1022230-N 1022230-T
M2 *05* C316 F011 F012 F013 F014 F015 F019 F511 F610 G010 G013 G100 H2 H211 H5 H541 H8 J0 J011 J3 J311 K0 K3 K353 L943 M1 M113 M123 M147 M210 M211 M212 M240 M273 M281 M282 M311 M321 M342 M373 M391 M413 M510 M522 M532 M540 M710 P420 P421 P446 P520 P522 P523 P526 P617 P625 P633 P714 P731 P738 P814 P816 P820 P922 P943 M905 M904
DCN: RAGQMP-N RAGQMP-T
DCR: 1022231-N 1022231-T
M2 *06* C316 F011 F012 F013 F014 F015 F019 F511 F610 G010 G013 G019 G100 H2 H211 H5 H541 H8 J5 J581 K0 K3 K353 L943 M1 M113 M123 M129 M131 M147 M210 M211 M212 M240 M273 M281 M311 M321 M342 M373 M391 M413 M510 M522 M533 M540 M710 P420 P421 P446 P520 P522 P523 P526 P617 P625 P633 P714 P731 P738 P814 P816 P820 P922 P943 M905 M904
DCN: RAGQMQ-N RAGQMQ-T
DCR: 1022232-N 1022232-T
M2 *07* C316 F011 F012 F013 F014 F015 F019 F511 F610 G010 G013 G019 G100 H2 H211 H5 H541 H8 J0 J011 J2 J211 K0 K3 K353 L943 M1 M113 M123 M147 M210 M211 M240 M272 M281 M311 M322 M342 M373 M392 M413 M510 M522 M533 M540 M710 P420 P421 P446 P520 P522 P523 P526 P617 P625 P633 P714 P731 P738 P814 P816 P820 P922 P943 M905 M904
DCN: RAGQMS-N RAGQMS-T
DCR: 1022234-N 1022234-T
M2 *08* C316 F011 F012 F013 F014 F015 F019 F511 F610 G010 G013 G019 G100 H2 H211 H5 H541 H8 J0 J011 J1 J111 K0 K3 K353 L943 M1 M113 M123 M147 M210 M211 M240 M281 M311 M322 M342 M373 M392 M413 M510 M522 M533 M540 M710 P420 P421 P446 P520 P522 P523 P526 P617 P625 P633 P714 P731 P738 P814 P816 P820 P922 P943 M905 M904
DCN: RAGQMT-N RAGQMT-T
DCR: 1022235-N 1022235-T
M2 *09* C316 F011 F012 F013 F014 F015 F019 F511 F610 G010 G013 G100 H2 H211 H5 H541 H8 J0 J011 J2 J211 K0 K3 K353 L943 M1 M113 M123 M147 M210 M211 M240 M272 M273 M281 M311 M321 M342 M373 M391 M413 M510 M522 M532 M540 M710 P420 P421 P446 P520 P522 P523 P526 P617 P625 P633 P714 P731 P738 P814 P816 P820 P922 P943 M905 M904
DCN: RAGQMU-N RAGQMU-T
DCR: 1022236-N 1022236-T
M2 *10* C316 F011 F012 F013 F014 F015 F019 F511 F610 G010 G013 G100 H2 H211 H5 H541 H8 J0 J011 J1 J111 K0 K3 K353 L943 M1 M113 M123 M147 M210 M211 M240 M273 M281 M311 M321 M342 M373 M391 M413 M510 M522 M532 M540 M710 P420 P421 P446 P520 P522 P523 P526 P617 P625 P633 P714 P731 P738 P814 P816 P820 P922 P943 M905 M904
DCN: RAGQMV-N RAGQMV-T
DCR: 1022237-N 1022237-T

M2 *11* C316 F011 F012 F013 F014 F015 F019 F511 F610 G010 G013 G100 H2 H211 H5 H541 H7 H713 H721 H8 J0 J011 J2 J211 K0 K3 K353 L943 M1 M113 M123 M147 M210 M211 M212 M240 M272 M273 M281 M311 M321 M342 M373 M391 M413 M510 M522 M532 M540 M710 P420 P421 P446 P520 P522 P523 P526 P617 P625 P633 P714 P731 P738 P814 P816 P820 P922 P943 M905 M904
DCN: RAGQMW-N RAGQMW-T
DCR: 1022238-N 1022238-T

M2 *12* C316 F011 F012 F013 F014 F015 F019 F511 F610 G010 G013 G100 H2 H211 H5 H541 H7 H713 H721 H8 J0 J011 J1 J111 K0 K3 K353 L943 M1 M113 M123 M147 M210 M211 M212 M240 M273 M281 M311 M321 M342 M373 M391 M413 M510 M522 M532 M540 M710 P420 P421 P446 P520 P522 P523 P526 P617 P625 P633 P714 P731 P738 P814 P816 P820 P922 P943 M905 M904
DCN: RAGQMX-N RAGQMX-T
DCR: 1022239-N 1022239-T

M2 *13* C316 F011 F012 F013 F014 F015 F019 F511 F610 G010 G013 G019 G100 H2 H211 H5 H541 H6 H685 H8 J0 J011 J2 J211 K0 K3 K353 L943 M1 M113 M123 M147 M210 M211 M240 M272 M281 M311 M322 M342 M344 M353 M373 M391 M413 M510 M522 M533 M540 M710 P420 P421 P446 P520 P522 P523 P526 P617 P625 P633 P714 P731 P738 P814 P816 P820 P922 P943 M905 M904
DCN: RAGQMY-N RAGQMY-T
DCR: 1022240-N 1022240-T

M2 *14* C316 F011 F012 F013 F014 F015 F019 F511 F610 G010 G013 G100 H2 H211 H5 H541 H8 J0 J011 J2 J211 K0 K3 K353 L943 M1 M113 M123 M147 M210 M211 M213 M231 M240 M272 M273 M281 M311 M321 M342 M373 M391 M413 M510 M522 M532 M540 M710 P420 P421 P446 P520 P522 P523 P526 P617 P625 P633 P714 P731 P738 P814 P816 P820 P922 P943 M905 M904
DCN: RAGQMZ-N RAGQMZ-T
DCR: 1022241-N 1022241-T

M2 *15* C316 F011 F012 F013 F014 F015 F019 F511 F610 G010 G013 G100 H2 H211 H5 H541 H8 J0 J011 J3 J311 K0 K3 K353 L943 M1 M113 M123 M147 M210 M211 M212 M240 M273 M281 M282 M311 M321 M342 M373 M391 M413 M510 M522 M532 M540 M710 P420 P421 P446 P520 P522 P523 P526 P617 P625 P633 P714 P731 P738 P814 P816 P820 P922 P943 M905 M904
DCN: RAGQN0-N RAGQN0-T
DCR: 1022242-N 1022242-T

M2 *16* C316 F011 F012 F013 F014 F015 F019 F511 F610 G010 G013 G100 H2 H211 H5 H541 H8 J0 J011 J3 J311 K0 K3 K353 L943 M1 M113 M123 M147 M210 M211 M212 M240 M273 M281 M283 M311 M321 M342 M373 M391 M413 M510 M522 M532 M540 M710 P420 P421 P446 P520 P522 P523 P526 P617 P625 P633 P714 P731 P738 P814 P816 P820 P922 P943 M905 M904
DCN: RAGQN1-N RAGQN1-T
DCR: 1022243-N 1022243-T

M2 *17* C316 F011 F012 F013 F014 F015 F019 F511 F610 G010 G013 G030 G112 G530 H2 H211 H5 H541 H8 J0 J011 J3 J311 K0 K3 K353 L943 M1 M113 M123 M147 M210 M211 M212 M240 M273 M281 M311 M322 M342 M373 M392 M413 M510 M522 M532 M541 M710 P420 P421 P446 P520 P522 P523 P526 P617 P625 P633 P714 P731 P738 P814 P816 P820 P922 P943 M905 M904
DCN: RAGQN2-N RAGQN2-T
DCR: 1022244-N 1022244-T

M2 *18* C316 F011 F012 F013 F014 F015 F019 F511 F610 G010 G013 G019 G100 H2 H211 H5 H541 H8 J0 J011 J3 J311 K0 K3 K353 L943 M1 M113 M123 M147 M210 M211 M212 M240 M273 M281 M311 M322 M342 M373 M392 M413 M510 M522 M533 M540 M710 P420 P421 P446 P520 P522 P523 P526 P617

P625 P633 P714 P731 P738 P814 P816 P820 P922 P943 M905 M904
DCN: RAGQN3-N RAGQN3-T
DCR: 1022245-N 1022245-T

M2 *19* C316 F011 F012 F013 F014 F015 F019 F433 F511 F610 G010 G013 G100 H2 H212 H5 H541 H8 J0 J011 J3 J311 K0 K3 K353 L943 M1 M113 M123 M147 M210 M211 M212 M240 M273 M281 M311 M321 M342 M373 M391 M413 M510 M523 M532 M540 M710 P420 P421 P446 P520 P522 P523 P526 P617 P625 P633 P714 P731 P738 P814 P816 P820 P922 P943 M905 M904
DCN: RAGQN4-N RAGQN4-T
DCR: 1022246-N 1022246-T

M2 *20* C316 F011 F012 F013 F014 F015 F019 F511 F610 G010 G013 G100 H2 H211 H5 H541 H8 J0 J011 J2 J211 K0 K3 K353 L943 M1 M113 M123 M147 M210 M211 M212 M240 M272 M273 M281 M282 M311 M321 M342 M373 M391 M413 M510 M522 M532 M540 M710 P420 P421 P446 P520 P522 P523 P526 P617 P625 P633 P714 P731 P738 P814 P816 P820 P922 P943 M905 M904
DCN: RAGQN5-N RAGQN5-T
DCR: 1022247-N 1022247-T

M2 *21* C216 C316 F010 F011 F013 F014 F019 F020 F021 F029 F511 G001 G002 G003 G010 G011 G012 G013 G014 G015 G016 G017 G019 G020 G021 G022 G029 G030 G040 G050 G100 G111 G112 G113 G221 G299 G553 G563 H102 H103 H121 H141 H161 H181 H211 H401 H402 H441 H442 H521 H522 H541 H542 H543 H561 H581 H592 H594 H596 H598 H599 H600 H608 H641 H642 J011 J012 J013 J111 J211 J311 J312 J321 J331 J332 J341 J351 J361 J371 J581 J582 J583 K0 K3 K353 K442 K499 L432 L462 L463 L640 L650 L660 L943 M1 M121 M122 M123 M124 M125 M126 M129 M132 M135 M136 M137 M139 M143 M147 M149 M150 M210 M211 M212 M213 M214 M215 M216 M220 M221 M222 M223 M224 M225 M226 M231 M232 M233 M240 M262 M271 M272 M273 M280 M281 M282 M283 M311 M312 M313 M314 M315 M316 M321 M322 M323 M331 M332 M333 M340 M342 M349 M372 M373 M381 M382 M383 M391 M392 M393 M413 M510 M521 M522 M523 M531 M532 M533 M540 M541 M542 M630 M640 M650 M710 P420 P421 P446 P520 P522 P523 P526 P617 P625 P633 P714 P731 P738 P814 P816 P820 P922 P943 M905 M904
MCN: 0148-98901-N 0148-98901-T

M2 *24* K0 L2 L240 M280 M320 M416 M431 M620 M782 P420 P421 P446 P520 P522 P523 P526 P617 P625 P633 P714 P731 P738 P814 P816 P820 P922 P943 M905 M904
DCN: R03018-K R03018-M R03018-T
DCR: 8534-K 8534-M 8534-T

M2 *25* C017 C100 C720 C800 C801 C803 C804 C805 C806 C807 G011 G013 G100 H1 H181 K0 L7 L722 M1 M121 M135 M210 M211 M212 M240 M273 M281 M283 M311 M314 M321 M331 M342 M373 M391 M411 M431 M510 M520 M532 M540 M640 M782 P420 P421 P446 P520 P522 P523 P526 P617 P625 P633 P714 P731 P738 P814 P816 P820 P922 P943 M905 M904
DCN: RA0JOR-K RA0JOR-M RA0JOR-T
DCR: 91469-K 91469-M 91469-T

M2 *26* F013 F431 J0 J011 J1 J111 M280 M320 M413 M431 M510 M521 M530 M540 M782 P420 P421 P446 P520 P522 P523 P526 P617 P625 P633 P714 P731 P738 P814 P816 P820 P922 P943 M905 M904 M910
DCN: R00190-K R00190-M R00190-T R12975-K R12975-M R12975-T
DCR: 6756-K 6756-M 6756-T 6756-U

M2 *27* G011 G100 J0 J012 J1 J131 J2 J241 M210 M211 M262 M281 M320 M414 M431 M510 M520 M531 M540 M782 P420 P421 P446 P520 P522 P523 P526 P617 P625 P633 P714 P731 P738 P814 P816 P820 P922 P943 M905 M904 M910
DCN: R00034-K R00034-M R00034-T R06663-K R06663-M R06663-T
DCR: 130269-U 138321-U 87874-K 87874-M 87874-T 87874-U 87878-U

```
=> => d que stat l20
L13             STR
```




```
VAR G1=12/10
VPA 3-13/14/15/16/17/18 U
NODE ATTRIBUTES:
CONNECT IS E2  RC AT   2
CONNECT IS E2  RC AT  12
DEFAULT MLEVEL IS ATOM
GGCAT   IS UNS  AT   1
GGCAT   IS UNS  AT   7
DEFAULT ECLEVEL IS LIMITED
ECOUNT  IS X8 C  AT   2

GRAPH ATTRIBUTES:
RING(S) ARE ISOLATED OR EMBEDDED
NUMBER OF NODES IS  17

STEREO ATTRIBUTES: NONE
L18     1320380 SEA FILE=REGISTRY ABB=ON  PLU=ON  N2C3/ES OR NCOC2/ES
L20          41 SEA FILE=REGISTRY SUB=L18 SSS FUL L13

100.0% PROCESSED   52164 ITERATIONS                              41 ANSWERS
SEARCH TIME: 00.00.01


=> d que stat l22
L1             2 SEA FILE=HCAPLUS ABB=ON  PLU=ON  US2006-563708/APPS
L2             1 SEA FILE=HCAPLUS ABB=ON  PLU=ON  L1 NOT PIXEL/TI
L5               TRANSFER  PLU=ON  L2 1- RN :      37 TERMS
L6            37 SEA FILE=REGISTRY ABB=ON  PLU=ON  L5
L13              STR
```




```
VAR G1=12/10
VPA 3-13/14/15/16/17/18 U
NODE ATTRIBUTES:
CONNECT IS E2  RC AT   2
CONNECT IS E2  RC AT  12
DEFAULT MLEVEL IS ATOM
```

```
GGCAT   IS UNS  AT   1
GGCAT   IS UNS  AT   7
DEFAULT ECLEVEL IS LIMITED
ECOUNT  IS X8 C  AT   2

GRAPH ATTRIBUTES:
RING(S) ARE ISOLATED OR EMBEDDED
NUMBER OF NODES IS  17

STEREO ATTRIBUTES: NONE
L18     1320380 SEA FILE=REGISTRY ABB=ON  PLU=ON  N2C3/ES OR NCOC2/ES
L20          41 SEA FILE=REGISTRY SUB=L18 SSS FUL L13
L21          21 SEA FILE=REGISTRY ABB=ON  PLU=ON  L6 AND L20
L22           1 SEA FILE=REGISTRY ABB=ON  PLU=ON  L21 AND "C26 H25 F3 N4 O6
                S"/MF


=> d ide l22
YOU HAVE REQUESTED DATA FROM FILE 'REGISTRY' - CONTINUE? (Y)/N:y



L22  ANSWER 1 OF 1  REGISTRY  COPYRIGHT 2008 ACS on STN
RN   827018-07-5  REGISTRY
ED   Entered STN:  07 Feb 2005
CN   1H-Pyrazole-4-carboxylic acid, 1-ethyl-3-[[[4-[[5-methyl-2-[4-
     (trifluoromethyl)phenyl]-4-oxazolyl]methoxy]phenyl]sulfonyl]amino]-, ethyl
     ester  (CA INDEX NAME)
MF   C26 H25 F3 N4 O6 S
SR   CA
LC   STN Files:   CA, CAPLUS, TOXCENTER, USPATFULL
```




```
**PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT**

               1 REFERENCES IN FILE CA (1907 TO DATE)
               1 REFERENCES IN FILE CAPLUS (1907 TO DATE)


=> file stnguide
FILE 'STNGUIDE' ENTERED AT 12:51:59 ON 02 OCT 2008
USE IS SUBJECT TO THE TERMS OF YOUR CUSTOMER AGREEMENT
COPYRIGHT (C) 2008 AMERICAN CHEMICAL SOCIETY (ACS)

FILE CONTAINS CURRENT INFORMATION.
LAST RELOADED: Sep 26, 2008 (20080926/UP).
```

```
=> => d que stat l20
L13             STR
```




```
VAR G1=12/10
VPA 3-13/14/15/16/17/18 U
NODE ATTRIBUTES:
CONNECT IS E2  RC AT   2
CONNECT IS E2  RC AT  12
DEFAULT MLEVEL IS ATOM
GGCAT   IS UNS  AT   1
GGCAT   IS UNS  AT   7
DEFAULT ECLEVEL IS LIMITED
ECOUNT  IS X8 C  AT   2

GRAPH ATTRIBUTES:
RING(S) ARE ISOLATED OR EMBEDDED
NUMBER OF NODES IS  17

STEREO ATTRIBUTES: NONE
L18     1320380 SEA FILE=REGISTRY ABB=ON  PLU=ON  N2C3/ES OR NCOC2/ES
L20          41 SEA FILE=REGISTRY SUB=L18 SSS FUL L13

100.0% PROCESSED   52164 ITERATIONS                              41 ANSWERS
SEARCH TIME: 00.00.01


=> d que stat l22
L1             2 SEA FILE=HCAPLUS ABB=ON  PLU=ON  US2006-563708/APPS
L2             1 SEA FILE=HCAPLUS ABB=ON  PLU=ON  L1 NOT PIXEL/TI
L5               TRANSFER  PLU=ON  L2 1- RN :      37 TERMS
L6            37 SEA FILE=REGISTRY ABB=ON  PLU=ON  L5
L13              STR
```




```
VAR G1=12/10
VPA 3-13/14/15/16/17/18 U
NODE ATTRIBUTES:
CONNECT IS E2  RC AT   2
CONNECT IS E2  RC AT  12
DEFAULT MLEVEL IS ATOM
```

```
GGCAT   IS UNS  AT   1
GGCAT   IS UNS  AT   7
DEFAULT ECLEVEL IS LIMITED
ECOUNT  IS X8 C  AT   2

GRAPH ATTRIBUTES:
RING(S) ARE ISOLATED OR EMBEDDED
NUMBER OF NODES IS  17

STEREO ATTRIBUTES: NONE
L18     1320380 SEA FILE=REGISTRY ABB=ON  PLU=ON  N2C3/ES OR NCOC2/ES
L20          41 SEA FILE=REGISTRY SUB=L18 SSS FUL L13
L21          21 SEA FILE=REGISTRY ABB=ON  PLU=ON  L6 AND L20
L22           1 SEA FILE=REGISTRY ABB=ON  PLU=ON  L21 AND "C26 H25 F3 N4 O6
                S"/MF


=> d que stat l38
L13             STR
```




```
VAR G1=12/10
VPA 3-13/14/15/16/17/18 U
NODE ATTRIBUTES:
CONNECT IS E2  RC AT   2
CONNECT IS E2  RC AT  12
DEFAULT MLEVEL IS ATOM
GGCAT   IS UNS  AT   1
GGCAT   IS UNS  AT   7
DEFAULT ECLEVEL IS LIMITED
ECOUNT  IS X8 C  AT   2

GRAPH ATTRIBUTES:
RING(S) ARE ISOLATED OR EMBEDDED
NUMBER OF NODES IS  17

STEREO ATTRIBUTES: NONE
L36     3910521 SEA FILE=REGISTRY ABB=ON  PLU=ON  NCNC2/ES OR N2CNC/ES OR
                NCSC2/ES OR SC4/ES
L38          31 SEA FILE=REGISTRY SUB=L36 SSS FUL L13

100.0% PROCESSED  160297 ITERATIONS                          31 ANSWERS
SEARCH TIME: 00.00.03


=> d que stat l41
L13             STR
```



VAR G1=12/10
VPA 3-13/14/15/16/17/18 U
NODE ATTRIBUTES:
CONNECT IS E2 RC AT 2
CONNECT IS E2 RC AT 12
DEFAULT MLEVEL IS ATOM
GGCAT IS UNS AT 1
GGCAT IS UNS AT 7
DEFAULT ECLEVEL IS LIMITED
ECOUNT IS X8 C AT 2

GRAPH ATTRIBUTES:
RING(S) ARE ISOLATED OR EMBEDDED
NUMBER OF NODES IS 17

STEREO ATTRIBUTES: NONE
L36 3910521 SEA FILE=REGISTRY ABB=ON PLU=ON NCNC2/ES OR N2CNC/ES OR
NCSC2/ES OR SC4/ES
L38 31 SEA FILE=REGISTRY SUB=L36 SSS FUL L13
L39 STR



VAR G1=12/10
NODE ATTRIBUTES:
CONNECT IS E2 RC AT 2
CONNECT IS E2 RC AT 12
DEFAULT MLEVEL IS ATOM
DEFAULT ECLEVEL IS LIMITED
ECOUNT IS X8 C AT 2

GRAPH ATTRIBUTES:
RSPEC 19 13
NUMBER OF NODES IS 20

STEREO ATTRIBUTES: NONE
L41 23 SEA FILE=REGISTRY SUB=L38 SSS FUL L39

100.0% PROCESSED 23 ITERATIONS 23 ANSWERS
SEARCH TIME: 00.00.01

```
=> d que stat l32
L13             STR
```




```
VAR G1=12/10
VPA 3-13/14/15/16/17/18 U
NODE ATTRIBUTES:
CONNECT IS E2  RC AT   2
CONNECT IS E2  RC AT  12
DEFAULT MLEVEL IS ATOM
GGCAT   IS UNS  AT   1
GGCAT   IS UNS  AT   7
DEFAULT ECLEVEL IS LIMITED
ECOUNT  IS X8 C  AT   2

GRAPH ATTRIBUTES:
RING(S) ARE ISOLATED OR EMBEDDED
NUMBER OF NODES IS  17

STEREO ATTRIBUTES: NONE
L32          47 SEA FILE=WPIX SSS FUL L13

100.0% PROCESSED   55333 ITERATIONS                              47 ANSWERS
SEARCH TIME: 00.00.20


=> d his l32-l35

     (FILE 'WPIX' ENTERED AT 12:56:10 ON 02 OCT 2008)
L32          47 S L13 FUL
                SAVE TEMP L32 GAR708WPIS/A
                SELECT L32 1- SDCN
L33           6 S E13-E59/DCN OR L32/DCR
L34           1 S L33 AND L24-L25
L35           5 S L33 NOT L34

=> d que l35
L13             STR
```




```
VAR G1=12/10
```

```
VPA 3-13/14/15/16/17/18 U
NODE ATTRIBUTES:
CONNECT IS E2  RC AT   2
CONNECT IS E2  RC AT  12
DEFAULT MLEVEL IS ATOM
GGCAT   IS UNS  AT   1
GGCAT   IS UNS  AT   7
DEFAULT ECLEVEL IS LIMITED
ECOUNT  IS X8 C  AT   2

GRAPH ATTRIBUTES:
RING(S) ARE ISOLATED OR EMBEDDED
NUMBER OF NODES IS  17

STEREO ATTRIBUTES: NONE
L24             QUE  ABB=ON  PLU=ON  VEDANANDA, T?/AU
L25             QUE  ABB=ON  PLU=ON  NOVARTIS/CS,SO,PA
L32          47 SEA FILE=WPIX SSS FUL L13
L33           6 SEA FILE=WPIX ABB=ON  PLU=ON  (RAC2TR/DCN OR RAC2TS/DCN OR
                RAC2TZ/DCN OR RAGQML/DCN OR RAGQMM/DCN OR RAGQMN/DCN OR
                RAGQMO/DCN OR RAGQMP/DCN OR RAGQMQ/DCN OR RAGQMS/DCN OR
                RAGQMT/DCN OR RAGQMU/DCN OR RAGQMV/DCN OR RAGQMW/DCN OR
                RAGQMX/DCN OR RAGQMY/DCN OR RAGQMZ/DCN OR RAGQN0/DCN OR
                RAGQN1/DCN OR RAGQN2/DCN OR RAGQN3/DCN OR RAGQN4/DCN OR
                RAGQN5/DCN OR RAHXNT/DCN OR RAQKGB/DCN OR RAQKGC/DCN OR
                RAQKGD/DCN OR RAQKGG/DCN OR RAQKGH/DCN OR RAQKGI/DCN OR
                RAQKGJ/DCN OR RAQKGK/DCN OR RAQKGL/DCN OR RAQKGM/DCN OR
                RAQKGN/DCN OR RAQKGO/DCN OR RAQKGP/DCN OR RAQKGQ/DCN OR
                RAQKGR/DCN OR RAQKGS/DCN OR RAQKGT/DCN OR RARI2C/DCN OR
                RARI2G/DCN OR RARI2H/DCN OR RARI27/DCN OR RA9ISR/DCN OR
                RA9ITM/DCN) OR L32/DCR
L34           1 SEA FILE=WPIX ABB=ON  PLU=ON  L33 AND (L24 OR L25)
L35           5 SEA FILE=WPIX ABB=ON  PLU=ON  L33 NOT L34


=> d his l49

     (FILE 'USPATFULL, USPATOLD, USPAT2' ENTERED AT 13:10:42 ON 02 OCT 2008)
L49           1 S L47 NOT L48

=> d que nos l49
L1            2 SEA FILE=HCAPLUS ABB=ON  PLU=ON  US2006-563708/APPS
L2            1 SEA FILE=HCAPLUS ABB=ON  PLU=ON  L1 NOT PIXEL/TI
L5              TRANSFER  PLU=ON  L2 1- RN :      37 TERMS
L6           37 SEA FILE=REGISTRY ABB=ON  PLU=ON  L5
L13             STR
L18     1320380 SEA FILE=REGISTRY ABB=ON  PLU=ON  N2C3/ES OR NCOC2/ES
L20          41 SEA FILE=REGISTRY SUB=L18 SSS FUL L13
L21          21 SEA FILE=REGISTRY ABB=ON  PLU=ON  L6 AND L20
L22           1 SEA FILE=REGISTRY ABB=ON  PLU=ON  L21 AND "C26 H25 F3 N4 O6
                S"/MF
L24             QUE  ABB=ON  PLU=ON  VEDANANDA, T?/AU
L25             QUE  ABB=ON  PLU=ON  NOVARTIS/CS,SO,PA
L36     3910521 SEA FILE=REGISTRY ABB=ON  PLU=ON  NCNC2/ES OR N2CNC/ES OR
                NCSC2/ES OR SC4/ES
L38          31 SEA FILE=REGISTRY SUB=L36 SSS FUL L13
L39             STR
L41          23 SEA FILE=REGISTRY SUB=L38 SSS FUL L39
L47           2 SEA L20 OR L22 OR L41
L48           1 SEA L47 AND (L24 OR L25)
```

```
L49           1 SEA L47 NOT L48


=> d que nos l52
L1            2 SEA FILE=HCAPLUS ABB=ON  PLU=ON  US2006-563708/APPS
L2            1 SEA FILE=HCAPLUS ABB=ON  PLU=ON  L1 NOT PIXEL/TI
L5              TRANSFER  PLU=ON  L2 1- RN :      37 TERMS
L6           37 SEA FILE=REGISTRY ABB=ON  PLU=ON  L5
L13             STR
L18     1320380 SEA FILE=REGISTRY ABB=ON  PLU=ON  N2C3/ES OR NCOC2/ES
L20          41 SEA FILE=REGISTRY SUB=L18 SSS FUL L13
L21          21 SEA FILE=REGISTRY ABB=ON  PLU=ON  L6 AND L20
L22           1 SEA FILE=REGISTRY ABB=ON  PLU=ON  L21 AND "C26 H25 F3 N4 O6
                S"/MF
L24             QUE  ABB=ON  PLU=ON  VEDANANDA, T?/AU
L25             QUE  ABB=ON  PLU=ON  NOVARTIS/CS,SO,PA
L36     3910521 SEA FILE=REGISTRY ABB=ON  PLU=ON  NCNC2/ES OR N2CNC/ES OR
                NCSC2/ES OR SC4/ES
L38          31 SEA FILE=REGISTRY SUB=L36 SSS FUL L13
L39             STR
L41          23 SEA FILE=REGISTRY SUB=L38 SSS FUL L39
L50           1 SEA FILE=TOXCENTER ABB=ON  PLU=ON  L20 OR L22 OR L41
L51           1 SEA FILE=TOXCENTER ABB=ON  PLU=ON  L50 AND (L24 OR L25)
L52           0 SEA FILE=TOXCENTER ABB=ON  PLU=ON  L50 NOT L51


=> d his l53

     (FILE 'MEDLINE, BIOSIS, EMBASE, BIOTECHNO, CABA, DRUGU, VETU' ENTERED AT
     13:12:48 ON 02 OCT 2008)
L53           0 S L20 OR L22 OR L41

=> d que l53
L1            2 SEA FILE=HCAPLUS ABB=ON  PLU=ON  US2006-563708/APPS
L2            1 SEA FILE=HCAPLUS ABB=ON  PLU=ON  L1 NOT PIXEL/TI
L5              TRANSFER  PLU=ON  L2 1- RN :      37 TERMS
L6           37 SEA FILE=REGISTRY ABB=ON  PLU=ON  L5
L13             STR
```




```
VAR G1=12/10
VPA 3-13/14/15/16/17/18 U
NODE ATTRIBUTES:
CONNECT IS E2  RC AT   2
CONNECT IS E2  RC AT  12
DEFAULT MLEVEL IS ATOM
GGCAT   IS UNS  AT   1
GGCAT   IS UNS  AT   7
DEFAULT ECLEVEL IS LIMITED
ECOUNT  IS X8 C  AT   2
```

GRAPH ATTRIBUTES:
RING(S) ARE ISOLATED OR EMBEDDED
NUMBER OF NODES IS 17

STEREO ATTRIBUTES: NONE
L18 1320380 SEA FILE=REGISTRY ABB=ON PLU=ON N2C3/ES OR NCOC2/ES
L20 41 SEA FILE=REGISTRY SUB=L18 SSS FUL L13
L21 21 SEA FILE=REGISTRY ABB=ON PLU=ON L6 AND L20
L22 1 SEA FILE=REGISTRY ABB=ON PLU=ON L21 AND "C26 H25 F3 N4 O6 S"/MF
L36 3910521 SEA FILE=REGISTRY ABB=ON PLU=ON NCNC2/ES OR N2CNC/ES OR NCSC2/ES OR SC4/ES
L38 31 SEA FILE=REGISTRY SUB=L36 SSS FUL L13
L39 STR



VAR G1=12/10
NODE ATTRIBUTES:
CONNECT IS E2 RC AT 2
CONNECT IS E2 RC AT 12
DEFAULT MLEVEL IS ATOM
DEFAULT ECLEVEL IS LIMITED
ECOUNT IS X8 C AT 2

GRAPH ATTRIBUTES:
RSPEC 19 13
NUMBER OF NODES IS 20

STEREO ATTRIBUTES: NONE
L41 23 SEA FILE=REGISTRY SUB=L38 SSS FUL L39
L53 0 SEA L20 OR L22 OR L41

=> d que stat l55
L39 STR



VAR G1=12/10
NODE ATTRIBUTES:
CONNECT IS E2 RC AT 2
CONNECT IS E2 RC AT 12
DEFAULT MLEVEL IS ATOM
DEFAULT ECLEVEL IS LIMITED

ECOUNT IS X8 C AT 2

GRAPH ATTRIBUTES:
RSPEC 19 13
NUMBER OF NODES IS 20

STEREO ATTRIBUTES: NONE
L55 5 SEA FILE=BEILSTEIN SSS FUL L39

100.0% PROCESSED 5282 ITERATIONS 5 ANSWERS
SEARCH TIME: 00.00.11

=> d que stat l57
L13 STR



VAR G1=12/10
VPA 3-13/14/15/16/17/18 U
NODE ATTRIBUTES:
CONNECT IS E2 RC AT 2
CONNECT IS E2 RC AT 12
DEFAULT MLEVEL IS ATOM
GGCAT IS UNS AT 1
GGCAT IS UNS AT 7
DEFAULT ECLEVEL IS LIMITED
ECOUNT IS X8 C AT 2

GRAPH ATTRIBUTES:
RING(S) ARE ISOLATED OR EMBEDDED
NUMBER OF NODES IS 17

STEREO ATTRIBUTES: NONE
L39 STR



VAR G1=12/10
NODE ATTRIBUTES:
CONNECT IS E2 RC AT 2
CONNECT IS E2 RC AT 12
DEFAULT MLEVEL IS ATOM
DEFAULT ECLEVEL IS LIMITED

```
ECOUNT  IS X8 C  AT   2

GRAPH ATTRIBUTES:
RSPEC  19  13
NUMBER OF NODES IS  20

STEREO ATTRIBUTES: NONE
L55           5 SEA FILE=BEILSTEIN SSS FUL L39
L57           5 SEA FILE=BEILSTEIN SUB=L55 SSS FUL L13

100.0% PROCESSED       5 ITERATIONS                              5 ANSWERS
SEARCH TIME: 00.00.02



=> d que stat l59
L39             STR
```




```
VAR G1=12/10
NODE ATTRIBUTES:
CONNECT IS E2  RC AT   2
CONNECT IS E2  RC AT  12
DEFAULT MLEVEL IS ATOM
DEFAULT ECLEVEL IS LIMITED
ECOUNT  IS X8 C  AT   2

GRAPH ATTRIBUTES:
RSPEC  19  13
NUMBER OF NODES IS  20

STEREO ATTRIBUTES: NONE
L59           0 SEA FILE=CHEMINFORMRX SSS FUL L39 (     0 REACTIONS)

100.0% DONE    1308 VERIFIED       0 HIT RXNS                        0 DOCS
SEARCH TIME: 00.00.13



=> d que l46
L1            2 SEA FILE=HCAPLUS ABB=ON  PLU=ON  US2006-563708/APPS
L2            1 SEA FILE=HCAPLUS ABB=ON  PLU=ON  L1 NOT PIXEL/TI
L5              TRANSFER  PLU=ON  L2 1- RN :      37 TERMS
L6           37 SEA FILE=REGISTRY ABB=ON  PLU=ON  L5
L13             STR
```



VAR G1=12/10
VPA 3-13/14/15/16/17/18 U
NODE ATTRIBUTES:
CONNECT IS E2 RC AT 2
CONNECT IS E2 RC AT 12
DEFAULT MLEVEL IS ATOM
GGCAT IS UNS AT 1
GGCAT IS UNS AT 7
DEFAULT ECLEVEL IS LIMITED
ECOUNT IS X8 C AT 2

GRAPH ATTRIBUTES:
RING(S) ARE ISOLATED OR EMBEDDED
NUMBER OF NODES IS 17

STEREO ATTRIBUTES: NONE
L18 1320380 SEA FILE=REGISTRY ABB=ON PLU=ON N2C3/ES OR NCOC2/ES
L20 41 SEA FILE=REGISTRY SUB=L18 SSS FUL L13
L21 21 SEA FILE=REGISTRY ABB=ON PLU=ON L6 AND L20
L22 1 SEA FILE=REGISTRY ABB=ON PLU=ON L21 AND "C26 H25 F3 N4 O6 S"/MF
L24 QUE ABB=ON PLU=ON VEDANANDA, T?/AU
L25 QUE ABB=ON PLU=ON NOVARTIS/CS,SO,PA
L26 2 SEA FILE=HCAPLUS ABB=ON PLU=ON L20
L27 1 SEA FILE=HCAPLUS ABB=ON PLU=ON L22
L28 2 SEA FILE=HCAPLUS ABB=ON PLU=ON (L26 OR L27)
L29 1 SEA FILE=HCAPLUS ABB=ON PLU=ON L28 AND (L24 OR L25)
L30 1 SEA FILE=HCAPLUS ABB=ON PLU=ON L28 NOT L29
L36 3910521 SEA FILE=REGISTRY ABB=ON PLU=ON NCNC2/ES OR N2CNC/ES OR NCSC2/ES OR SC4/ES
L38 31 SEA FILE=REGISTRY SUB=L36 SSS FUL L13
L39 STR



VAR G1=12/10
NODE ATTRIBUTES:
CONNECT IS E2 RC AT 2
CONNECT IS E2 RC AT 12
DEFAULT MLEVEL IS ATOM
DEFAULT ECLEVEL IS LIMITED
ECOUNT IS X8 C AT 2

```
GRAPH ATTRIBUTES:
RSPEC  19  13
NUMBER OF NODES IS  20

STEREO ATTRIBUTES: NONE
L41          23 SEA FILE=REGISTRY SUB=L38 SSS FUL L39
L42           3 SEA FILE=HCAPLUS ABB=ON  PLU=ON  L41
L43           0 SEA FILE=HCAPLUS ABB=ON  PLU=ON  L42 AND (L24 OR L25)
L44           1 SEA FILE=HCAPLUS ABB=ON  PLU=ON  L29 OR L43
L45           3 SEA FILE=HCAPLUS ABB=ON  PLU=ON  L42 NOT L44
L46           3 SEA FILE=HCAPLUS ABB=ON  PLU=ON  L45 OR L30


=> dup rem l46 l35 l49 l52 l57 l59
L52 HAS NO ANSWERS
L59 HAS NO ANSWERS
DUPLICATE IS NOT AVAILABLE IN 'BEILSTEIN, CHEMINFORMRX'.
ANSWERS FROM THESE FILES WILL BE CONSIDERED UNIQUE
FILE 'HCAPLUS' ENTERED AT 13:27:49 ON 02 OCT 2008
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2008 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'WPIX' ENTERED AT 13:27:49 ON 02 OCT 2008
COPYRIGHT (C) 2008 THOMSON REUTERS

FILE 'USPATFULL' ENTERED AT 13:27:49 ON 02 OCT 2008
CA INDEXING COPYRIGHT (C) 2008 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'BEILSTEIN' ENTERED AT 13:27:49 ON 02 OCT 2008
COPYRIGHT (c) 2008 Beilstein-Institut zur Foerderung der Chemischen Wissenschaften
licensed to Beilstein GmbH and MDL Information Systems GmbH
PROCESSING COMPLETED FOR L46
PROCESSING COMPLETED FOR L35
PROCESSING COMPLETED FOR L49
PROCESSING COMPLETED FOR L52
PROCESSING COMPLETED FOR L57
PROCESSING COMPLETED FOR L59
L62          13 DUP REM L46 L35 L49 L52 L57 L59 (1 DUPLICATE REMOVED)
                ANSWERS '1-3' FROM FILE HCAPLUS
                ANSWERS '4-7' FROM FILE WPIX
                ANSWER '8' FROM FILE USPATFULL
                ANSWERS '9-13' FROM FILE BEILSTEIN


=> file stnguide
FILE 'STNGUIDE' ENTERED AT 13:28:02 ON 02 OCT 2008
USE IS SUBJECT TO THE TERMS OF YOUR CUSTOMER AGREEMENT
COPYRIGHT (C) 2008 AMERICAN CHEMICAL SOCIETY (ACS)

FILE CONTAINS CURRENT INFORMATION.
LAST RELOADED: Sep 26, 2008 (20080926/UP).
```

```
=> d ibib ed abs hitstr 1-3
YOU HAVE REQUESTED DATA FROM FILE 'WPIX, HCAPLUS, USPATFULL, BEILSTEIN' - CONTINUE?
(Y)/N:y



L62  ANSWER 1 OF 13  HCAPLUS  COPYRIGHT 2008 ACS on STN DUPLICATE 1
ACCESSION NUMBER:         2007:410236  HCAPLUS  Full-text
DOCUMENT NUMBER:          146:401987
TITLE:                    Preparation of N-(1,3,4-thiadiazol-2-yl)benzene
                          sulfonamides as PPAR alpha, delta and gamma agonist
INVENTOR(S):              Keil, Stefanie; Schoenafinger, Karl; Matter, Hans;
                          Urmann, Matthias; Glien, Maike; Wendler, Wolfgang;
                          Schaefer, Hans-Ludwig; Falk, Eugen
PATENT ASSIGNEE(S):       Sanofi-Aventis Deutschland GmbH, Germany
SOURCE:                   PCT Int. Appl., 92pp.
                          CODEN: PIXXD2
DOCUMENT TYPE:            Patent
LANGUAGE:                 English
FAMILY ACC. NUM. COUNT:   1
PATENT INFORMATION:

     PATENT NO.           KIND   DATE        APPLICATION NO.         DATE
     ---------------      ----   --------    --------------------    --------
     WO 2007039171         A1    20070412    WO 2006-EP9297          20060926
         W:  AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH,
             CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD,
             GE, GH, GM, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP,
             KR, KZ, LA, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN,
             MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS,
             RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ,
             UA, UG, US, UZ, VC, VN, ZA, ZM, ZW
         RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE,
             IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ,
             CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH,
             GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY,
             KG, KZ, MD, RU, TJ, TM
     AU 2006299085         A1    20070412    AU 2006-299085          20060926
     CA 2624726            A1    20070412    CA 2006-2624726         20060926
     EP 1937658            A1    20080702    EP 2006-805856          20060926
         R:  AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE,
             IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, AL,
             BA, HR, MK, RS
     MX 200804341          A     20080416    MX 2008-4341            20080401
     KR 2008053931         A     20080616    KR 2008-708301          20080404
PRIORITY APPLN. INFO.:                       EP 2005-21786       A   20051006
                                             WO 2006-EP9297      W   20060926
OTHER SOURCE(S):          MARPAT 146:401987
ED   Entered STN:  13 Apr 2007
GI
```



I



II

AB Title compds. represented by the formula I [wherein R1 = alkyl, alkylene-cycloalkyl, alkylene-aryl, etc.; R2, R3 = independently H, halo, CN, etc.; R4-R7 = independently H, alkyl, alkylene-aryl, etc.; m = 0 or 1; ring A = (hetero)aryl; ring B = (hetero)aryl or cycloalkyl; Z = a bond, O, absent, etc.; R8, R9 = independently H, halo, alkyl, etc.; p = 0-3; n = 0-2; and their stereoisomers, enantiomers, or physiol. acceptable salts or tautomers thereof] were prepared as PPAR α, δ and γ agonist. 6For example, II was provided in a multi-step synthesis starting from p-phenolsulfonic acid sodium salt. I showed agonic activity of PPAR α, δ and γ with EC50 values of 100 nM 10 μM, 200 nM - 10 μM and 1 nM - 10 μM. Thus, I and their pharmaceutical compns. are useful for the treatment and/or prevention of disorders of fatty acid metabolism and glucose utilization disorders as well as of disorders in which insulin resistance is involved and demyelinating and other neurodegenerative disorders of the central and peripheral nervous system.

IT 933786-85-7P, N-(5-Isopropyl-[1,3,4]thiadiazol-2-yl)-4-[[4-methyl-2-(4-trifluoromethylphenyl)thiazol-5-yl]methoxy]benzenesulfonamide 933786-91-5P, N-(5-Isopropyl-[1,3,4]thiadiazol-2-yl)-4-[[4-methyl-2-(3-trifluoromethylphenyl)thiazol-5-yl]methoxy]benzenesulfonamide 933786-95-9P, 4-[[4-Butyl-2-(4-trifluoromethylphenyl)thiazol-5-yl]methoxy]-N-(5-isopropyl-[1,3,4]thiadiazol-2-yl)benzenesulfonamide 933786-96-0P, N-(5-Isopropyl-[1,3,4]thiadiazol-2-yl)-4-[[5-methyl-2-(4-phenoxyphenyl)oxazol-4-yl]methoxy]benzenesulfonamide 933786-97-1P, 4-[(2-Cyclohexyloxazol-4-yl)methoxy]-N-(5-isopropyl-[1,3,4]thiadiazol-2-yl)benzenesulfonamide 933786-99-3P, N-(5-Isopropyl-[1,3,4]thiadiazol-2-yl)-4-[[2-(4-methoxyphenyl)-5-methyloxazol-4-yl]methoxy]benzenesulfonamide 933787-00-9P, 4-[[2-(Biphenyl-4-yl)-5-methyloxazol-4-yl]methoxy]-N-(5-isopropyl-[1,3,4]thiadiazol-2-yl)benzenesulfonamide 933787-02-1P, N-(5-Isopropyl-[1,3,4]thiadiazol-2-yl)-4-[[2-(4-methoxyphenyl)oxazol-4-yl]methoxy]benzenesulfonamide 933787-06-5P, 4-[[5-Ethyl-2-(3-trifluoromethylphenyl)oxazol-4-yl]methoxy]-N-(5-isopropyl-[1,3,4]thiadiazol-2-yl)benzenesulfonamide 933787-07-6P, N-(5-Isopropyl-[1,3,4]thiadiazol-2-yl)-4-[[5-methyl-2-(4-trifluoromethoxyphenyl)oxazol-4-yl]methoxy]benzenesulfonamide 933787-08-7P, N-(5-Isopropyl-[1,3,4]thiadiazol-2-yl)-4-[[5-isopropyl-2-(4-trifluoromethylphenyl)oxazol-4-yl]methoxy]benzenesulfonamide 933787-09-8P, 4-[[5-Ethyl-2-(2-trifluoromethylphenyl)oxazol-4-yl]methoxy]-N-(5-isopropyl-[1,3,4]thiadiazol-2-yl)benzenesulfonamide 933787-10-1P, 4-[2-[5-Methyl-2-(4-trifluoromethylphenyl)thiazol-4-yl]ethoxy]-N-(5-trifluoromethyl-[1,3,4]thiadiazol-2-yl)benzenesulfonamide

933787-12-3P, N-(5-Isopropyl-[1,3,4]thiadiazol-2-yl)-4-[2-[5-methyl-2-(4-trifluoromethylphenyl)oxazol-4-yl]ethoxy]benzenesulfonamide
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of N-(1,3,4-thiadiazol-2-yl)benzene sulfonamides as PPAR α, δ and γ agonist)

RN 933786-85-7 HCAPLUS
CN Benzenesulfonamide, N-[5-(1-methylethyl)-1,3,4-thiadiazol-2-yl]-4-[[4-methyl-2-[4-(trifluoromethyl)phenyl]-5-thiazolyl]methoxy]- (CA INDEX NAME)



RN 933786-91-5 HCAPLUS
CN Benzenesulfonamide, N-[5-(1-methylethyl)-1,3,4-thiadiazol-2-yl]-4-[[4-methyl-2-[3-(trifluoromethyl)phenyl]-5-thiazolyl]methoxy]- (CA INDEX NAME)



RN 933786-95-9 HCAPLUS
CN Benzenesulfonamide, 4-[[4-butyl-2-[4-(trifluoromethyl)phenyl]-5-thiazolyl]methoxy]-N-[5-(1-methylethyl)-1,3,4-thiadiazol-2-yl]- (CA INDEX NAME)



RN 933786-96-0 HCAPLUS
CN Benzenesulfonamide, N-[5-(1-methylethyl)-1,3,4-thiadiazol-2-yl]-4-[[5-methyl-2-(4-phenoxyphenyl)-4-oxazolyl]methoxy]- (CA INDEX NAME)



RN 933786-97-1 HCAPLUS
CN Benzenesulfonamide, 4-[(2-cyclohexyl-4-oxazolyl)methoxy]-N-[5-(1-methylethyl)-1,3,4-thiadiazol-2-yl]- (CA INDEX NAME)



RN 933786-99-3 HCAPLUS
CN Benzenesulfonamide, 4-[[2-(4-methoxyphenyl)-5-methyl-4-oxazolyl]methoxy]-N-[5-(1-methylethyl)-1,3,4-thiadiazol-2-yl]- (CA INDEX NAME)



RN 933787-00-9 HCAPLUS
CN Benzenesulfonamide, 4-[(2-[1,1'-biphenyl]-4-yl-5-methyl-4-oxazolyl)methoxy]-N-[5-(1-methylethyl)-1,3,4-thiadiazol-2-yl]- (CA INDEX NAME)



RN 933787-02-1 HCAPLUS

CN Benzenesulfonamide, 4-[[2-(4-methoxyphenyl)-4-oxazolyl]methoxy]-N-[5-(1-methylethyl)-1,3,4-thiadiazol-2-yl]- (CA INDEX NAME)



RN 933787-06-5 HCAPLUS

CN Benzenesulfonamide, 4-[[5-ethyl-2-[3-(trifluoromethyl)phenyl]-4-oxazolyl]methoxy]-N-[5-(1-methylethyl)-1,3,4-thiadiazol-2-yl]- (CA INDEX NAME)



RN 933787-07-6 HCAPLUS

CN Benzenesulfonamide, N-[5-(1-methylethyl)-1,3,4-thiadiazol-2-yl]-4-[[5-methyl-2-[4-(trifluoromethoxy)phenyl]-4-oxazolyl]methoxy]- (CA INDEX NAME)



RN 933787-08-7 HCAPLUS

CN Benzenesulfonamide, N-[5-(1-methylethyl)-1,3,4-thiadiazol-2-yl]-4-[[5-(1-methylethyl)-2-[4-(trifluoromethyl)phenyl]-4-oxazolyl]methoxy]- (CA INDEX NAME)



RN 933787-09-8 HCAPLUS
CN Benzenesulfonamide, 4-[[5-ethyl-2-[2-(trifluoromethyl)phenyl]-4-oxazolyl]methoxy]-N-[5-(1-methylethyl)-1,3,4-thiadiazol-2-yl]- (CA INDEX NAME)



RN 933787-10-1 HCAPLUS
CN Benzenesulfonamide, 4-[2-[5-methyl-2-[4-(trifluoromethyl)phenyl]-4-thiazolyl]ethoxy]-N-[5-(trifluoromethyl)-1,3,4-thiadiazol-2-yl]- (CA INDEX NAME)



RN 933787-12-3 HCAPLUS
CN Benzenesulfonamide, N-[5-(1-methylethyl)-1,3,4-thiadiazol-2-yl]-4-[2-[5-methyl-2-[4-(trifluoromethyl)phenyl]-4-oxazolyl]ethoxy]- (CA INDEX NAME)



IT 933786-90-4P, N-(5-Isopropyl-[1,3,4]thiadiazol-2-yl)-4-[[4-methyl-2-(4-trifluoromethylphenyl)thiazol-5-yl]methoxy]-N-[[2-(trimethylsilanyl)ethoxy]methyl]benzenesulfonamide
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of N-(1,3,4-thiadiazol-2-yl)benzene sulfonamides as PPAR α, δ and γ agonist)
RN 933786-90-4 HCAPLUS

CN Benzenesulfonamide, N-[5-(1-methylethyl)-1,3,4-thiadiazol-2-yl]-4-[[4-methyl-2-[4-(trifluoromethyl)phenyl]-5-thiazolyl]methoxy]-N-[[2-(trimethylsilyl)ethoxy]methyl]- (CA INDEX NAME)



REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L62 ANSWER 2 OF 13 HCAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2003:809341 HCAPLUS Full-text
DOCUMENT NUMBER: 139:323513
TITLE: Preparation of sulfonamides and their use as anti-HIV agents
INVENTOR(S): Yamamoto, Osamu; Fujii, Masahiro; Ogami, Tetsuro; Masuda, Naoyuki; Fujiyasu, Jiro; Kontani, Toru; Moritomo, Ayako; Kageyama, Toshiharu; Inoe, Hiroshi; Hatta, Toshifumi; Kodama, Eiichi; Matsuoka, Masao
PATENT ASSIGNEE(S): Yamanouchi Pharmaceutical Co., Ltd., Japan; Soyaku Gijutsu Kenkyusho K. K.
SOURCE: Jpn. Kokai Tokkyo Koho, 52 pp.
CODEN: JKXXAF
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 2003292485	A	20031015	JP 2002-98332	20020401

PRIORITY APPLN. INFO.: JP 2002-98332 20020401
OTHER SOURCE(S): MARPAT 139:323513
ED Entered STN: 15 Oct 2003
GI



I

AB Sulfonamides I [the broken lines may be bond; at least one of them is bond; R1, R2 = none, H, lower (halo)alkyl, lower alkylene-OH, lower alkylene-heterocyclyl, lower alkylene-CO2H, etc.; X = O, S; ring A = (un)substituted (hetero)aryl; ring B = (un)substituted N-containing heterocyclyl] or their salts are prepared Thus, 2-amino-5-tert-butyl-4- methylthiazole HCl salt was

condensed with 3-nitrobenzenesulfonyl chloride to give N-(5-tert-butyl-4-methylthiazol-2-yl)-3-nitrobenzenesulfonamide, which was treated with NaH and MeI to afford N-(5-tert-butyl-3,4-dimethyl- 2,3-dihydrothiazol-2-ylidene)-3-nitrobenzenesulfonamide. The product inhibited reverse transcriptase of wild type, Y181C mutant, and K103N mutant HIV-1 with IC50 values of 0.27, 0.066, and 13 μM, resp.

IT 612537-28-7P
RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(preparation of sulfonamides as reverse transcriptase inhibitors and anti-HIV agents)

RN 612537-28-7 HCAPLUS
CN Benzenesulfonamide, 5-chloro-N-[5-(1,1-dimethylethyl)-3,4-dimethyl-2(3H)-thiazolylidene]-2-[[1-(triphenylmethyl)-1H-imidazol-5-yl]methoxy]- (CA INDEX NAME)



IT 612537-29-8P 612537-41-4P 612537-57-2P
612537-58-3P 612537-66-3P 612537-70-9P
612537-73-2P 612537-82-3P 612537-86-7P
612538-93-9P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of sulfonamides as reverse transcriptase inhibitors and anti-HIV agents)

RN 612537-29-8 HCAPLUS
CN Benzenesulfonamide, 5-chloro-N-[5-(1,1-dimethylethyl)-3,4-dimethyl-2(3H)-thiazolylidene]-2-(1H-imidazol-5-ylmethoxy)- (CA INDEX NAME)



RN 612537-41-4 HCAPLUS
CN Benzenesulfonamide, 5-chloro-N-[5-(1,1-dimethylethyl)-3,4-dimethyl-2(3H)-thiazolylidene]-2-[(4-methyl-2-thiazolyl)methoxy]- (CA INDEX NAME)



RN 612537-57-2 HCAPLUS
CN Benzenesulfonamide, 5-chloro-N-[5-(1,1-dimethylethyl)-3,4-dimethyl-2(3H)-thiazolylidene]-2-(2-thienylmethoxy)- (CA INDEX NAME)



RN 612537-58-3 HCAPLUS
CN Benzenesulfonamide, 5-chloro-N-[5-(1,1-dimethylethyl)-3,4-dimethyl-2(3H)-thiazolylidene]-2-(3-thienylmethoxy)- (CA INDEX NAME)



RN 612537-66-3 HCAPLUS
CN Benzenesulfonamide, 5-bromo-N-[5-(1,1-dimethylethyl)-3,4-dimethyl-2(3H)-thiazolylidene]-2-(1H-imidazol-5-ylmethoxy)- (CA INDEX NAME)



RN 612537-70-9 HCAPLUS
CN Benzenesulfonamide, 5-bromo-N-[5-(1,1-dimethylethyl)-3,4-dimethyl-2(3H)-thiazolylidene]-2-(2H-tetrazol-5-ylmethoxy)- (CA INDEX NAME)



RN 612537-73-2 HCAPLUS
CN Benzenesulfonamide, 5-bromo-N-[5-(1,1-dimethylethyl)-3,4-dimethyl-2(3H)-thiazolylidene]-2-(1,2,4-oxadiazol-3-ylmethoxy)- (CA INDEX NAME)



RN 612537-82-3 HCAPLUS
CN Benzenesulfonamide, 5-bromo-N-[5-(1,1-dimethylethyl)-3,4-dimethyl-2(3H)-thiazolylidene]-2-[2-(1H-imidazol-5-yl)ethoxy]- (CA INDEX NAME)



RN 612537-86-7 HCAPLUS
CN Benzenesulfonamide, 5-bromo-N-[5-(1,1-dimethylethyl)-3,4-dimethyl-2(3H)-thiazolylidene]-2-[(1-methyl-1H-imidazol-5-yl)methoxy]-, hydrochloride, hydrate (1:1:2) (CA INDEX NAME)





RN 612538-93-9 HCAPLUS
CN Benzenesulfonamide, 5-bromo-N-[4-chloro-3-methyl-5-(1-methylethyl)-2(3H)-thiazolylidene]-2-(2-furanylmethoxy)- (CA INDEX NAME)



IT 612540-93-9
RL: RCT (Reactant); RACT (Reactant or reagent)
(preparation of sulfonamides as reverse transcriptase inhibitors and anti-HIV agents)
RN 612540-93-9 HCAPLUS
CN Benzenesulfonamide, 5-bromo-N-[5-(1,1-dimethylethyl)-3,4-dimethyl-2(3H)-thiazolylidene]-2-[[1-(triphenylmethyl)-1H-imidazol-5-yl]methoxy]- (CA INDEX NAME)



L62 ANSWER 3 OF 13 HCAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 1992:235529 HCAPLUS Full-text
DOCUMENT NUMBER: 116:235529
ORIGINAL REFERENCE NO.: 116:39897a,39900a
TITLE: Synthesis and antifungal activity of some N-substituted benzenesulfonamides pendant with 2-thioxo-1,3,4-oxadiazoles, 3-mercapto-4-phenyl-1,2,4(H)-triazoles
AUTHOR(S): Vidyasagar, A.; Dave, A. M.; Mehta, M. H.; Agrawal, Y. K.
CORPORATE SOURCE: Res. Cent., Gujarat State Fert. Co. Ltd., Baroda, 391 750, India
SOURCE: Journal of the Indian Chemical Society (1991), 68(10), 576-8
CODEN: JICSAH; ISSN: 0019-4522
DOCUMENT TYPE: Journal
LANGUAGE: English
OTHER SOURCE(S): CASREACT 116:235529
ED Entered STN: 13 Jun 1992
GI



I



II



III

AB Title oxadiazole I was prepared by the cyclization of acid hydrazide II with CS2 in presence of KOH. Title triazoles III (R = H, Cl, Me, OMe) were similarly prepared by the reaction of II with 4-RC6H4NCS in presence of NaOH. I and III were tested for antifungal activity, and were active.

IT 141233-24-1P 141233-25-2P 141233-26-3P 141233-27-4P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
(preparation and antifungal activity of)

RN 141233-24-1 HCAPLUS

CN Benzenesulfonamide, 4-[(4,5-dihydro-4-phenyl-5-thioxo-1H-1,2,4-triazol-3-yl)methoxy]-N-(5-methyl-3-isoxazolyl)- (CA INDEX NAME)



RN 141233-25-2 HCAPLUS
CN Benzenesulfonamide, 4-[[4-(4-chlorophenyl)-4,5-dihydro-5-thioxo-1H-1,2,4-triazol-3-yl]methoxy]-N-(5-methyl-3-isoxazolyl)- (CA INDEX NAME)



RN 141233-26-3 HCAPLUS
CN Benzenesulfonamide, 4-[[4,5-dihydro-4-(4-methoxyphenyl)-5-thioxo-1H-1,2,4-triazol-3-yl]methoxy]-N-(5-methyl-3-isoxazolyl)- (CA INDEX NAME)



RN 141233-27-4 HCAPLUS
CN Benzenesulfonamide, 4-[[4,5-dihydro-4-(4-methylphenyl)-5-thioxo-1H-1,2,4-triazol-3-yl]methoxy]-N-(5-methyl-3-isoxazolyl)- (CA INDEX NAME)



```
=> d iall abeq tech abex hitstr 4-7
YOU HAVE REQUESTED DATA FROM FILE 'WPIX, HCAPLUS, USPATFULL, BEILSTEIN' - CONTINUE?
(Y)/N:y



L62  ANSWER 4 OF 13  WPIX COPYRIGHT 2008       THOMSON REUTERS on STN
ACCESSION NUMBER:     2007-797043 [74]   WPIX
CROSS REFERENCE:      2007-797042; 2007-797044
DOC. NO. CPI:         C2007-276390 [74]
TITLE:                New carbonyl compound useful in the treatment of disease
                      ameliorated by modulation of histone deacetylase e.g.
                      cancer and autoimmune disease
DERWENT CLASS:        B05
INVENTOR:             BONNEFOUS C; HASSIG C A; HOFFMAN T Z; PAYNE J E; SCRANTON
                      S A; SMITH N D; WASH P L
PATENT ASSIGNEE:      (KALY-N) KALYPSYS INC
COUNTRY COUNT:        116

PATENT INFORMATION:

      PATENT NO      KIND DATE     WEEK     LA  PG          MAIN IPC
      ------------------------------------------------------------------
      WO 2007067994   A1 20070614 (200774)* EN  62[0]
      US 20070135431  A1 20070614 (200774)  EN

APPLICATION DETAILS:

      PATENT NO      KIND                   APPLICATION    DATE
      ------------------------------------------------------------------
      WO 2007067994 A1                      WO 2006-US61821 20061208
      US 20070135431 A1 Provisional         US 2005-748823P 20051209
      US 20070135431 A1 Provisional         US 2006-802823P 20060522
      US 20070135431 A1                     US 2006-608726 20061208

PRIORITY APPLN. INFO: US 2006-802823P      20060522
                      US 2005-748823P      20051209
                      US 2006-608726       20061208
INT. PATENT CLASSIF.:
   IPC ORIGINAL:      A61K0031-44 [I,A]; A61K0031-44 [I,C]; A61K0031-4427 [I,C]
                      ; A61K0031-4439 [I,A]; A61K0031-4523 [I,C]; A61K0031-454
                      [I,A]; A61K0031-5375 [I,C]; A61K0031-5377 [I,A];
                      A61P0035-00 [I,A]; A61P0035-00 [I,C]; C07C0323-00 [I,C];
                      C07C0323-29 [I,A]; C07D0209-00 [I,C]; C07D0209-08 [I,A];
                      C07D0213-00 [I,C]; C07D0213-76 [I,A]; C07D0231-00 [I,C];
                      C07D0231-12 [I,A]; C07D0235-00 [I,C]; C07D0235-06 [I,A];
                      C07D0239-00 [I,C]; C07D0239-26 [I,A]; C07D0239-42 [I,A];
                      C07D0271-00 [I,C]; C07D0271-12 [I,A]; C07D0277-00 [I,C];
                      C07D0277-62 [I,A]; C07D0311-00 [I,C]; C07D0311-14 [I,A];
                      C07D0311-70 [I,A]; C07D0401-00 [I,C]; C07D0401-12 [I,A];
                      C07D0401-14 [I,A]; C07D0413-00 [I,C]; C07D0413-14 [I,A]
ECLA:                 C07D0211-46; C07D0213-30C; C07D0213-38; C07D0213-76D;
                      C07D0295-08A3; C07D0295-08A4; C07D0295-22C2; C07D0401-12;
                      C07D0413-12
USCLASS NCLM:         514/235.200
        NCLS:         514/326.000; 514/340.000; 544/124.000; 546/207.000;
```

546/277.100

BASIC ABSTRACT:

WO 2007067994 A1 UPAB: 20071119

NOVELTY - A carbonyl compound, or its salt, ester or prodrug is new.

DETAILED DESCRIPTION - A carbonyl compound of formula G5-G4-G3-G2-G1(CO)C(R1R2)-S-G6 (I), or its salt, ester, or prodrug is new.

G1=5 or 6-membered (hetero)aryl (optionally substituted);

G2=N-sulfonamide moiety of formula -S(O2)N(R3)-, S-sulfonamide moiety of formula -N(R4)S(O2)-, amide of form -NR3C(O)- or amide of form -C(O)NR3-;

G3=phenyl, 5 or 6-membered (hetero)aryl (all optionally substituted);

R1 and R2=H, lower alkyl, halogen or perhaloalkyl;

R1+R2=(hetero)cycloalkyl (optionally substituted);

R3 and R4=lower alkyl, aryl (both optionally substituted) or H;

G4=-(CR5R6)m-, -(X1)n1O(X2)n2-, -(X1)n1NR7(X2)n2-, -SO2-, -(X1)n1C(O)NR7(X2)n2- or -(X1)n1NR7C(O)(X2)n2 (all optionally substituted with R9S attached to any carbon atom);

R5 and R6=lower alkyl, lower alkoxy, aryl, lower perhaloalkyl (all optionally substituted) or H;

R7=lower alkyl, heteroalkyl, lower alkoxy (all optionally substituted) or H;

R9=lower alkyl, lower alkylene, lower alkynylene, lower alkoxy, lower amine, halogen, lower perhaloalkyl or hydroxyl;

m=1 - 6;

X1 and X2=lower alkylene, alkenylene or alkynylene (all optionally substituted);

n1 and n2=0 - 5;

G5=aryl, heteroaryl, cycloalkyl, heterocycloalkyl, fused aryl, fused heteroaryl, fused heterocycloalkyl or fused cycloalkyl (all optionally substituted);

G6=acyl, aryl, alkyl, heteroaryl, alkylthio, arylthio, heteroarylthio (all optionally substituted) or H.

An INDEPENDENT CLAIM is included for treating a histone deacetylase (HDAC)-related disease in a patient involving administration of the compound (I), and optionally chemotherapeutic agent.

ACTIVITY - Cytostatic; Neuroprotective; Immunosuppressive; Dermatological; Ophthalmological; Osteopathic; Cardiovascular-Gen; CNS-Gen; Antiinflammatory; Osteopathic; Antianemic; Antiangiogenic; Antisickling; Anticonvulsant; Analgesic; Antidepressant; Neuroleptic; Cardiant; Antipsoriatic; Nootropic; Antiarthritic; Gastrointestinal-Gen.; Antirheumatic; Antiulcer.

MECHANISM OF ACTION - Histone deacetylase (HDAC) inhibitor. Thioacetic acid S-(2-oxo-2-(4-(4-O-tolyloxy-benzenesulfonylamino)-phenyl)- ethyl)ester (Ie) was evaluate to inhibit acetyl-lysine deacetylation in vitro and was used as both a primary screening and for IC50 determination of confirmed inhibitors. In vitro HDAC-inhibition assay was performed in vitro using an HDAC enzyme source (e.g. partially purified nuclear extract or immuno-purified HDAC complexes) and a proprietary fluorescent substrate/developer system. The assay was run in 1536-well Greiner white-bottom plates by adding enzyme (2.5 mul) source, (Ie) (50 mul) with pin transfer device, and Fluor deLys (2.5 mul) substrate incubate at room temperature for 30 minutes. (Ie) showed IC50 value of less than or equal to 1 muM.

USE - In the manufacture of a medicament for the prevention or treatment of a disease or condition ameliorated by the modulation of histone deacetylase (HDAC) disease in a patient; for inhibiting the catalytic activity of HDAC; for treating multiple myeloma, hyperproliferative condition (including hematologic cancer (e.g. multiple myeloma, leukemia, and lymphomas) and nonhematologic cancers), neurological disorder, cardiovascular condition, autoimmune disease, dermatologic disorder, and ophthalmologic disorder (claimed); for treating disease states e.g. tissue damage, central nervous system disorders, neurodegenerative disorders, fibrosis, bone disorders,

polyglutamine-repeat disorders, anemias, thalassemias, inflammatory conditions, disorders in which angiogenesis plays a role in pathogenesis; for treating cancer of e.g. oral cavity and pharynx, respiratory system, skin, Wilm's tumor and epithelial ovarian cancer; for treating hematologic disorder (e.g. sickle cell anemia, myelodysplastic disorders (MDS), and myeloproliferative disorders (such as polycythemia vera, myelofibrosis and thrombocythemia)); for treating neurological disorder (e.g. epilepsy, neuropathic pain, depression and bipolar disorders); for treating cardiovascular conditions (e.g. cardiac hypertrophy, idiopathic cardiomyopathies, and heart failure); for treating autoimmune disease (e.g. systemic lupus erythromatosus, multiple sclerosis, and systemic lupus nephritis); for treating dermatologic disorder (e.g. psoriasis, melanoma, basal cell carcinoma, squamous cell carcinoma, and other non-epithelial skin cancers); for treating ophthalmologic disorder (e.g. dry eye, closed angle glaucoma and wide angle glaucoma); for treating polyglutamine-repeat disorder (e.g. Huntington's disease, Spinocerebellar ataxia 1 (SCA 1), Machado-Joseph disease (MJD)/Spinocerebella ataxia 3 (SCA 3), Kennedy disease/Spinal and bulbar muscular atrophy (SBMA) and Dentatorubral pallidolusyian atrophy (DRPLA)); and for treating inflammatory condition (e.g. rheumatoid arthritis, inflammatory bowel disease (IBD), ulcerative colitis and psoriasis).

ADVANTAGE - The compound effectively inhibits catalytic activity of histone deacetylase, and effectively treats cancer and autoimmune disease without any side effects.

MANUAL CODE: CPI: B01-B01; B01-B02; B02-D; B02-T; B04-G01; B05-B01A; B06-D03; B06-H; B07-H; B10-A08; B10-A10; B10-B01; B10-B02; B10-B04; B10-D03; B14-C01; B14-C03; B14-C09B; B14-D08; B14-E08; B14-E10C; B14-F01; B14-F02; B14-F04; B14-F08; B14-G02D; B14-H01; B14-H05; B14-J01; B14-J07; B14-N01; B14-N03; B14-N10; B14-N17; B14-S01; B14-S16

TECH

ORGANIC CHEMISTRY - Preparation (Disclosed): 5 methods for preparation of (I) are given e.g. reacting 4-iodo-benzenesulfonyl chloride with 1-(4-amino-phenyl)-ethanone in the presence of pyridine, tetrahydro furan (THF) at 40degreesC for 6 hours to form 1-(4-amino-phenyl)-ethanone (Ia); reacting (Ia) in the presence of alcohol of formula (R100OH), copper iodide, 1,10-phenanthroline and cesium carbonate at 120degreesC for 24 hours to form benzenesulfonamide compound of formula (Ib); reacting (Ib) in the presence of trimethylphenylammonium tribromide, THF at 50degreesC for 5 hours or in the presence of hydrogen bromide/acetic acid, trimethylphenylammonium tribromide, methylene dichloride, methanol, THF at room temperature for 30 minutes to yield amide compound of formula (Ic); reacting (Ic) with potassium thioacetate, methanol at room temperature for 18 hours to form carbonyl compound of formula (Id).

PHARMACEUTICALS - Preferred Components: The chemotherapeutic agent is selected from aromatase inhibitors, antiestrogen, anti-androgen, or gonadorelin agonists, topoisomerase 1 and 2 inhibitors, microtubule active agents, alkylating agents, antineoplastic antimetabolite, or platin containing compound, lipid or protein kinase targeting agents, protein or lipid phosphatase targeting agents, anti-angiogentic agents, agents that induce cell differentiation, bradykinin 1 receptor and angiotensin II antagonists, cyclooxygenase inhibitors, heparanase inhibitors, lymphokines or cytokine inhibitors, bisphosphanates, rapamycin derivatives, anti-apoptotic pathway inhibitors, apoptotic pathway agonists, peroxisome proliferator-activated receptors (PPAR) agonists, inhibitors of Ras isoforms, telomerase inhibitors, protease inhibitors, metalloproteinase inhibitors, and aminopeptidase inhibitors (preferably alkylating agents, anthracyclines, corticosteroids, IMiDs (RTM: immunomodulatory drug) , protease inhibitors, insulin-like growth factor (I) (IGF-I) inhibitors, CD40 antibody, Smac mimetics, fibroblast growth factor-3 (FGF3) modulator, mammalian target of Rapamycin (mTOR) inhibitor, HDAC inhibitors, ikappa B

kinase (IKK) inhibitors, P38 mitogen activated kinase (MAPK) inhibitors, heat shock protein 90 (HSP 90) inhibitor, and akt inhibitor, especially melphalan, doxorubicin, dexamethasone, prednisone, thalidomide, lenalidomide, bortezomib, and Salinosporamide A (NPI 0052).

ABEX DEFINITIONS - Preferred Definitions: - G2= N-sulfonamide; - G6=acyl(optionally substituted) or H; - G3=phenyl; - G4=-(X1)n1O(X2)n2-, -(CR5R6)m- or -(X1)n1NR7(X2)n2; - n1=0; - G5=phenyl, piperdino (both optionally substituted), N-morpholino, pyridinyl, or pyrrolidinyl; - G1=pyridinyl or phenyl.

ADMINISTRATION - The compounds are administered at a dosage of 0.1 - 500 mg/kg/day, 5 mg - 2 g/day in adult human, or 5 - 500 (preferably 10 - 200) mg orally or via injection. The compounds are administered parenterally (including subcutaneously, intradermally, intramuscularly, intravenously, intraarticularly or intramedullaryly), intraperitoneally, transmucosally, transdermally, rectally and topically (including dermally, bucally, sublingually and intraocularly), bucally, sublingually, or topically.

SPECIFIC COMPOUNDS - 30 compounds are specifically claimed as (I), e.g., thioacetic acid S-(2-oxo-2-(4-(4-O-tolyloxy-benzenesulfonylamino)-phenyl)-ethyl)ester (Ie); thioacetic acid S-(2-oxo-2-(4-(4-phenoxy-benzenesulfonylamino)-phenyl)-ethyl)ester; thioacetic acid-S-(2-(4-(4-(4-chloro-phenoxy)-bezenesulfonylamino)-phenyl)-2-oxo-ethyl)ester; thioacetic acid S-(2-(4-(4-(morpholine-4-sulfonyl)-benzenesulfonylamino)-phenyl)-2-oxo-ethyl)ester; and thioacetic acid S-(2-(4-(4-morpholin-4-ylmethyl-enzenesulfonylamino)-phenyl)-2-oxo-ethyl) ester.

EXAMPLE - A mixture of 4-O-tolyloxy-benzenesulfonyl chloride (1 g), 1-(4-amino-phenyl)-ethanone (0.62 g), and pyridine (1.9 ml) in THF (10 ml) was heated to 40degreesC for 6 hours. After worked up, N-(4-acetyl-phenyl)-4-o-tolyloxy-benzenesulfonamide (1f) (1.2 g) was obtained as white solid. A mixture of (1f) (1.2 g) and trimethylphenylammonium tribromide (1.3 g) in THF (20 ml) was heated to 40degreesC for 2 hours to afford 2 g N-(4-(2-bromo-acetyl)-phenyl)-4-O-tolyloxy-benzenesulfonamide (1g) with unreacted starting material. A mixture of compound (1g) (2g) and potassium thioacetate (594 mg) in methyl alcohol (20 ml) was stirred at room temperature for 18 hours. After worked up, thioacetic acid S-(2-oxo-2-(4-(4-O-tolyloxy-benzenesulfonylamino)-phenyl)-ethyl) ester (Ie) (1.12 g) was obtained as a white solid.

AN.S DCR-1530720

CN.S Thioacetic acid S-(2-oxo-2-{6-[4-(2-pyridin-2-yl-ethoxy)-benzenesulfonylamino]-pyridin-3-yl}-ethyl) ester

SDCN RARI27



AN.S DCR-1530725
CN.S Thioacetic acid S-(2-oxo-2-{6-[4-(pyridin-2-ylmethoxy)-
benzenesulfonylamino]-pyridin-3-yl}-ethyl) ester
SDCN RARI2C



AN.S DCR-1530729
CN.S Thioacetic acid S-(2-oxo-2-{6-[4-(pyridin-3-ylmethoxy)-
benzenesulfonylamino]-pyridin-3-yl}-ethyl) ester
SDCN RARI2G



AN.S DCR-1530730
CN.S Thioacetic acid S-(2-oxo-2-{6-[4-(3-pyridin-2-yl-propoxy)-
benzenesulfonylamino]-pyridin-3-yl}-ethyl) ester
SDCN RARI2H



L62 ANSWER 5 OF 13 WPIX COPYRIGHT 2008 THOMSON REUTERS on STN
ACCESSION NUMBER: 2005-358496 [37] WPIX
DOC. NO. CPI: C2005-110641 [37]
DOC. NO. NON-CPI: N2005-292774 [37]
TITLE: Photothermographic image forming material for image formation, comprises phenol derivative in photosensitive layer having silver particles, organic silver salt, reducing agent and binder, or layer adjacent to photosensitive layer
DERWENT CLASS: A89; E19; G06; P83
INVENTOR: HANIYU T
PATENT ASSIGNEE: (KONS-C) KONICA MINOLTA MG KK
COUNTRY COUNT: 1

PATENT INFORMATION:

PATENT NO	KIND	DATE	WEEK	LA	PG	MAIN IPC
JP 2005084175	A	20050331	(200537)*	JA	30[0]	

APPLICATION DETAILS:

PATENT NO	KIND	APPLICATION	DATE
JP 2005084175	A	JP 2003-313697	20030905

PRIORITY APPLN. INFO: JP 2003-313697 20030905
INT. PATENT CLASSIF.:
IPC RECLASSIF.: G03C0001-498 [I,A]; G03C0001-498 [I,C]
BASIC ABSTRACT:
JP 2005084175 A UPAB: 20051222
NOVELTY - A photothermographic image forming material has a photosensitive layer (A), layer (B) adjacent to photosensitive layer and

protective layer, in order on a support structure. Layer (A) contains photosensitive halogenated silver particles, organic silver salt, a reducing agent and a binder. A phenol derivative is present in layer (A or B).

DETAILED DESCRIPTION - A photothermographic image forming material has a photosensitive layer (A), layer (B) adjacent to photosensitive layer and protective layer, in order on a support structure. Layer (A) contains photosensitive halogenated silver particles, organic silver salt, a reducing agent and a binder. A phenol derivative of formula (1) is present in layer (A or B).

R1,R2 = OH;

R3-R9 = H, halogen atom, linear, branched or cyclic alkyl, aryl, acyl, alkoxycarbonyl, aryloxy carbonyl, cyano, carboxyl, alkoxy, aryloxy, acyloxy, acylamino, alkoxy carbonylamino, aryloxy carbonylamino, sulfonyl amino, carbamoyl, mercapto or alkylthio;and

Z1,Z2 = heterocyclic ring.

USE - For image formation.

ADVANTAGE - The photothermographic image forming material has high sensitivity, low fogging and excellent preservability. MANUAL CODE: CPI: A12-L01; E05-M03B; E06-D06; E06-H; E07-H; E08-H; E09-H; E10-A08; E10-A10; E10-A14B; E10-E02D4; E10-F02; E10-G02U; E10-H04; E35-B; G06-A08; G06-C08; G06-F; G06-F01; G06-G01; G06-G10; G06-H19

TECH

IMAGING AND COMMUNICATION - Preferred Layer: The layer (A or B) contains phthalazine compound, poly halo methane compound, reducing agent, and compound having isocyanate and/or vinyl sulfonyl. The reducing agent is bisphenol compound of formula (2) having unsaturated group(s) connecting two phenol groups.

R = H, alkyl, aromatic or heterocyclic ring;and

R',R'' = linear or branched alkyl.

ABEX SPECIFIC COMPOUNDS - 24 phenol derivatives are disclosed, such as compounds of formulae (VB-1,VB-2).

EXAMPLE - Binder (PVB-1) (2.6 g/m2), phenol derivative (VB-1) (in mol/m2) (3.2x10-4), bisphenol compound (2.2x10-4), phthalazine compound, (1.2x10-4), dye (2x10-5), pyridinium hydrobromide perbromide (0.3 mg/m2), isothiazolone (1.2 mg/m2), reducing agent (3.3 mmol/m2), hexamethylene diisocyanate (cross-linking agent) (2x10-5) and methyl ethyl ketone were mixed, to obtain coating liquid. The liquid was applied on undercoat layer of polyethylene terephthalate support and dried, to form a photosensitive layer. Surface protective layer was further formed, to obtain a photothermographic image forming material. The material had excellent freshness preservation property, image preservability, sensitivity of 112 and fogging of 0.02.

AN.S DCR-1079730

CN.S N-Phthalazin-6-yl-4-[2-(5-thioxo-4,5-dihydro-tetrazol-1-yl)-ethoxy]-benzenesulfonamide

SDCN RAHXNT



L62 ANSWER 6 OF 13 WPIX COPYRIGHT 2008 THOMSON REUTERS on STN
ACCESSION NUMBER: 2003-788232 [74] WPIX
DOC. NO. CPI: C2003-217648 [74]
TITLE: New uracil derivatives useful as inhibitors of tumor necrosis factor alpha converting enzyme and matrix metalloproteinases for treating e.g. inflammatory disorders, asthma, congestive heart failure and sepsis syndrome
DERWENT CLASS: B02; B03
INVENTOR: MADUSKUIE T P
PATENT ASSIGNEE: (BRIM-C) BRISTOL-MYERS SQUIBB CO; (MADU-I) MADUSKUIE T P
COUNTRY COUNT: 101

PATENT INFORMATION:

PATENT NO	KIND	DATE	WEEK	LA	PG	MAIN IPC
WO 2003079986	A2	20031002	(200374)*	EN	105[0]	
US 20030229081	A1	20031211	(200382)	EN		
AU 2003220401	A1	20031008	(200432)	EN		
AU 2003220401	A8	20051027	(200624)	EN		
US 7101883	B2	20060905	(200660)	EN		

APPLICATION DETAILS:

PATENT NO	KIND	APPLICATION	DATE
WO 2003079986	A2	WO 2003-US8412	20030314
US 20030229081	A1 Provisional	US 2002-365334P	20020318
AU 2003220401	A1	AU 2003-220401	20030314
AU 2003220401	A8	AU 2003-220401	20030314
US 20030229081	A1	US 2003-389529	20030314
US 7101883	B2 Provisional	US 2002-365334P	20020318
US 7101883	B2	US 2003-389529	20030314

FILING DETAILS:

PATENT NO	KIND		PATENT NO	
AU 2003220401	A1	Based on	WO 2003079986	A
AU 2003220401	A8	Based on	WO 2003079986	A

PRIORITY APPLN. INFO: US 2002-365334P 20020318
US 2003-389529 20030314
INT. PATENT CLASSIF.:
MAIN: A61K031-505
SECONDARY: C07D403-00
IPC ORIGINAL: A01N0043-48 [I,C]; A01N0043-58 [I,A]; A61K0031-50 [I,A]; A61K0031-50 [I,C]; C07D0239-00 [I,C]; C07D0239-02 [I,A]
IPC RECLASSIF.: A61P0025-00 [I,A]; A61P0025-00 [I,C]; C07D0239-00 [I,C]; C07D0239-545 [I,A]; C07D0239-69 [I,A]; C07D0401-00 [I,C]; C07D0401-12 [I,A]
ECLA: C07D0239-54C4; C07D0239-69; C07D0401-12+239B+215
ICO: M07D0239:54C4; M07D0239:69
USCLASS NCLM: 514/224.200
NCLS: 514/269.000; 544/051.000; 544/310.000
BASIC ABSTRACT:
WO 2003079986 A2 UPAB: 20050601
NOVELTY - Uracil derivatives (I) are new.
DETAILED DESCRIPTION - Uracil derivatives of formula A-W-U-X-Y-Z-Ua-Xa-Ya-Za (I) and their stereoisomers and salts, are new.
A = a group of formula (i)-(iv);
W = (CHRa)m;
U = absent, O, NRa1, CO, CRa(OH), COO, OCO, CONRa1, NRa1CO, OCOO, OCONRa1, NRa1COO, NRa1CONRa1, OSO2, SO2O, SOp, SOpNRa1, NRa1SOp or NRa1SO2NRa1;
X = absent, 1-3C alkylene, 2-3C alkenylene or 2-3C alkynylene;
Y = absent, O, NRa1, SOp or CO;
Z = 3-13C carbocyclyl or 5-14 membered heterocyclyl containing 1-4 N, O or SOp heteroatoms (both optionally substituted by 1-5 Rb);
Ua = absent, O, NRa1, CO, CRa(OH), COO, OCO, CONRa1, NRa1CO, OCOO, OCONRa1, NRa1COO, NRa1CONRa1, SOp, SOpNRa1, NRa1SOp or NRa1SO2NRa1;
Xa = absent, 1-10C alkylene, 2-10C alkenylene or 2-10C alkynylene;
Ya = absent, O, NRa1, SOp or CO;
Za = H, or 3-13C carbocyclyl or 5-14 membered heterocyclyl containing 1-4 N, O or S(O)p (both optionally substituted by 1-5 Rc);
R1 = 1-6C alkyl, 2-6C alkenyl, 2-6C alkynyl, (CRaRa1)r-3-10C carbocyclyl or (CRaRa1)r-5-10 membered heterocyclyl containing 1-4 N, O or S(O)p heteroatoms (all optionally substituted by 1-5 Rd), H, CF3, (CRaRa1)sORa1 or (CRaRa1)rNRaRa1;
R2, R3 = 1-6C alkyl, 2-6C alkenyl or 2-6C alkynyl (all optionally substituted by Rb) or H;
Ra = H, 1-6C alkyl, phenyl or benzyl;
Ra1 = 1-6C alkyl, 2-6C alkenyl, 2-6C alkynyl, (CH2)r-3-8 membered carbocyclyl or heterocyclyl containing 1 or 2 N, NRa2, O or S(O)p (all optionally substituted by 1-3 Re) or H, or
NRa + NRa1 = 5- or 6-membered heterocyclyl optionally containing one additional N, NRa2, O or S(O)p heteroatoms;
Ra2 = 1-4C alkyl, phenyl or benzyl;
Rb = 1-6C alkyl (optionally substituted);
Ra3 = 1-6C alkyl, 2-6C alkenyl, 2-6C alkynyl, (CH2)r-3-8 membered carbocyclyl or heterocyclyl containing 1 or 2 N, NRa2, O or S(O)p (all optionally substituted) or H;
Rc = H, ORa, Cl, F, Br, I, O CN, NO2, CF3, CF2CF3, OCF3, (CRaRa1)rNRaRa1, (CRaRa1)rC(NCN)NRaRa1, (CRaRa1)rC(NRa)NRaRa1, (CRaRa1)rC(NORa)NRaRa1, (CRaRa1)rCONRaOH, (CRaRa1)rCORa1, (CRaRa1)rCORa1, (CRaRa1)rCSORa1, (CRaRa1)rCONRaRa1, (CRaRa1)rNRaCORa1, (CRaRa1)rCSNRaRa1, (CRaRa1)rOCONRaRa1, (CRaRa1)rNRaCOORa1, (CRaRa1)rNRaCONRaRa1, (CRaRa1)rS(O)pRa3, (CRaRa1)rSO2NRaRa1, (CRaRa1)rNRaSO2Ra3 or (CRaRa1)rNRaSO2NRaRa1), or 1-6C alkyl, 2-6C alkenyl, 2-6C alkynyl, (CRaRa1)r-3-10C carbocyclyl or (CRaRa1)r-5-14 membered heterocyclyl containing 1-4 N, O or S(O)p heteroatoms (all optionally substituted), or

CRcRc = spiro ring C that is a 3-11 membered carbocyclyl or heterocyclyl optionally containing 1-4 O, N or S(O)p heteroatoms and optionally 1 or 2 double bonds (optionally substituted), provided that ring C does not contain a S-S, O-O or S-O bond, or 5-7 membered carbocyclyl or heterocyclyl ring D optionally containing 1 or 2 N, O or S(O)p heteroatoms and optionally 1-3 double bonds (optionally substituted);

Rd = 1-6C alkyl (optionally substituted by 1 or 2 Re), 2-6C alkenyl, 2-6C alkynyl, ORa, Cl, F, Br, I, O, CN, NO2, NRaRa1, CORa1, COORa, CONRaRa1, C(S)NRaRa1, RaNCONRaRa1, OCONRaRa1, SO2NRaRa1, NRaSO2Ra3, NRaSO2NRaRa1, OSO2NRaRa1, NRaSO2Ra3, S(O)pRa3, CF3 or CF2CF3;

Re = H, 1-6C alkyl, ORa, Cl, F, Br, I, O, CN, NO2, NRaRa, CORa, COORa, CONRaRa, RaNCONRaRa, OCONRaRa, RaNCOORa, SO2NRaRa, NRaSO2NRaRa, NRaSO2NRaRa, OSO2NRaRa, S(O)pRa2, CF3, OCF3, CF2CF3, CH2F or CHF2;

m = 0-3;

p = 0-2;

r = 0-4, and

s = 1-4;

with specified provisos.

Full Definitions are given in the Definitions Field (Full Definitions).

An INDEPENDENT CLAIM is also included for a medical device for implanting into the body, which has a coating material comprising (I), for reducing inflammation or restenosis.

ACTIVITY - Antiinflammatory; Antiasthmatic; Antiarteriosclerotic; Immunosuppressive; Hepatotropic; Virucide; Antiallergic; Antiasthmatic; Anabolic; Eating-Disorders-Gen.; Vasotropic; Immunomodulator; Immunomodulator; Antipyretic; Respiratory-Gen.; Cardiovascular-Gen.; Cardiant; Antigout; Hemostatic; Anti-HIV; Antibacterial; Neuroprotective; Osteopathic; Antiarthritic; Antirheumatic; Antipsoriatic; Uropathic; Ophthalmological; Dermatological; Cerebroprotective; Antiulcer.

MECHANISM OF ACTION - Tumor necrosis factor-alpha (TNF-alpha) converting enzyme (TACE) inhibitor; Matrix metalloproteinase (MMP) inhibitor; Aggrecanase inhibitor.

In a fluorometric assay (Copeland, R. A. et. al. Bioorganic Med. Chemical Lett. 1995, 5, 1947-1952), results showed that (I) exhibited Ki values of upto 10 micro-M for inhibiting recombinant MMP-1-3, 10 and 12-16.

USE - Used for treating inflammatory disorder, acute infection, acute phase response, age related macular degeneration, alcoholic liver disease, allergy, allergic asthma, aneurism, anorexia, aortic aneurism, asthma, atherosclerosis, atopic dermatitis, autoimmune disease, autoimmune hepatitis, Bechet's disease, cachexia, calcium pyrophosphate dihydrate deposition disease, cardiovascular effects, chronic fatigue syndrome, chronic obstruction pulmonary disease, coagulation, congestive heart failure, corneal ulceration, Crohn's disease, enteropathic arthropathy, Felty's syndrome fever, fibromyalgia syndrome, fibrotic disease, gingivitis, glucocorticoid withdrawal syndrome, gout, graft versus host disease, hemorrhage, HIV infection, hyperoxic alveolar injury, infectious arthritis, inflammation, intermittent hydrarthrosis, Lyme disease, meningitis, multiple sclerosis, myasthenia gravis, mycobacterial infection, neovascular glaucoma, osteoarthritis, pel vic inflammatory disease, periodontitis, polymyositis/dermatomyositis, post-ischemic reperfusion injury, post-radiation asthenia, psoriasis, psoriatic arthritis, pulmonary emphysema, pydoderma gangrenosum, relapsing polychondritis, Reiter's syndrome, rheumatic fever, rheumatoid arthritis, sarcoidosis, scleroderma, sepsis syndrome, Still's disease, shock, Sjogren's syndrome, skin inflammatory diseases, solid tumor growth and tumor invasion by secondary metastases, spondylitis, stroke, systemic lupus erythematosus, ulcerative colitis, uveitis, vasculitis, and Wegener's granulomatosis (all claimed).

ADVANTAGE - (I) Have improved characteristics of pharmaceutical properties, dosage requirements, factors which decrease blood concentration peak-to-trough characteristics, factors that increase the concentration of active a drug

at the receptor, factors that decrease the liability for clinical drug-dug interaction, factors that decrease the potential for adverse side-effects and factors that improve manufacturing costs or feasibility.

MANUAL CODE: CPI: B06-H; B07-D12; B14-A01; B14-C03; B14-F01B; B14-K01A; B14-S06

TECH

ORGANIC CHEMISTRY - Preparation: Preparation of comprises e.g. treating a 5-aminouracil with an acid chloride compound of formula (II)in pyridine or dioxane with aqueous carbonate at room temperature to give a compound of formula (I').

ABEX DEFINITIONS - Full Definitions: - A = a group of formula (i)-(iv); - W = (CHRa)m; - U = absent, O, NRa1, CO, CRa(OH), COO, OCO, CONRa1, NRa1CO, OCOO, OCONRa1, NRa1COO, NRa1CONRa1, OSO2, SO2O, SOp, SOpNRa1, NRa1SOp or NRa1SO2NRa1; - X = absent, 1-3C alkylene, 2-3C alkenylene or 2-3C alkynylene; - Y = absent, O, NRa1, SOp or CO; - Z = 3-13C carbocyclyl or 5-14 membered heterocyclyl containing 1-4 N, O or SOp heteroatoms (both optionally substituted by 1-5 Rb); - Ua = absent, O, NRa1, CO, CRa(OH), COO, OCO, CONRa1, NRa1CO, OCOO, OCONRa1, NRa1COO, NRa1CONRa1, SOp, SOpNRa1, NRa1SOp or NRa1SO2NRa1; - Xa = absent, 1-10C alkylene, 2-10C alkenylene or 2-10C alkynylene; - Ya = absent, O, NRa1, SOp or CO; - Za = H, or 3-13C carbocyclyl or 5-14 membered heterocyclyl containing 1-4 N, O or S(O)p (both optionally substituted by 1-5 Rc); - R1 = 1-6C alkyl, 2-6C alkenyl, 2-6C alkynyl, (CRaRa1)r-3-10C carbocyclyl or (CRaRa1)r-5-10 membered heterocyclyl containing 1-4 N, O or S(O)p heteroatoms (all optionally substituted by 1-5 Rd), H, CF3, (CRaRa1)sORa1 or (CRaRa1)rNRaRa1; - R2, R3 = 1-6C alkyl, 2-6C alkenyl or 2-6C alkynyl (all optionally substituted by Rb) or H; - Ra = H, 1-6C alkyl, phenyl or benzyl; - Ra1 = 1-6C alkyl, 2-6C alkenyl, 2-6C alkynyl, (CH2)r-3-8 membered carbocyclyl or heterocyclyl containing 1 or 2 N, NRa2, O or S(O)p (all optionally substituted by 1-3 Re) or H, or - NRa + NRa1 = 5- or 6-membered heterocyclyl optionally containing one additional N, NRa2, O or S(O)p heteroatoms; - Ra2 = 1-4C alkyl, phenyl or benzyl; - Rb = 1-6C alkyl (optionally substituted by Rc1, ORa, SRa, Cl, F, Br, I, O, CN, NO2, NRaRa1, CORa, COORa, CONRaRa1, CSNRaRa1, NRaCONRaRa1, OCONRaRa1, NRaCOORa, SO2NRaRa1, NRaSO2Ra3, NRaSO2NRaRa1, OSO2NRaRa1, NRaSO2Ra3, SOpRa3, CF3, CF3CF3, CHF2, CH2F or phenyl; - Ra3 = 1-6C alkyl, 2-6C alkenyl, 2-6C alkynyl, (CH2)r-3-8 membered carbocyclyl or heterocyclyl containing 1 or 2 N, NRa2, O or S(O)p (all optionally substituted by 1-3 Rc1) or H; - Rc = H, ORa, Cl, F, Br, I, O CN, NO2, CF3, CF2CF3, OCF3, (CRaRa1)rNRaRa1, (CRaRa1)rC(NCN)NRaRa1, (CRaRa1)rC(NRa)NRaRa1, (CRaRa1)rC(NORa)NRaRa1, (CRaRa1)rCONRaOH, (CRaRa1)rCORa1, (CRaRa1)rCORa1, (CRaRa1)rCSORa1, (CRaRa1)rCONRaRa1, (CRaRa1)rNRaCORa1, (CRaRa1)rCSNRaRa1, (CRaRa1)rOCONRaRa1, (CRaRa1)rNRaCOORa1, (CRaRa1)rNRaCONRaRa1, (CRaRa1)rS(O)pRa3, (CRaRa1)rSO2NRaRa1, (CRaRa1)rNRaSO2Ra3 or (CRaRa1)rNRaSO2NRaRa1), or 1-6C alkyl, 2-6C alkenyl, 2-6C alkynyl, (CRaRa1)r-3-10C carbocyclyl or (CRaRa1)r-5-14 membered heterocyclyl containing 1-4 N, O or S(O)p heteroatoms (all optionally substituted by Rc1), or - CRcRc = spiro ring C that is a 3-11 membered carbocyclyl or heterocyclyl optionally containing 1-4 O, N or S(O)p heteroatoms and optionally 1 or 2 double bonds (optionally substituted by 1 or 2 Rc1), provided that ring C does not contain a S-S, O-O or S-O bond, or 5-7 membered carbocyclyl or heterocyclyl ring D optionally containing 1 or 2 N, O or S(O)p heteroatoms and optionally 1-3 double bonds (optionally substituted by Rc1); - Rc1 = H, 1-6C alkyl, ORa, Cl, F, Br, I O, CN, NO2, NRaRa1, CORa, COORa, CONRaRa1, RaNCONRaRa1, OCONRaRa1, RaNCOORa1, SO2NRaRa1, NRaSO2Ra2, NRaSO2Ra1, NRaOSO2NRaRa1, OSO2NRaRa1, NRaSO2Ra2, CF3, OCF3, CF2CF3, CH2F or CHF2; - Rd = 1-6C alkyl (optionally substituted by 1 or 2 Re), 2-6C alkenyl, 2-6C alkynyl, ORa, Cl, F, Br, I, O, CN, NO2, NRaRa1, CORa1, COORa, CONRaRa1, C(S)NRaRa1, RaNCONRaRa1, OCONRaRa1, SO2NRaRa1, NRaSO2Ra3, NRaSO2NRaRa1, OSO2NRaRa1, NRaSO2Ra3, S(O)pRa3, CF3

or CF2CF3; - Re = H, 1-6C alkyl, ORa, Cl, F, Br, I, O, CN, NO2, NRaRa, CORa, COORa, CONRaRa, RaNCONRaRa, OCONRaRa, RaNCOORa, SO2NRaRa, NRaSO2NRaRa, NRaSO2NRaRa, OSO2NRaRa, S(O)pRa2, CF3, OCF3, CF2CF3, CH2F or CHF2; - m = 0-3; - p = 0-2; - r = 0-4, and - s = 1-4, - provided that: - (1) when Z is phenylene or naphthylene, then Ua-Xa-Ya-Za does not form H, 1-6C alkyl, NH2, NHCOMe or naphthyl; - (2) when W-U-X-Y forms NHSO2, Z is naphthylene and Za is not phenyl optionally substituted by 1-5 Rc; - (3) when W-U-X-Y forms NHSO2 and Z is phenylene, then Ua-Xa-Ya forms a bond and Z is not phenyl optionally substituted by 1-5 Rc; - (4) when W-U-X-Y forms NRa1SO2 and Z is phenylene, then Za is not phenyl substituted by 5- or 6-membered carbocyclyl or heterocyclyl (optionally substituted by 1 or 2 Rc1); - (5) when R1 is (CRaR1)rNRaRa1 or (CRaRa1)rCONRaRa1 and Z is phenylene or naphthylene, then Ua-Xa-Ya does not form a bond and Za is not H, and - (6) when W-U-X-Y forms NHSO2CH2 or NHCOCH2 and Z is naphthyl, then Ua-Xa-Ya is not CH2CH2NR1a.

ADMINISTRATION - Dosage is 0.001-1000 (preferably 0.1-20) mg/kg/day orally or 1-10 mg/kg/minute intravenously. Administration is also intraperitoneal, subcutaneous or intramuscular. Administration is optionally in combination with antiinflammatory agents (specifically cyclooxygenase-2 inhibitors, interleukin-1 antagonists, dihydroorotate synthase inhibitors, p38 mitogen-activated protein kinase inhibitors, TNF-alpha inhibitors, TNF-alpha sequestration agents and/or methotrexate).

SPECIFIC COMPOUNDS - 10 Compounds (I) are specifically claimed e.g: - N-(2,4-dioxo-1,2,3,4-tetrahydro-5-pyrimidinyl)-4-((2-methyl-4-quinolinyl)methoxy)benzene sulfonamide (Ia).

EXAMPLE - Sodium hydroxide 3 M (8.7 ml) was added to a suspension of 4-hydroxybezenesulfonic acid sodium salt (5 g), 4-chloromethyl-2-methylquinoline (5 g) and sodium iodide (0.4 g) in ethanol (80 ml). The reaction was refluxed for 18 hours and cooled to room temperature. The mixture was worked up to give 4-((2-methyl-4-quinolinyl)methoxy)benzenesulfonic acid sodium salt (A) (5.5 g). A catalytic amount of dimethylformamide was added to a solution of (A) (1.0 g) in thionyl chloride (3 ml). The reaction was heated to 60degreesC for 2 hours and cooled to room temperature. The mixture was worked up to give 4-((2-methyl-4-quinolinyl)methoxy)benzenesulfonyl chloride (B) (0.95 g). A solution of (B) (0.23 g) was added to 5-aminouracil (0.15 g) in pyridine (5 ml) at room temperature. The reaction was stirred for 2.5 hours and work up produced N-(2,4-dioxo-1,2,3,4-tetrahydro-5-pyrimidinyl)-4-((2-methyl-4-quinolinyl) methoxy)benzene sulfonamide (Ia) trifluoroacetate (0.075 g; 60%).

AN.S DCR-796213
CN.S N-(2,4-Dioxo-hexahydro-pyrimidin-5-yl)-4-(2-methyl-quinolin-4-ylmethoxy)-benzenesulfonamide
SDCN RAC2TZ

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *
AN.S DCR-796206
CN.S N-(4-Amino-2,6-dihydroxy-pyrimidin-5-yl)-4-(2-methyl-quinolin-4-ylmethoxy)-benzenesulfonamide
SDCN RAC2TS



AN.S DCR-796205
CN.S N-(2,4-Dihydroxy-pyrimidin-5-yl)-4-(2-methyl-quinolin-4-ylmethoxy)-benzenesulfonamide
SDCN RAC2TR



L62 ANSWER 7 OF 13 WPIX COPYRIGHT 2008 THOMSON REUTERS on STN
ACCESSION NUMBER: 2003-167243 [16] WPIX
DOC. NO. CPI: C2003-043379 [16]
TITLE: New hydantoin derivatives are matrix metalloproteinase inhibitors used for treating e.g. acute infection, asthma, inflammation, multiple sclerosis, stroke and solid tumor growth
DERWENT CLASS: B02; B03
INVENTOR: DUAN J; SHEPPECK J E; WASSERMAN Z; XUE C; XUE C B
PATENT ASSIGNEE: (BRIM-C) BRISTOL-MYERS SQUIBB CO; (BRIM-C) BRISTOL-MYERS SQUIBB PHARMA CO; (DUAN-I) DUAN J; (SHEP-I) SHEPPECK J E; (WASS-I) WASSERMAN Z; (XUEC-I) XUE C
COUNTRY COUNT: 99

PATENT INFORMATION:

PATENT NO	KIND	DATE	WEEK	LA	PG	MAIN IPC

WO 2002096426	A1	20021205 (200316)*	EN	184[0]
US 20030130273	A1	20030710 (200347)	EN	
EP 1397137	A1	20040317 (200420)	EN	
AU 2002314801	A1	20021209 (200452)	EN	
US 20040209874	A1	20041021 (200470)	EN	
JP 2004535411	W	20041125 (200477)	JA	531
US 6890915	B2	20050510 (200532)	EN	
US 6906053	B2	20050614 (200540)	EN	
US 20050171096	A1	20050804 (200552)	EN	

APPLICATION DETAILS:

PATENT NO	KIND	APPLICATION	DATE
WO 2002096426	A1	WO 2002-US16381	20020523
US 20030130273	A1 Provisional	US 2001-293571P	20010525
US 20040209874	A1 Provisional	US 2001-293571P	20010525
US 6890915	B2 Provisional	US 2001-293571P	20010525
US 6906053	B2 Provisional	US 2001-293571P	20010525
US 20050171096	A1 Provisional	US 2001-293571P	20010525
AU 2002314801	A1	AU 2002-314801	20020523
EP 1397137	A1	EP 2002-741724	20020523
JP 2004535411	W	JP 2002-592936	20020523
US 20030130273	A1	US 2002-155575	20020523
US 20040209874	A1 Div Ex	US 2002-155575	20020523
US 6890915	B2	US 2002-155575	20020523
US 6906053	B2 Div Ex	US 2002-155575	20020523
US 20050171096	A1 Div Ex	US 2002-155575	20020523
EP 1397137	A1	WO 2002-US16381	20020523
JP 2004535411	W	WO 2002-US16381	20020523
US 20040209874	A1	US 2004-844219	20040512
US 6906053	B2	US 2004-844219	20040512
US 20050171096	A1 Div Ex	US 2004-844219	20040512
US 20050171096	A1	US 2005-93670	20050330

FILING DETAILS:

PATENT NO	KIND	PATENT NO
US 6906053 B2	Div ex	US 6890915 B
US 20050171096 A1	Div ex	US 6890915 B
US 20050171096 A1	Div ex	US 6906053 B
EP 1397137 A1	Based on	WO 2002096426 A
AU 2002314801 A1	Based on	WO 2002096426 A
JP 2004535411 W	Based on	WO 2002096426 A

PRIORITY APPLN. INFO: US 2001-293571P 20010525
US 2002-155575 20020523
US 2004-844219 20040512
US 2005-93670 20050330

INT. PATENT CLASSIF.:
MAIN: A61K031-4709; C07D233-76
IPC RECLASSIF.: A61K0031-4164 [I,C]; A61K0031-4166 [I,A]; A61K0031-4184 [I,A]; A61K0031-4188 [I,A]; A61K0031-4353 [I,C]; A61K0031-437 [I,A]; A61K0031-4427 [I,C]; A61K0031-4439 [I,A]; A61K0031-4523 [I,C]; A61K0031-454 [I,A]; A61K0031-4709 [I,A]; A61K0031-4709 [I,C]; A61K0031-472 [I,C]; A61K0031-4725 [I,A]; A61K0031-4738 [I,C]; A61K0031-4741 [I,A]; A61K0031-5415 [I,A]; A61K0031-5415

[I,C]; A61K0045-00 [I,C]; A61K0045-06 [I,A]; A61P0001-00
[I,A]; A61P0001-00 [I,C]; A61P0001-02 [I,A]; A61P0001-04
[I,A]; A61P0001-14 [I,A]; A61P0001-16 [I,A]; A61P0011-00
[I,A]; A61P0011-00 [I,C]; A61P0011-06 [I,A]; A61P0017-00
[I,A]; A61P0017-00 [I,C]; A61P0017-02 [I,A]; A61P0017-06
[I,A]; A61P0019-00 [I,A]; A61P0019-00 [I,C]; A61P0019-02
[I,A]; A61P0019-06 [I,A]; A61P0019-08 [I,A]; A61P0021-00
[I,A]; A61P0021-00 [I,C]; A61P0021-04 [I,A]; A61P0025-00
[I,A]; A61P0025-00 [I,C]; A61P0025-04 [I,A]; A61P0027-00
[I,C]; A61P0027-02 [I,A]; A61P0027-06 [I,A]; A61P0029-00
[I,A]; A61P0029-00 [I,C]; A61P0003-00 [I,A]; A61P0003-00
[I,C]; A61P0031-00 [I,A]; A61P0031-00 [I,C]; A61P0031-04
[I,A]; A61P0031-18 [I,A]; A61P0035-00 [I,A]; A61P0035-00
[I,C]; A61P0037-00 [I,C]; A61P0037-02 [I,A]; A61P0037-08
[I,A]; A61P0043-00 [I,A]; A61P0043-00 [I,C]; A61P0007-00
[I,A]; A61P0007-00 [I,C]; A61P0007-02 [I,A]; A61P0007-04
[I,A]; A61P0009-00 [I,C]; A61P0009-04 [I,A]; A61P0009-08
[I,A]; A61P0009-10 [I,A]; C07D0233-00 [I,C]; C07D0233-76
[I,A]; C07D0401-00 [I,C]; C07D0401-06 [I,A]; C07D0401-12
[I,A]; C07D0401-14 [I,A]; C07D0403-00 [I,C]; C07D0403-12
[I,A]; C07D0405-00 [I,C]; C07D0405-14 [I,A]; C07D0409-00
[I,C]; C07D0409-14 [I,A]; C07D0417-00 [I,C]; C07D0417-12
[I,A]; C07D0417-14 [I,A]; C07D0471-00 [I,C]; C07D0471-10
[I,A]; C07D0487-00 [I,C]; C07D0487-10 [I,A]; C07D0491-00
[I,C]; C07D0491-10 [I,A]; C07D0491-107 [I,A]; C07D0519-00
[I,A]; C07D0519-00 [I,C]

ECLA: A61K0031-4709+M; A61K0045-06; C07D0233-76;
C07D0401-06+233+211; C07D0401-12+233+215;
C07D0401-12+235+215; C07D0401-14+233+215+211;
C07D0401-14+233+215+213+211; C07D0401-14+233+217+211;
C07D0403-12+235C+233; C07D0405-14+309+233+215;
C07D0409-14+335+233+211; C07D0417-12+279+235;
C07D0417-14+279+233+211; C07D0471-10+235B+221B;
C07D0487-10+235B+209B; C07D0491-10+307B+235B;
C07D0491-10+311B+235B

ICO: M07D0233:76

USCLASS NCLM: 514/183.000

NCLS: 514/235.200; 514/235.500; 514/235.800; 514/254.050;
514/311.000; 514326000; 514385000; 514389000; 514396000;
514399000; 514409000; 514412000; 514422000; 514425000;
544060000; 544139000; 544370000; 546016000; 546112000;
546134000; 546210000; 548300100; 548300700; 548311100;
548317100; 548407000; 548408000; 548409000

BASIC ABSTRACT:

WO 2002096426 A1 UPAB: 20060118

NOVELTY - Hydantoin derivatives (I) are new.

DETAILED DESCRIPTION - Hydantoin derivatives of formula (I) and their salts are new.

R11 = W-U-X-Y-Z-Ua-Xa-Ya-Za;

R11a = W-Ub-X-Y-Z-Ua-Xa-Ya-Za;

W = e.g. 2-3C alkenylene or 2-3C alkynylene;

U, Ua = e.g. absent, O, C(O), C(O)O or S(O)p;

Ub = e.g. O, C(O), C(O)O or S(O)p;

X = absent, 1-3C alkylene, 2-3C alkenylene or 2-3C alkynylene;

Y, Ya = e.g. absent, O or S(O)p;

Z, Za = 3-13C carbocyclyl or 5-14 membered heterocyclyl containing 1-4 N, O or S(O)p (both optionally substituted);

Xa = absent, 1-10C alkylene, 2-10C alkenylene, or 2-10C alkynylene;

CR1CR2 = 3-8 membered carbocyclyl or heterocyclyl containing 1 or 2 O, N, NR10 or S(O)p, optionally 1 or 2 carbonyl groups and optionally 1 or 2

double bonds (optionally substituted), with carbocyclyl or heterocyclyl optionally fused to a 5- or 6-membered carbocyclyl or heterocyclyl containing 1-3 N, O or S(O)p (both optionally substituted);

R3, R3a, R1a = e.g. Q, 1-6C alkylene-Q, 2-6C alkylene-Q or 2-6C alkynylene-Q;

R2a = Q1, 1-6C alkylene-Q1, 2-6C alkylene-Q1 or 2-6C alkynylene-Q1;

Q = H, CHF2, CH2F, CF3 or 3-13C carbocyclyl or 5-14 membered heterocyclyl containing 1-4 N, O or S(O)p (both optionally substituted);

Q1 = H or 3-13C carbocyclyl or 5-14 membered heterocyclyl containing 1-4 N, NR10, O or S(O)p (both optionally substituted);

R4, R5 = H or 1-6C alkyl, 2-6C alkenyl or 2-6C alkynyl (all optionally substituted);

n = 0 or 1;

R6, R7 = H, 1-4C alkyl, 2-4C alkenyl, or 2-4C alkynyl, and

p = 0-2.

See 'Definitions' Section for 'Full definitions'.

ACTIVITY - Antiallergic; Antiasthmatic; Immunosuppressive; Antiarteriosclerotic; Dermatological; Hepatotropic; Antiinflammatory; Virucide; Vasotropic; Immunomodulator; Cardiant; Antiulcer; Antipyretic; Antigout; Hemostatic; Anti-HIV; Antiarthritic; Antibacterial; Ophthalmological; Neuroprotective; Osteopathic; Antipsoriatic; Uropathic; Antirheumatic; Cerebroprotective.

MECHANISM OF ACTION - Matrix metalloproteinase (MMP) inhibitor; Tumor necrosis factor-alpha (TNF) converting enzyme inhibitor; Aggrecanase inhibitor.

In a fluorometric assay (Copeland, R.A. et al. Bioorganic Med. Chemical Lett. 1995, 5, 1947-1952), some (I) and (II) exhibited Ki values of upto 10 micro-M for inhibiting MMP-1-3, 7-10 and 12-16.

USE - Used for treating acute infection, acute phase response, age related macular degeneration, alcoholic liver disease, allergy, allergic asthma, anorexia, aneurism, aortic aneurism, asthma, atherosclerosis, atopic dermatitis, autoimmune disease, autoimmune hepatitis, Behcet's disease, cachexia, calcium pyrophosphate dihydrate deposition disease, cardiovascular effects, chronic fatigue syndrome, chronic obstruction pulmonary disease, coagulation, congestive heart failure, corneal ulceration, Crohn's disease, enteropathic arthropathy, Felty's syndrome, fever, fibromyalgia syndrome, fibrotic disease, gingivitis, glucocorticoid withdrawal syndrome, gout, graft versus host disease, hemorrhage, HIV infection, hyperoxic alveolar injury, infectious arthritis, inflammation, intermittent hydrarthrosis, Lyme disease, meningitis, multiple sclerosis, myasthenia gravis, mycobacterial infection, neovascular glaucoma, osteoarthritis, pelvic inflammatory disease, periodontitis, polymyositis/dermatomyositis, post ischemic reperfusion injury, post-radiation asthenia, psoriasis, psoriatic arthritis, pulmonary emphysema, pyoderma gangrenosum, relapsing polychondritis, Reiter's syndrome, rheumatic fever, rheumatoid arthritis, sarcoidosis, scleroderma, sepsis syndrome, Still's disease, shock, Sjoegren's syndrome, skin inflammatory diseases, solid tumor growth and tumor invasion by secondary metastases, spondylitis, stroke, systemic lupus erythematosus, ulcerative colitis, uveitis, vasculitis, and Wegener's granulomatosis.

MANUAL CODE: CPI: B06-H; B07-D09; B14-A01B1; B14-A02B1; B14-B04A; B14-C02; B14-C03; B14-C04; B14-C09; B14-E08; B14-E10C; B14-F01B; B14-F07; B14-F08; B14-G02A; B14-G02C; B14-G02D; B14-H01; B14-K01A; B14-N03; B14-N05; B14-N06B; B14-N07; B14-N12; B14-N16; B14-N17; B14-S01; B14-S06

TECH

ORGANIC CHEMISTRY - Preparation: No relevant preparation of (I) or (II) is given in the source material.

ABEX DEFINITIONS - Full Definitions: - R11 = W-U-X-Y-Z-Ua-Xa-Ya-Za; - W = (CRaRa1)m, 2-3C alkenylene or 2-3C alkynylene; - U, Ua = absent or E1; - E1 = O, NRa1, C(O), CRa(OH), C(O)O, OC(O), C(O)NRa1, NRa1C(O), OC(O)O, OC(O)NRa1, NRa1C(O)O, NRa1C(O)NRa1, S(O)p, S(O)NRa1, NRa1S(O)p or

NRa1SO2NRa1; - X = absent, 1-3C alkylene, 2-3C alkenylene or 2-3C alkynylene; - Y, Ya = absent, O, NRa1, S(O)p or C(O); - Z = G1 (optionally substituted by 1-5 Rb); - G1 = 3-13C carbocyclyl or 5-14 membered heterocyclyl containing 1-4 N, O or S(O)p; - Xa = absent, 1-10C alkylene, 2-10C alkenylene or 2-10C alkynylene; - Za = G1 (optionally substituted by 1-5 Rc); - CR1CR2 = 3-8 membered carbocyclyl or heterocyclyl containing 1 or 2 O, N, NR10 or S(O)p, optionally 1 or 2 carbonyl groups and optionally 1 or 2 double bonds (both optionally by 1-3 R9) and optionally fused to T1); - T1 = 5- or 6-membered carbocyclyl or heterocyclyl containing 1-3 N, O or S(O)p heteroatoms (both optionally substituted by 1-3 R9); - R3, R1a = Q, 1-6C alkylene-Q, 2-6C alkenylene-Q, 2-6C alkynylene-Q, (CRaRa1)rO(CRaRa1)s-Q, (CRaRa1)rNRa(CRaRa1)s-Q, (CRaRa1)rC(O)(CRaRa1)s-Q, (CRaRa1)rC(O)O(CRaRa1)s-Q, (CRaRa1)rOC(O)(CRaRa1)s-Q, (CRaRa1)rC(O)NRaRa1, (CRaRa1)rC(O)NRa(CRaRa1)s-Q, (CRaRa1)rNRaC(O) (CRaRa1)s-Q, (CRaRa1)rOC(O)O(CRaRa1)s-Q, (CRaRa1)rOC(O)NRa(CRaRa1)s-Q, (CRaRa1)rNRaC(O)O(CRaRa1)s-Q, (CRaRa1)rNRaC(O)NRa(CRaRa1)s-Q, (CRaRa1)rS(O)p(CRaRa1)s-Q, (CRaRa1)rS(O)2NRa(CRaRa1)s-Q, (CRaRa1)rNRaSO2(CRaRa1)s-Q or (CRaRa1)rNRaSO2NRa(CRaRa1)s-Q; - Q = G1 (optionally substituted by 1-5 Rd), H, CHF2, CH2F or CF3; - n = 0 or 1; - R4, R5 = 1-6C alkyl, 2-6C alkenyl or 2-6C alkynyl (all optionally substituted by Rb) or H, or - in (I), when = 1, then - CR4R5 = 3-8 membered carbocyclyl or heterocyclyl containing 1 or 2 O, N, NR10 or S(O)p and optionally 1 or 2 double bonds (both optionally substituted by 1-3 R9); - Ra = H, 1-6C alkyl, phenyl or benzyl; - Ra1, Ra3 = 1-6C alkyl, 2-6C alkenyl or 2-6C alkynyl (all optionally substituted by Rc1), H or (CH2)r-3-8C membered carbocyclyl or heterocyclyl containing 1 or 2 N, NRa2, O or S(O)p (optionally substituted by 1-3 Rc1), or - NRaRa1 = 5- or 6-membered heterocyclyl containing N, NRa2, O or S(O)p; - Ra2 = 1-4C alkyl, phenyl or benzyl; - Rb = 1-6C alkyl optionally substituted by Rc1, ORa, SRa, halo, =O, CN, NO2, NRaRa1, C(O)Ra, C(O)ORa, C(O)NRaRa1, C(S)NRaRa1, OC(O)NRaRa1, NRaC(O)ORa, S(O)2NRaRa1, NRaS(O)2Ra3, NRaS(O)2NRaRa1, OS(O)2NRaRa1, S(O)pRa3, CF3, CF2CF3, CHF2, CH2F or phenyl; - Rc = G2 or (CRaRa1)r-5-14 membered heterocyclyl containing 1-4 N, O or S(O)p (all optionally substituted by 1 or 2 Rc1), H, ORa, halo, =O, CN, NO2, CF3, CF2CF3, CHF2, CH2F, G3, (CRaRa1)rC(=NCN)NRaRa1, (CRaRa1)rC(=NRa)NRaRa1, (CRaRa1)rC(=NORa)NRaRa1 or (CRaRa1)rC(O)Ra1, or - CRcRc = 3-8 membered carbocyclic or heterocyclic spiro ring (C1) optionally containing 1-4 O, N or S(O)p and 1 or 2 double bonds (both optionally substituted by 1 or 2 Rc1), or - Rc + Rc (on adjacent C atoms) = 5-7 membered carbocyclyl or heterocyclyl containing 1 or 2 N, O or S(O)p and optionally 1-3 double bonds (both optionally substituted by 1 or 2 Rc1); - G2 = 1-6C alkyl, 2-6C alkenyl, 2-6C alkynyl or (CRaRa1)r-3-10C carbocyclyl; - G3 = (CRaRa1)rNRaRa1), (CRaRa1)rC(O)NRaOH, (CRaRa1)rC(O)ORa1, (CRaRa1)rC(S)ORa1, (CRaRa1)rC(O)NRaRa1, (CRaRa1)rNRaC(O)Ra1, (CRaRa1)rC(S)NRaRa1, (CRaRa1)rOC(O)NRaRa1, (CRaRa1)rNRaC(O)ORa1, (CRaRa1)rNRaC(O)NRaRa1, (CRaRa1)rS(O)pRa3, (CRaRa1)rSO2NRaRa1, (CRaRa1)rNRaSO2Ra3, (CRaRa1)rNRaSO2NRaRa1, or - Rc1 = H, 1-4C alkyl, ORa, halo, =O, CF3, CN, NO2, C(O)Ra, C(O)ORa, C(O)NRaRa1 or S(O)pRa; - Rd = 1-6C alkyl, ORa, halo, =O, CN, NO2, NRaRa1, C(O)Ra, C(O)ORa, C(O)NRaRa1, C(S)NRaRa1, RaNC(O)NRaRa1, OC(O)NRaRa1, RaNC(O)O, S(O)2NRaRa1, NRaS(O)2Ra3, NRaS(O)2NRaRa1, OS(O)2NRaRa1, S(O)pRa3, CF3, CF2CF3, 3-10C carbocyclyl or 5-14 membered heterocyclyl containing 1-4 N, O or S(O)p; - Re = 3-10C carbocyclyl or 5-10 membered heterocyclyl containing 1-4 N, O or S(O)p (both optionally substituted by 1 or 2 Rc1), H, 1-6C alkyl, 1-6C alkoxy, phenoxy or benzoxy; - R6, R7 = H, 1-4C alkyl, 2-4C alkenyl or 2-4C alkynyl; - R9 = G2 or (CRaRa1)r-5-10 membered heterocyclyl containing 1-4 N, O or S(O)p (all optionally substituted by 1 or 2 Rc1), H, G3 or (CRaRa1)rC(O)(CRaRa1)sRe; - R10 = G2 or (CRaRa1)r-5-10 membered heterocyclyl containing 1-4 N, O or S(O)p (all optionally substituted by 1 or 2 Rc1), H, (CRaRa1)tNRaRa1), (CRaRa1)rC(O)NRaOH,

(CRaRa1)rC(O)(CRaRa1)sRe, (CRaRa1)rC(O)ORa1, (CRaRa1)rC(S)ORa1, (CRaRa1)rC(O)NRaRa1, (CRaRa1)tNRaC(O)Ra1, (CRaRa1)rC(S)NRaRa1, (CRaRa1)tOC(O)NRaRa1, (CRaRa1)tNRaC(O)ORa1, (CRaRa1)tNRaC(O)NRaRa1, (CRaRa1)rS(O)pRa3, (CRaRa1)rSO2NRaRa1, (CRaRa1)tNRaSO2Ra3, (CRaRa1)tNRaSO2NRaRa1; - m = 0-3; - p = 0-2; - r, s = 0-4; - t = 1-4; - R11a = W-Ub-X-Y-Z-Ua-Xa-Ya-Za; - Ub = E1; - R2a = Q1, 1-6C alkylene-Q1, 2-6C alkenylene-Q1, 2-6C alkynylene-Q1, (CRaRa1)rO(CRaRa1)s-Q1, (CRaRa1)rNRa(CRaRa1)s-Q1, (CRaRa1)rC(O)(CRaRa1)s-Q1, (CRaRa1)rC(O)O(CRaRa1)s-Q1, (CRaRa1)rOC(O)(CRaRa1)s-Q1, (CRaRa1)rC(O)NRaRa1, (CRaRa1)rC(O)NRa(CRaRa1)s-Q1, (CRaRa1)rNRaC(O)(CRaRa1)s-Q1, (CRaRa1)rOC(O)O(CRaRa1)s-Q1, (CRaRa1)rOC(O)NRa(CRaRa1)s-Q1, (CRaRa1)rNRaC(O)O(CRaRa1)s-Q1, (CRaRa1)rNRaC(O)NRa(CRaRa1)s-Q1, (CRaRa1)rS(O)p(CRaRa1)s-Q1, (CRaRa1)rS(O)2NRa(CRaRa1)s-Q1, (CRaRa1)rNRaSO2(CRaRa1)s-Q1 or (CRaRa1)rNRaSO2NRa(CRaRa1)s-Q1; - Q1 = G1 (optionally substituted by 1-5 Rd) or H; - R3a = Q, 1-6C alkylene-Q, 2-6C alkenylene-Q, 2-6C alkynylene-Q, (CRaRa1)rO(CRaRa1)s-Q, (CRaRa1)rNRa(CRaRa1)s-Q, (CRaRa1)rC(O)(CRaRa1)s-Q, (CRaRa1)rC(O)O(CRaRa1)s-Q, (CRaRa1)rC(O)NRaRa1, (CRaRa1)rC(O)NRa(CRaRa1)s-Q, (CRaRa1)rNRaC(O)(CRaRa1)s-Q, (CRaRa1)rS(O)p(CRaRa1)s-Q, (CRaRa1)rS(O)2NRa(CRaRa1)s-Q or (CRaRa1)rNRaSO2(CRaRa1)s-Q, or - in (II), CR2aR3a, CR3a + CR4 (when n = 1), CR4 + R5 = M1, and - M1 = 3-8 membered carbocyclyl or heterocyclyl containing 1 or 2 O, N, NR10 or S(O)p and optionally 1 or 2 double bonds (both optionally substituted by 1-3 R9) and optionally fused to 5- or 6-membered carbocyclyl or heterocyclyl containing 1 or 2 N, NR10 or S(O)p (both optionally substituted by 1-3 R9); - provided that: - (1) U, Y, Z, Ua, Ya and Za do not combine to form a N-N, N-O, O-N, O-O, S(O)p-O, O-S(O)p or S(O)p-S(O)p group; - (2) when carbocyclyl of CR1 + CR2 is fused to 6 membered aromatic carbocyclyl, then Z is not 1,4-piperidinyl; - (3) ring (C1) does not contain S-S, O-O, or S-O; - (4) in (II), when Z is 2,4-thiazolyl or 1,3-cyclohexyl, then Ub is not O, NRa1 or S(O)p; - (5) in (II), when Z is 3,5-pyrazolyl, then Za is not 3-6C cycloalkyl; - (6) in (II), when Z is 1,4-piperazinyl, then Za is not 7-oxo-5H-pyrrolo(3,4-d)-pyrimidinyl; - (7) in (II), when Z is phenylene, then Za is not 4,5-dihydro-pyridazinonyl, phenyl substituted by benzoxy, or benzimidazolyl substituted by C(=NRa)NRaRa1; - (8) in (II), when Z is 8-14 membered bicyclic heterocyclyl, then Za is not 5-9 membered mono- or bi-cyclic heterocyclyl; - (9) in (II), when R2a is C(O)OH, then Ub is not NRa1S(O)2; - (10) in (II), when Ub-X-Y and Ua-Xa-Ya forms OCH2 and Zb is phenylene, then Za is not phenyl, and - (11) in (II), when Ub-X-Y forms CONHCH2CO, then Zb is not 5 membered heterocyclyl.

ADMINISTRATION - The dosage is 0.001-1000 (especially 1-20) mg/kg/day orally or 1-10mg/kg/minute intravenously. Administration is also intraperitoneal, subcutaneous, intramuscular, intranasal, transdermal or liposome delivery systems. - Administration is optionally in combination with at least one additional antiinflammatory agent such as selective cyclooxygenase-2 inhibitor, interleukin-1 antagonist, dihydroorotate synthase inhibitor, p38 MAP kinase inhibitor, TNF-alpha inhibitor, TNF-alpha sequestration agent and methotrexate.

SPECIFIC COMPOUNDS - 97 Compounds (I) are specifically claimed e.g: - (cis, trans)-tert-butyl-6-((4-(2-methyl-4-quinolynyl)methoxy)benzoyl)amino)-2,4-dioxo-1,3,8-triazaspiro(4.5)decane-8-carboxylate (Ia). - 50 Compounds (II) are specifically claimed e.g: - 2-(2,5-dioxo-4-imidazolidinyl)-N-(4-((2-methyl-4-quinolinyl)methoxy)phenyl)acetamide (IIa).

EXAMPLE - To a solution of 1,2,3,6-tetrahydropyridine (2.65 g), triethylamine (8.9 ml) was dissolved in acetonitrile (MeCN) (150 ml) and treated with tert-butyldicarbonate (8.35 g) and DMAP (195 mg). The reaction was stirred overnight at room temperature. Acetonitrile (MeCN) was removed on a rotary evaporator and the residue was extracted from 10% NaHSO4 with three times of ethylacetate. The combined organic extracts

were dried over MgSO4, filtered and worked up to give (cis, trans)-tert-butyl-6-((4-(2-methyl-4-quinolynyl)methoxy)benzoyl)amino)-2,4-dioxo-1,3,8-triazaspiro(4.5)decane-8-carboxylate (96%).

AN.S DCR-662451

CN.S N-(2,4-Dioxo-1,3-diaza-spiro[4.4]non-6-yl)-4-(2-methyl-quinolin-4-ylmethoxy)-benzenesulfonamide

SDCN RA9ISR



AN.S DCR-662482

CN.S N-(2,4-Dioxo-7-oxa-1,3-diaza-spiro[4.5]dec-10-yl)-4-(2-methyl-quinolin-4-ylmethoxy)-benzenesulfonamide

SDCN RA9ITM



```
=> d ibib ab hitstr 8
YOU HAVE REQUESTED DATA FROM FILE 'WPIX, HCAPLUS, USPATFULL, BEILSTEIN' - CONTINUE?
(Y)/N:y
```

L62 ANSWER 8 OF 13 USPATFULL on STN

ACCESSION NUMBER:	2007:202224 USPATFULL Full-text		
TITLE:	DISPLAY PANEL AND DEVICE UTILIZING THE SAME AND PIXEL STRUCTURE		
INVENTOR(S):	Yeh, Tsung-Lin, Taoyuan County, TAIWAN, PROVINCE OF CHINA		
PATENT ASSIGNEE(S):	QUANTA DISPLAY INC., Taoyuan County, TAIWAN, PROVINCE OF CHINA (non-U.S. corporation)		
	NUMBER	KIND	DATE
PATENT INFORMATION:	US 20070176874	A1	20070802
APPLICATION INFO.:	US 2006-563708	A1	20061128 (11)
	NUMBER		DATE
PRIORITY INFORMATION:	TW 2006-95103470		20060127
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	APPLICATION		
LEGAL REPRESENTATIVE:	THOMAS, KAYDEN, HORSTEMEYER & RISLEY, LLP, 100 GALLERIA PARKWAY, NW, STE 1750, ATLANTA, GA, 30339-5948, US		
NUMBER OF CLAIMS:	26		
EXEMPLARY CLAIM:	1		
NUMBER OF DRAWINGS:	7 Drawing Page(s)		
LINE COUNT:	467		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB A display panel includes a first row line, a second row line, a first column line, a first transistor, and a second transistor. The second row line is parallel to the first row line. The first column line is vertical to the first row line and the second row line. The first transistor includes a first terminal, a second terminal, and a first control terminal coupled to the first row line. The second transistor includes a third terminal coupled to the first column line, a fourth terminal coupled to the first terminal, and a second control terminal coupled to the second row line.

IT 827018-08-6P 827018-09-7P
(preparation of N-pyrazolylbenzenesulfonylamide derivs. as activators of PPAR receptors)

RN 827018-08-6 USPATFULL

CN 1H-Pyrazole-4-carboxylic acid, 1-ethyl-3-[[[4-[(5-methyl-2-phenyl-4-oxazolyl)methoxy]phenyl]sulfonyl]amino]-, ethyl ester (CA INDEX NAME)



RN 827018-09-7 USPATFULL
CN 1H-Pyrazole-4-carboxylic acid, 1-ethyl-3-[[[4-[(5-methyl-2-phenyl-4-oxazolyl)methoxy]phenyl]sulfonyl]amino]- (CA INDEX NAME)



IT 827018-10-0P 827018-11-1P 827018-12-2P
827018-13-3P 827018-14-4P 827018-15-5P
827018-16-6P 827018-17-7P 827018-18-8P
827018-19-9P 827018-20-2P 827018-21-3P
827018-22-4P 827018-23-5P 827018-24-6P
827018-25-7P 827018-26-8P 827018-27-9P
(preparation of N-pyrazolylbenzenesulfonylamide derivs. as activators of PPAR receptors)

RN 827018-10-0 USPATFULL
CN 1H-Pyrazole-4-carboxamide, 1-ethyl-3-[[[4-[(5-methyl-2-phenyl-4-oxazolyl)methoxy]phenyl]sulfonyl]amino]- (CA INDEX NAME)



RN 827018-11-1 USPATFULL
CN 1H-Pyrazole-4-carboxamide, N,1-diethyl-3-[[[4-[(5-methyl-2-phenyl-4-oxazolyl)methoxy]phenyl]sulfonyl]amino]- (CA INDEX NAME)



RN 827018-12-2 USPATFULL
CN Benzenesulfonamide, N-(4-benzoyl-1-ethyl-1H-pyrazol-3-yl)-4-[(5-methyl-2-phenyl-4-oxazolyl)methoxy]- (CA INDEX NAME)



RN 827018-13-3 USPATFULL
CN 1H-Pyrazole-4-carboxylic acid, 3-[[[4-[(5-methyl-2-phenyl-4-oxazolyl)methoxy]phenyl]sulfonyl]amino]- (CA INDEX NAME)



RN 827018-14-4 USPATFULL
CN 1H-Pyrazole-4-carboxylic acid, 3-[[[4-[(5-methyl-2-phenyl-4-oxazolyl)methoxy]phenyl]sulfonyl]amino]-1-(phenylmethyl)-, ethyl ester (CA INDEX NAME)



RN 827018-15-5 USPATFULL
CN 1H-Pyrazole-4-carboxylic acid, 3-[[[4-[(5-methyl-2-phenyl-4-oxazolyl)methoxy]phenyl]sulfonyl]amino]-1-(phenylmethyl)- (CA INDEX NAME)



RN 827018-16-6 USPATFULL
CN 1H-Pyrazole-4-carboxylic acid, 1-methyl-3-[[[4-[(5-methyl-2-phenyl-4-

oxazolyl)methoxy]phenyl]sulfonyl]amino]-, ethyl ester (CA INDEX NAME)



RN 827018-17-7 USPATFULL
CN 1H-Pyrazole-4-carboxylic acid, 1-methyl-3-[[[4-[(5-methyl-2-phenyl-4-oxazolyl)methoxy]phenyl]sulfonyl]amino]- (CA INDEX NAME)



RN 827018-18-8 USPATFULL
CN 1H-Pyrazole-4-carboxylic acid, 3-[[[4-[(5-methyl-2-phenyl-4-oxazolyl)methoxy]phenyl]sulfonyl]amino]-1-(2-propen-1-yl)-, ethyl ester (CA INDEX NAME)



RN 827018-19-9 USPATFULL
CN 1H-Pyrazole-4-carboxylic acid, 3-[[[4-[(5-methyl-2-phenyl-4-oxazolyl)methoxy]phenyl]sulfonyl]amino]-1-(2-propen-1-yl)- (CA INDEX NAME)



RN 827018-20-2 USPATFULL
CN 1H-Pyrazole-4-carboxylic acid, 3-[[[4-[[5-methyl-2-[4-(trifluoromethyl)phenyl]-4-oxazolyl]methoxy]phenyl]sulfonyl]amino]-1-phenyl-, ethyl ester (CA INDEX NAME)



RN 827018-21-3 USPATFULL
CN 1H-Pyrazole-4-carboxylic acid, 1-(1-methylethyl)-3-[[[4-[(5-methyl-2-phenyl-4-oxazolyl)methoxy]phenyl]sulfonyl]amino]-, ethyl ester (CA INDEX NAME)



RN 827018-22-4 USPATFULL
CN 1H-Pyrazole-4-carboxamide, 1-ethyl-N-methyl-3-[[[4-[(5-methyl-2-phenyl-4-oxazolyl)methoxy]phenyl]sulfonyl]amino]- (CA INDEX NAME)



RN 827018-23-5 USPATFULL
CN 1H-Pyrazole-4-carboxamide, 1-ethyl-N,N-dimethyl-3-[[[4-[(5-methyl-2-phenyl-4-oxazolyl)methoxy]phenyl]sulfonyl]amino]- (CA INDEX NAME)



RN 827018-24-6 USPATFULL
CN 1H-Pyrazole-4-carboxamide, N-(cyclopropylmethyl)-1-ethyl-3-[[[4-[(5-methyl-2-phenyl-4-oxazolyl)methoxy]phenyl]sulfonyl]amino]- (CA INDEX NAME)



RN 827018-25-7 USPATFULL
CN 1H-Pyrazole-4-carboxamide, 1-ethyl-3-[[[4-[(5-methyl-2-phenyl-4-oxazolyl)methoxy]phenyl]sulfonyl]amino]-N-(phenylmethyl)- (CA INDEX NAME)



RN 827018-26-8 USPATFULL
CN Benzenesulfonamide, N-[1-ethyl-4-(1-piperidinylcarbonyl)-1H-pyrazol-3-yl]-4-[(5-methyl-2-phenyl-4-oxazolyl)methoxy]- (CA INDEX NAME)



RN 827018-27-9 USPATFULL
CN 1H-Pyrazole-4-carboxylic acid, 1-ethyl-3-[methyl[[4-[(5-methyl-2-phenyl-4-oxazolyl)methoxy]phenyl]sulfonyl]amino]-, ethyl ester (CA INDEX NAME)



IT 827018-07-5P
(preparation of N-pyrazolylbenzenesulfonylamide derivs. as activators of PPARs)
RN 827018-07-5 USPATFULL
CN 1H-Pyrazole-4-carboxylic acid, 1-ethyl-3-[[[4-[[5-methyl-2-[4-(trifluoromethyl)phenyl]-4-oxazolyl]methoxy]phenyl]sulfonyl]amino]-, ethyl ester (CA INDEX NAME)



=> d ide 9
YOU HAVE REQUESTED DATA FROM FILE 'WPIX, HCAPLUS, USPATFULL, BEILSTEIN' - CONTINUE? (Y)/N:y

L62 ANSWER 9 OF 13 BEILSTEIN COPYRIGHT 2008 BEILSTEIN MDL on STN

Beilstein Records (BRN):	5464121
Beilstein Pref. RN (BPR):	141233-26-3
CAS Reg. No. (RN):	141233-26-3
Chemical Name (CN):	4-<5-mercapto-4-(4-methoxy-phenyl)-4H-<1,2,4>triazol-3-ylmethoxy>-N-(5-methyl-isoxazol-3-yl)-benzenesulfonamide
Autonom Name (AUN):	4-<5-mercapto-4-(4-methoxy-phenyl)-4H-<1,2,4>triazol-3-ylmethoxy>-N-(5-methyl-isoxazol-3-yl)-benzenesulfonamide
Molec. Formula (MF):	C20 H19 N5 O5 S2

Molecular Weight (MW):	473.52
Lawson Number (LN):	31559, 30073, 14892, 13884, 289
Compound Type (CTYPE):	heterocyclic
Constitution ID (CONSID):	4803040
Tautomer ID (TAUTID):	5217474
Beilstein Citation (BSO):	6-27
Entry Date (DED):	1993/05/04
Update Date (DUPD):	1994/02/18



Field Availability:

Code	Name	Occurrence
BRN	Beilstein Records	1
BPR	Beilstein Preferred RN	1
RN	CAS Registry Number	1
CN	Chemical Name	1
AUN	Autonomname	1
MF	Molecular Formula	1
FW	Formular Weight	1
LN	Lawson Number	5
CTYPE	Compound Type	1
CONSID	Constitution ID	1
TAUTID	Tautomer ID	1
BSO	Beilstein Citation	1
ED	Entry Date	1
UPD	Update Date	1
IR	Infrared Spectrum	1
MP	Melting Point	1
NMR	Nuclear Magnetic Resonance	1
PHARM	Pharmacological Data	1

This substance also occurs in Reaction Documents:

Code	Name	Occurrence
RX	Reaction Documents	1
RXPRO	Substance is Reaction Product	1

=> d rx 9
YOU HAVE REQUESTED DATA FROM FILE 'WPIX, HCAPLUS, USPATFULL, BEILSTEIN' - CONTINUE?

(Y)/N:y

L62 ANSWER 9 OF 13 BEILSTEIN COPYRIGHT 2008 BEILSTEIN MDL on STN

Reaction:
RX

Reaction ID (.ID):	3414742
Reactant BRN (.RBRN):	5452422, 606967
Reactant (.RCT):	4-hydrazinocarbonylmethoxy-N-(5-methyl-isoxazol-3-yl)-benzenesulfonamide, 1-isothiocyanato-4-methoxy-benzene
Product BRN (.PBRN):	5464121
Product (.PRO):	4-<5-mercapto-4-(4-methoxy-phenyl)-4H-<1,2,4>triazol-3-ylmethoxy>-N-(5-methyl-isoxazol-3-yl)-benzenesulfonamide
No. of React. Details (.NVAR):	1

Reaction Details:
RX

Reaction RID (.RID):	3414742.1
Reaction Classification (.CL):	Preparation
Reagent (.RGT):	2.) 2 N aq. NaOH
Other Conditions (.COND):	1.) EtOH, reflux, 4 h, 2.) reflux
Note(s) (.COM):	Yield given. Multistep reaction
Reference(s):	

1. Vidyasagar, A.; Dave, A. M.; Mehta, M. H.; Agrawal, Y. K., J.Indian Chem.Soc., CODEN: JICSAH, 68(10), <1991>, 576-578; BABS-5654306

=> d ide 10
YOU HAVE REQUESTED DATA FROM FILE 'WPIX, HCAPLUS, USPATFULL, BEILSTEIN' - CONTINUE?
(Y)/N:y

L62 ANSWER 10 OF 13 BEILSTEIN COPYRIGHT 2008 BEILSTEIN MDL on STN

Beilstein Records (BRN):	5463783
Beilstein Pref. RN (BPR):	141233-25-2
CAS Reg. No. (RN):	141233-25-2
Chemical Name (CN):	4-<4-(4-chloro-phenyl)-5-mercapto-4H-<1,2,4>triazol-3-ylmethoxy>-N-(5-methyl-isoxazol-3-yl)-benzenesulfonamide
Autonom Name (AUN):	4-<4-(4-chloro-phenyl)-5-mercapto-4H-<1,2,4>triazol-3-ylmethoxy>-N-(5-methyl-isoxazol-3-yl)-benzenesulfonamide
Molec. Formula (MF):	C19 H16 Cl N5 O4 S2
Molecular Weight (MW):	477.94
Lawson Number (LN):	31559, 30073, 14132, 13884
Compound Type (CTYPE):	heterocyclic
Constitution ID (CONSID):	4802835
Tautomer ID (TAUTID):	5217211
Beilstein Citation (BSO):	6-27
Entry Date (DED):	1993/05/04

Update Date (DUPD): 1994/02/18



Field Availability:

Code	Name	Occurrence
BRN	Beilstein Records	1
BPR	Beilstein Preferred RN	1
RN	CAS Registry Number	1
CN	Chemical Name	1
AUN	Autonomname	1
MF	Molecular Formula	1
FW	Formular Weight	1
LN	Lawson Number	4
FS	File Segment	1
CTYPE	Compound Type	1
CONSID	Constitution ID	1
TAUTID	Tautomer ID	1
BSO	Beilstein Citation	1
ED	Entry Date	1
UPD	Update Date	1
IR	Infrared Spectrum	1
MP	Melting Point	1
NMR	Nuclear Magnetic Resonance	1
PHARM	Pharmacological Data	1

This substance also occurs in Reaction Documents:

Code	Name	Occurrence
RX	Reaction Documents	1
RXPRO	Substance is Reaction Product	1

=> d rx 10
YOU HAVE REQUESTED DATA FROM FILE 'WPIX, HCAPLUS, USPATFULL, BEILSTEIN' - CONTINUE?
(Y)/N:y

L62 ANSWER 10 OF 13 BEILSTEIN COPYRIGHT 2008 BEILSTEIN MDL on STN

Reaction:
RX

Reaction ID (.ID):	2729171
Reactant BRN (.RBRN):	5452422, 471610
Reactant (.RCT):	4-hydrazinocarbonylmethoxy-N-(5-methyl-isoxazol-3-yl)-benzenesulfonamide, 1-chloro-4-isothiocyanato-benzene
Product BRN (.PBRN):	5463783
Product (.PRO):	4-<4-(4-chloro-phenyl)-5-mercapto-4H-<1,2,4>triazol-3-ylmethoxy>-N-(5-methyl-isoxazol-3-yl)-benzenesulfonamide
No. of React. Details (.NVAR):	1

Reaction Details:
RX

Reaction RID (.RID):	2729171.1
Reaction Classification (.CL):	Preparation
Reagent (.RGT):	2.) 2 N aq. NaOH
Other Conditions (.COND):	1.) EtOH, reflux, 4 h, 2.) reflux
Note(s) (.COM):	Yield given. Multistep reaction
Reference(s):	

1. Vidyasagar, A.; Dave, A. M.; Mehta, M. H.; Agrawal, Y. K., J.Indian Chem.Soc., CODEN: JICSAH, 68(10), <1991>, 576-578; BABS-5654306

=> d ide 11
YOU HAVE REQUESTED DATA FROM FILE 'WPIX, HCAPLUS, USPATFULL, BEILSTEIN' - CONTINUE? (Y)/N:y

L62 ANSWER 11 OF 13 BEILSTEIN COPYRIGHT 2008 BEILSTEIN MDL on STN

Beilstein Records (BRN):	5463125
Beilstein Pref. RN (BPR):	141233-27-4
CAS Reg. No. (RN):	141233-27-4
Chemical Name (CN):	4-(5-mercapto-4-p-tolyl-4H-<1,2,4>triazol-3-ylmethoxy)-N-(5-methyl-isoxazol-3-yl)-benzenesulfonamide
Autonom Name (AUN):	4-(5-mercapto-4-p-tolyl-4H-<1,2,4>triazol-3-ylmethoxy)-N-(5-methyl-isoxazol-3-yl)-benzenesulfonamide
Molec. Formula (MF):	C20 H19 N5 O4 S2
Molecular Weight (MW):	457.52
Lawson Number (LN):	31559, 30073, 14141, 13884
Compound Type (CTYPE):	heterocyclic
Constitution ID (CONSID):	4803424
Tautomer ID (TAUTID):	5216303
Beilstein Citation (BSO):	6-27
Entry Date (DED):	1993/05/04
Update Date (DUPD):	1994/02/18



Field Availability:

Code	Name	Occurrence
BRN	Beilstein Records	1
BPR	Beilstein Preferred RN	1
RN	CAS Registry Number	1
CN	Chemical Name	1
AUN	Autonomname	1
MF	Molecular Formula	1
FW	Formular Weight	1
LN	Lawson Number	4
CTYPE	Compound Type	1
CONSID	Constitution ID	1
TAUTID	Tautomer ID	1
BSO	Beilstein Citation	1
ED	Entry Date	1
UPD	Update Date	1
IR	Infrared Spectrum	1
MP	Melting Point	1
NMR	Nuclear Magnetic Resonance	1
PHARM	Pharmacological Data	1

This substance also occurs in Reaction Documents:

Code	Name	Occurrence
RX	Reaction Documents	1
RXPRO	Substance is Reaction Product	1

=> d rx 11
YOU HAVE REQUESTED DATA FROM FILE 'WPIX, HCAPLUS, USPATFULL, BEILSTEIN' - CONTINUE?
(Y)/N:y

L62 ANSWER 11 OF 13 BEILSTEIN COPYRIGHT 2008 BEILSTEIN MDL on STN

Reaction:

RX

Reaction ID (.ID):	2411275
Reactant BRN (.RBRN):	5452422, 386032
Reactant (.RCT):	4-hydrazinocarbonylmethoxy-N-(5-methyl-isoxazol-3-yl)-benzenesulfonamide, 1-isothiocyanato-4-methyl-benzene
Product BRN (.PBRN):	5463125
Product (.PRO):	4-(5-mercapto-4-p-tolyl-4H-<1,2,4>triazol-3-ylmethoxy)-N-(5-methyl-isoxazol-3-yl)-benzenesulfonamide
No. of React. Details (.NVAR):	1

Reaction Details:

RX

Reaction RID (.RID):	2411275.1
Reaction Classification (.CL):	Preparation
Reagent (.RGT):	2.) 2 N aq. NaOH
Other Conditions (.COND):	1.) EtOH, reflux, 4 h, 2.) reflux
Note(s) (.COM):	Yield given. Multistep reaction

Reference(s):

1. Vidyasagar, A.; Dave, A. M.; Mehta, M. H.; Agrawal, Y. K., J.Indian Chem.Soc., CODEN: JICSAH, 68(10), <1991>, 576-578; BABS-5654306

=> d ide 12
YOU HAVE REQUESTED DATA FROM FILE 'WPIX, HCAPLUS, USPATFULL, BEILSTEIN' - CONTINUE? (Y)/N:y

L62 ANSWER 12 OF 13 BEILSTEIN COPYRIGHT 2008 BEILSTEIN MDL on STN

Beilstein Records (BRN):	5462257
Beilstein Pref. RN (BPR):	141233-24-1
CAS Reg. No. (RN):	141233-24-1
Chemical Name (CN):	4-(5-mercapto-4-phenyl-4H-<1,2,4>triazol-3-ylmethoxy)-N-(5-methyl-isoxazol-3-yl)-benzenesulfonamide
Autonom Name (AUN):	4-(5-mercapto-4-phenyl-4H-<1,2,4>triazol-3-ylmethoxy)-N-(5-methyl-isoxazol-3-yl)-benzenesulfonamide
Molec. Formula (MF):	C19 H17 N5 O4 S2
Molecular Weight (MW):	443.49
Lawson Number (LN):	31559, 30073, 14131, 13884
Compound Type (CTYPE):	heterocyclic
Constitution ID (CONSID):	4800816
Tautomer ID (TAUTID):	5214780
Beilstein Citation (BSO):	6-27
Entry Date (DED):	1993/05/04
Update Date (DUPD):	1994/02/18



Field Availability:

Code	Name	Occurrence
BRN	Beilstein Records	1
BPR	Beilstein Preferred RN	1
RN	CAS Registry Number	1
CN	Chemical Name	1
AUN	Autonomname	1
MF	Molecular Formula	1
FW	Formular Weight	1
LN	Lawson Number	4
CTYPE	Compound Type	1
CONSID	Constitution ID	1
TAUTID	Tautomer ID	1
BSO	Beilstein Citation	1
ED	Entry Date	1
UPD	Update Date	1
IR	Infrared Spectrum	1
MP	Melting Point	1
NMR	Nuclear Magnetic Resonance	1
PHARM	Pharmacological Data	1

This substance also occurs in Reaction Documents:

Code	Name	Occurrence
RX	Reaction Documents	1
RXPRO	Substance is Reaction Product	1

=> d rx 12
YOU HAVE REQUESTED DATA FROM FILE 'WPIX, HCAPLUS, USPATFULL, BEILSTEIN' - CONTINUE?
(Y)/N:y

L62 ANSWER 12 OF 13 BEILSTEIN COPYRIGHT 2008 BEILSTEIN MDL on STN

Reaction:
RX
Reaction ID (.ID): 2719097

Reactant BRN (.RBRN): 5452422, 471392
Reactant (.RCT): 4-hydrazinocarbonylmethoxy-N-(5-methyl-isoxazol-3-yl)-benzenesulfonamide, isothiocyanatobenzene
Product BRN (.PBRN): 5462257
Product (.PRO): 4-(5-mercapto-4-phenyl-4H-<1,2,4>triazol-3-ylmethoxy)-N-(5-methyl-isoxazol-3-yl)-benzenesulfonamide
No. of React. Details (.NVAR): 1

Reaction Details:
RX
Reaction RID (.RID): 2719097.1
Reaction Classification (.CL): Preparation
Reagent (.RGT): 2.) 2 N aq. NaOH
Other Conditions (.COND): 1.) EtOH, reflux, 4 h, 2.) reflux
Note(s) (.COM): Yield given. Multistep reaction
Reference(s):
1. Vidyasagar, A.; Dave, A. M.; Mehta, M. H.; Agrawal, Y. K., J.Indian Chem.Soc., CODEN: JICSAH, 68(10), <1991>, 576-578; BABS-5654306

=> d ide 13
YOU HAVE REQUESTED DATA FROM FILE 'WPIX, HCAPLUS, USPATFULL, BEILSTEIN' - CONTINUE? (Y)/N:y

L62 ANSWER 13 OF 13 BEILSTEIN COPYRIGHT 2008 BEILSTEIN MDL on STN

Beilstein Records (BRN): 5456994
Beilstein Pref. RN (BPR): 141233-23-0
CAS Reg. No. (RN): 141233-23-0
Chemical Name (CN): 5-<N-(5-methyl-3-isoxazolyl)benzene sulphonamido-4-oxymethyl>-2-thio-1,3,4-oxadiazole
Autonom Name (AUN): N-(5-methyl-isoxazol-3-yl)-4-(5-thioxo-4,5-dihydro-<1,3,4>oxadiazol-2-ylmethoxy)-benzenesulfonamide
Molec. Formula (MF): C13 H12 N4 O5 S2
Molecular Weight (MW): 368.38
Lawson Number (LN): 32161, 31559, 13884
Compound Type (CTYPE): heterocyclic
Constitution ID (CONSID): 4790896
Tautomer ID (TAUTID): 5210018
Beilstein Citation (BSO): 6-27
Entry Date (DED): 1993/05/04
Update Date (DUPD): 1994/02/18



Field Availability:

Code	Name	Occurrence
BRN	Beilstein Records	1
BPR	Beilstein Preferred RN	1
RN	CAS Registry Number	1
CN	Chemical Name	1
AUN	Autonomname	1
MF	Molecular Formula	1
FW	Formular Weight	1
LN	Lawson Number	3
CTYPE	Compound Type	1
CONSID	Constitution ID	1
TAUTID	Tautomer ID	1
BSO	Beilstein Citation	1
ED	Entry Date	1
UPD	Update Date	1
IR	Infrared Spectrum	1
MP	Melting Point	1
NMR	Nuclear Magnetic Resonance	1
PHARM	Pharmacological Data	1

This substance also occurs in Reaction Documents:

Code	Name	Occurrence
RX	Reaction Documents	1
RXPRO	Substance is Reaction Product	1

```
=> d rx 13
YOU HAVE REQUESTED DATA FROM FILE 'WPIX, HCAPLUS, USPATFULL, BEILSTEIN' - CONTINUE?
(Y)/N:y
```

L62 ANSWER 13 OF 13 BEILSTEIN COPYRIGHT 2008 BEILSTEIN MDL on STN

Reaction:
RX
Reaction ID (.ID): 1611075
Reactant BRN (.RBRN): 5452422, 1098293

Reactant (.RCT):	4-hydrazinocarbonylmethoxy-N-(5-methyl-isoxazol-3-yl)-benzenesulfonamide, carbon disulfide
Product BRN (.PBRN):	5456994
Product (.PRO):	N-(5-methyl-isoxazol-3-yl)-4-(5-thioxo-4,5-dihydro-<1,3,4>oxadiazol-2-ylmethoxy)-benzenesulfonamide
No. of React. Details (.NVAR):	1

Reaction Details:
RX

Reaction RID (.RID):	1611075.1
Reaction Classification (.CL):	Preparation
Yield (.YDT):	50 percent (BRN=5456994)
Reagent (.RGT):	ethanolic KOH
Time (.TIM):	18 hour(s)
Other Conditions (.COND):	Heating

Reference(s):

1. Vidyasagar, A.; Dave, A. M.; Mehta, M. H.; Agrawal, Y. K., J.Indian Chem.Soc., CODEN: JICSAH, 68(10), <1991>, 576-578; BABS-5654306

```
=> d que nos l44
L1             2 SEA FILE=HCAPLUS ABB=ON  PLU=ON  US2006-563708/APPS
L2             1 SEA FILE=HCAPLUS ABB=ON  PLU=ON  L1 NOT PIXEL/TI
L5               TRANSFER  PLU=ON  L2 1- RN :      37 TERMS
L6            37 SEA FILE=REGISTRY ABB=ON  PLU=ON  L5
L13              STR
L18      1320380 SEA FILE=REGISTRY ABB=ON  PLU=ON  N2C3/ES OR NCOC2/ES
L20           41 SEA FILE=REGISTRY SUB=L18 SSS FUL L13
L21           21 SEA FILE=REGISTRY ABB=ON  PLU=ON  L6 AND L20
L22            1 SEA FILE=REGISTRY ABB=ON  PLU=ON  L21 AND "C26 H25 F3 N4 O6
                 S"/MF
L24              QUE  ABB=ON  PLU=ON  VEDANANDA, T?/AU
L25              QUE  ABB=ON  PLU=ON  NOVARTIS/CS,SO,PA
L26            2 SEA FILE=HCAPLUS ABB=ON  PLU=ON  L20
L27            1 SEA FILE=HCAPLUS ABB=ON  PLU=ON  L22
L28            2 SEA FILE=HCAPLUS ABB=ON  PLU=ON  (L26 OR L27)
L29            1 SEA FILE=HCAPLUS ABB=ON  PLU=ON  L28 AND (L24 OR L25)
L36      3910521 SEA FILE=REGISTRY ABB=ON  PLU=ON  NCNC2/ES OR N2CNC/ES OR
                 NCSC2/ES OR SC4/ES
L38           31 SEA FILE=REGISTRY SUB=L36 SSS FUL L13
L39              STR
L41           23 SEA FILE=REGISTRY SUB=L38 SSS FUL L39
L42            3 SEA FILE=HCAPLUS ABB=ON  PLU=ON  L41
L43            0 SEA FILE=HCAPLUS ABB=ON  PLU=ON  L42 AND (L24 OR L25)
L44            1 SEA FILE=HCAPLUS ABB=ON  PLU=ON  L29 OR L43


=> d que nos l34
L13              STR
L24              QUE  ABB=ON  PLU=ON  VEDANANDA, T?/AU
L25              QUE  ABB=ON  PLU=ON  NOVARTIS/CS,SO,PA
L32           47 SEA FILE=WPIX SSS FUL L13
L33            6 SEA FILE=WPIX ABB=ON  PLU=ON  (RAC2TR/DCN OR RAC2TS/DCN OR
                 RAC2TZ/DCN OR RAGQML/DCN OR RAGQMM/DCN OR RAGQMN/DCN OR
                 RAGQMO/DCN OR RAGQMP/DCN OR RAGQMQ/DCN OR RAGQMS/DCN OR
                 RAGQMT/DCN OR RAGQMU/DCN OR RAGQMV/DCN OR RAGQMW/DCN OR
                 RAGQMX/DCN OR RAGQMY/DCN OR RAGQMZ/DCN OR RAGQN0/DCN OR
                 RAGQN1/DCN OR RAGQN2/DCN OR RAGQN3/DCN OR RAGQN4/DCN OR
                 RAGQN5/DCN OR RAHXNT/DCN OR RAQKGB/DCN OR RAQKGC/DCN OR
                 RAQKGD/DCN OR RAQKGG/DCN OR RAQKGH/DCN OR RAQKGI/DCN OR
                 RAQKGJ/DCN OR RAQKGK/DCN OR RAQKGL/DCN OR RAQKGM/DCN OR
                 RAQKGN/DCN OR RAQKGO/DCN OR RAQKGP/DCN OR RAQKGQ/DCN OR
                 RAQKGR/DCN OR RAQKGS/DCN OR RAQKGT/DCN OR RARI2C/DCN OR
                 RARI2G/DCN OR RARI2H/DCN OR RARI27/DCN OR RA9ISR/DCN OR
                 RA9ITM/DCN) OR L32/DCR
L34            1 SEA FILE=WPIX ABB=ON  PLU=ON  L33 AND (L24 OR L25)


=> d his l48

     (FILE 'USPATFULL, USPATOLD, USPAT2' ENTERED AT 13:10:42 ON 02 OCT 2008)
L48            1 S L47 AND L24-L25

=> d que nos l48
L1             2 SEA FILE=HCAPLUS ABB=ON  PLU=ON  US2006-563708/APPS
L2             1 SEA FILE=HCAPLUS ABB=ON  PLU=ON  L1 NOT PIXEL/TI
L5               TRANSFER  PLU=ON  L2 1- RN :      37 TERMS
L6            37 SEA FILE=REGISTRY ABB=ON  PLU=ON  L5
L13              STR
```

```
L18     1320380 SEA FILE=REGISTRY ABB=ON  PLU=ON  N2C3/ES OR NCOC2/ES
L20          41 SEA FILE=REGISTRY SUB=L18 SSS FUL L13
L21          21 SEA FILE=REGISTRY ABB=ON  PLU=ON  L6 AND L20
L22           1 SEA FILE=REGISTRY ABB=ON  PLU=ON  L21 AND "C26 H25 F3 N4 O6
                S"/MF
L24             QUE  ABB=ON  PLU=ON  VEDANANDA, T?/AU
L25             QUE  ABB=ON  PLU=ON  NOVARTIS/CS,SO,PA
L36     3910521 SEA FILE=REGISTRY ABB=ON  PLU=ON  NCNC2/ES OR N2CNC/ES OR
                NCSC2/ES OR SC4/ES
L38          31 SEA FILE=REGISTRY SUB=L36 SSS FUL L13
L39             STR
L41          23 SEA FILE=REGISTRY SUB=L38 SSS FUL L39
L47           2 SEA L20 OR L22 OR L41
L48           1 SEA L47 AND (L24 OR L25)


=> d que nos l51
L1            2 SEA FILE=HCAPLUS ABB=ON  PLU=ON  US2006-563708/APPS
L2            1 SEA FILE=HCAPLUS ABB=ON  PLU=ON  L1 NOT PIXEL/TI
L5              TRANSFER  PLU=ON  L2 1- RN :      37 TERMS
L6           37 SEA FILE=REGISTRY ABB=ON  PLU=ON  L5
L13             STR
L18     1320380 SEA FILE=REGISTRY ABB=ON  PLU=ON  N2C3/ES OR NCOC2/ES
L20          41 SEA FILE=REGISTRY SUB=L18 SSS FUL L13
L21          21 SEA FILE=REGISTRY ABB=ON  PLU=ON  L6 AND L20
L22           1 SEA FILE=REGISTRY ABB=ON  PLU=ON  L21 AND "C26 H25 F3 N4 O6
                S"/MF
L24             QUE  ABB=ON  PLU=ON  VEDANANDA, T?/AU
L25             QUE  ABB=ON  PLU=ON  NOVARTIS/CS,SO,PA
L36     3910521 SEA FILE=REGISTRY ABB=ON  PLU=ON  NCNC2/ES OR N2CNC/ES OR
                NCSC2/ES OR SC4/ES
L38          31 SEA FILE=REGISTRY SUB=L36 SSS FUL L13
L39             STR
L41          23 SEA FILE=REGISTRY SUB=L38 SSS FUL L39
L50           1 SEA FILE=TOXCENTER ABB=ON  PLU=ON  L20 OR L22 OR L41
L51           1 SEA FILE=TOXCENTER ABB=ON  PLU=ON  L50 AND (L24 OR L25)


=> d que l53
L1            2 SEA FILE=HCAPLUS ABB=ON  PLU=ON  US2006-563708/APPS
L2            1 SEA FILE=HCAPLUS ABB=ON  PLU=ON  L1 NOT PIXEL/TI
L5              TRANSFER  PLU=ON  L2 1- RN :      37 TERMS
L6           37 SEA FILE=REGISTRY ABB=ON  PLU=ON  L5
L13             STR
```




```
VAR G1=12/10
VPA 3-13/14/15/16/17/18 U
NODE ATTRIBUTES:
CONNECT IS E2  RC AT   2
CONNECT IS E2  RC AT  12
```

```
DEFAULT MLEVEL IS ATOM
GGCAT   IS UNS  AT   1
GGCAT   IS UNS  AT   7
DEFAULT ECLEVEL IS LIMITED
ECOUNT  IS X8 C  AT   2

GRAPH ATTRIBUTES:
RING(S) ARE ISOLATED OR EMBEDDED
NUMBER OF NODES IS  17

STEREO ATTRIBUTES: NONE
L18     1320380 SEA FILE=REGISTRY ABB=ON  PLU=ON  N2C3/ES OR NCOC2/ES
L20          41 SEA FILE=REGISTRY SUB=L18 SSS FUL L13
L21          21 SEA FILE=REGISTRY ABB=ON  PLU=ON  L6 AND L20
L22           1 SEA FILE=REGISTRY ABB=ON  PLU=ON  L21 AND "C26 H25 F3 N4 O6
                S"/MF
L36     3910521 SEA FILE=REGISTRY ABB=ON  PLU=ON  NCNC2/ES OR N2CNC/ES OR
                NCSC2/ES OR SC4/ES
L38          31 SEA FILE=REGISTRY SUB=L36 SSS FUL L13
L39             STR
```




```
VAR G1=12/10
NODE ATTRIBUTES:
CONNECT IS E2  RC AT   2
CONNECT IS E2  RC AT  12
DEFAULT MLEVEL IS ATOM
DEFAULT ECLEVEL IS LIMITED
ECOUNT  IS X8 C  AT   2

GRAPH ATTRIBUTES:
RSPEC  19  13
NUMBER OF NODES IS  20

STEREO ATTRIBUTES: NONE
L41          23 SEA FILE=REGISTRY SUB=L38 SSS FUL L39
L53           0 SEA L20 OR L22 OR L41


=> d his l61

     (FILE 'MEDLINE, BIOSIS, EMBASE, PASCAL, CABA, CEABA-VTB, LIFESCI, BIOENG,
     BIOTECHNO, BIOTECHDS, DRUGU, DRUGB, VETU, VETB, SCISEARCH, CONFSCI,
     DISSABS, RDISCLOSURE' ENTERED AT 13:17:35 ON 02 OCT 2008)
L61           1 S L60 AND L24-L25

=> d que l61
L24             QUE  ABB=ON  PLU=ON  VEDANANDA, T?/AU
L25             QUE  ABB=ON  PLU=ON  NOVARTIS/CS,SO,PA
L60         794 SEA ?BENZENESULFONYLAMIN? OR ?BENZENESULPHONYLAMIN? OR
                (?BENZENE?(1T)(?SULFONYL? OR ?SULPHONYL?)(1T)(?AMINO OR
```

```
                ?AMINE))
L61             1 SEA L60 AND (L24 OR L25)


=> dup rem l44 l34 l48 l51 l61
DUPLICATE IS NOT AVAILABLE IN 'RDISCLOSURE'.
ANSWERS FROM THESE FILES WILL BE CONSIDERED UNIQUE
FILE 'HCAPLUS' ENTERED AT 13:33:35 ON 02 OCT 2008
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2008 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'WPIX' ENTERED AT 13:33:35 ON 02 OCT 2008
COPYRIGHT (C) 2008 THOMSON REUTERS

FILE 'USPATFULL' ENTERED AT 13:33:35 ON 02 OCT 2008
CA INDEXING COPYRIGHT (C) 2008 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'TOXCENTER' ENTERED AT 13:33:35 ON 02 OCT 2008
COPYRIGHT (C) 2008 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'PASCAL' ENTERED AT 13:33:35 ON 02 OCT 2008
Any reproduction or dissemination in part or in full,
by means of any process and on any support whatsoever
is prohibited without the prior written agreement of INIST-CNRS.
COPYRIGHT (C) 2008 INIST-CNRS. All rights reserved.
PROCESSING COMPLETED FOR L44
PROCESSING COMPLETED FOR L34
PROCESSING COMPLETED FOR L48
PROCESSING COMPLETED FOR L51
PROCESSING COMPLETED FOR L61
L63             3 DUP REM L44 L34 L48 L51 L61 (2 DUPLICATES REMOVED)
                  ANSWER '1' FROM FILE HCAPLUS
                  ANSWER '2' FROM FILE USPATFULL
                  ANSWER '3' FROM FILE PASCAL
```

```
=> d ibib ed abs hitstr

L63  ANSWER 1 OF 3  HCAPLUS  COPYRIGHT 2008 ACS on STN DUPLICATE 1
ACCESSION NUMBER:         2005:58199  HCAPLUS  Full-text
DOCUMENT NUMBER:          142:134592
TITLE:                    Preparation of N-pyrazolylbenzenesulfonylamide
                          derivatives as activators of PPARs
INVENTOR(S):              Vedananda, Thalaththani Ralalage
PATENT ASSIGNEE(S):       Novartis AG, Switz.; Novartis
                          Pharma GmbH
SOURCE:                   PCT Int. Appl., 61 pp.
                          CODEN: PIXXD2
DOCUMENT TYPE:            Patent
LANGUAGE:                 English
FAMILY ACC. NUM. COUNT:   1
PATENT INFORMATION:

     PATENT NO.           KIND   DATE        APPLICATION NO.         DATE
     ---------------      ----   --------    --------------------    --------
     WO 2005005421         A1    20050120    WO 2004-EP7442          20040707
         W:  AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH,
             CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD,
             GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC,
             LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI,
             NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY,
             TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
         RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM,
             AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK,
             EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE,
             SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE,
             SN, TD, TG
     AU 2004255342         A1    20050120    AU 2004-255342          20040707
     CA 2531418            A1    20050120    CA 2004-2531418         20040707
     EP 1646628            A1    20060419    EP 2004-740754          20040707
         R:  AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
             IE, SI, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK
     CN 1816546            A     20060809    CN 2004-80019234        20040707
     BR 2004012380         A     20060919    BR 2004-12380           20040707
     MX 2006PA00118        A     20060427    MX 2006-PA118           20060105
     IN 2006CN00071        A     20070629    IN 2006-CN71            20060105
     US 20070043020        A1    20070222    US 2006-563708          20060619
PRIORITY APPLN. INFO.:                       US 2003-485870P     P   20030708
                                             WO 2004-EP7442      W   20040707
OTHER SOURCE(S):          MARPAT 142:134592
ED   Entered STN:  21 Jan 2005
GI
```



I



II

AB Title compds. represented by the formula I [wherein R1, R2= independently H, halo, OH, (un)substituted alkyl(thio), alkoxy, (hetero)aralkyl; R1R2 = (un)substituted (hetero)aromatic ring, alkylene; R3 = H or (un)substituted alkyl; X = Z(CH2)pQW; Z = a bond, O, S, CO, etc.; p = 1-8, Q = a bond, O(alkylene), S(alkylene), CO, etc.; W = cycloalkyl, aryl, (hetero)aralkyl, etc.; L = heteroarom. ring; and pharmaceutically acceptable salts thereof, or prodrug derivs. thereof] were prepared as activators of PPARs (Peroxisome Proliferator-Activated Receptors). For example, II was given in a multi-step synthesis starting from 4-hydroxybenzenesulfonic acid sodium salt dihydrate. II showed an EC50 of about 5 nM in the PPARα receptor binding assay, and an EC50 of about 3 nM in the PPARγ receptor binding assay. Thus, I and their pharmaceutical compns. are useful for the treatment of conditions mediated by the PPAR receptor activity in mammals, such as dyslipidemia, hyperlipidemia, hypercholesteremia, atherosclerosis, hypertriglyceridemia, heart failure, myocardial infarction, vascular diseases, cardiovascular diseases, hypertension, obesity, inflammation, arthritis, cancer, Alzheimer's disease, skin disorders, respiratory diseases, opthalmic disorders, inflammatory bowel diseases (IBDs) ulcerative colitis and Crohn's disease, and conditions in which impaired glucose tolerance, hyperglycemia and insulin resistance are implicated, such as type-1 and type-2 diabetes, and Syndrome X (no data).

IT 827018-08-6P 827018-09-7P
RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(preparation of N-pyrazolylbenzenesulfonylamide derivs. as activators of PPAR receptors)

RN 827018-08-6 HCAPLUS

CN 1H-Pyrazole-4-carboxylic acid, 1-ethyl-3-[[[4-[(5-methyl-2-phenyl-4-oxazolyl)methoxy]phenyl]sulfonyl]amino]-, ethyl ester (CA INDEX NAME)



RN 827018-09-7 HCAPLUS

CN 1H-Pyrazole-4-carboxylic acid, 1-ethyl-3-[[[4-[(5-methyl-2-phenyl-4-oxazolyl)methoxy]phenyl]sulfonyl]amino]- (CA INDEX NAME)



IT 827018-10-0P 827018-11-1P 827018-12-2P
827018-13-3P 827018-14-4P 827018-15-5P
827018-16-6P 827018-17-7P 827018-18-8P
827018-19-9P 827018-20-2P 827018-21-3P
827018-22-4P 827018-23-5P 827018-24-6P
827018-25-7P 827018-26-8P 827018-27-9P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of N-pyrazolylbenzenesulfonylamide derivs. as activators of PPAR receptors)

RN 827018-10-0 HCAPLUS

CN 1H-Pyrazole-4-carboxamide, 1-ethyl-3-[[[4-[(5-methyl-2-phenyl-4-oxazolyl)methoxy]phenyl]sulfonyl]amino]- (CA INDEX NAME)



RN 827018-11-1 HCAPLUS

CN 1H-Pyrazole-4-carboxamide, N,1-diethyl-3-[[[4-[(5-methyl-2-phenyl-4-oxazolyl)methoxy]phenyl]sulfonyl]amino]- (CA INDEX NAME)



RN 827018-12-2 HCAPLUS

CN Benzenesulfonamide, N-(4-benzoyl-1-ethyl-1H-pyrazol-3-yl)-4-[(5-methyl-2-phenyl-4-oxazolyl)methoxy]- (CA INDEX NAME)



RN 827018-13-3 HCAPLUS
CN 1H-Pyrazole-4-carboxylic acid, 3-[[[4-[(5-methyl-2-phenyl-4-oxazolyl)methoxy]phenyl]sulfonyl]amino]- (CA INDEX NAME)



RN 827018-14-4 HCAPLUS
CN 1H-Pyrazole-4-carboxylic acid, 3-[[[4-[(5-methyl-2-phenyl-4-oxazolyl)methoxy]phenyl]sulfonyl]amino]-1-(phenylmethyl)-, ethyl ester (CA INDEX NAME)



RN 827018-15-5 HCAPLUS
CN 1H-Pyrazole-4-carboxylic acid, 3-[[[4-[(5-methyl-2-phenyl-4-oxazolyl)methoxy]phenyl]sulfonyl]amino]-1-(phenylmethyl)- (CA INDEX NAME)



RN 827018-16-6 HCAPLUS
CN 1H-Pyrazole-4-carboxylic acid, 1-methyl-3-[[[4-[(5-methyl-2-phenyl-4-oxazolyl)methoxy]phenyl]sulfonyl]amino]-, ethyl ester (CA INDEX NAME)



RN 827018-17-7 HCAPLUS
CN 1H-Pyrazole-4-carboxylic acid, 1-methyl-3-[[[4-[(5-methyl-2-phenyl-4-oxazolyl)methoxy]phenyl]sulfonyl]amino]- (CA INDEX NAME)



RN 827018-18-8 HCAPLUS
CN 1H-Pyrazole-4-carboxylic acid, 3-[[[4-[(5-methyl-2-phenyl-4-oxazolyl)methoxy]phenyl]sulfonyl]amino]-1-(2-propen-1-yl)-, ethyl ester (CA INDEX NAME)



RN 827018-19-9 HCAPLUS
CN 1H-Pyrazole-4-carboxylic acid, 3-[[[4-[(5-methyl-2-phenyl-4-oxazolyl)methoxy]phenyl]sulfonyl]amino]-1-(2-propen-1-yl)- (CA INDEX NAME)



RN 827018-20-2 HCAPLUS
CN 1H-Pyrazole-4-carboxylic acid, 3-[[[4-[[5-methyl-2-[4-

(trifluoromethyl)phenyl]-4-oxazolyl]methoxy]phenyl]sulfonyl]amino]-1-phenyl-, ethyl ester (CA INDEX NAME)



RN 827018-21-3 HCAPLUS
CN 1H-Pyrazole-4-carboxylic acid, 1-(1-methylethyl)-3-[[[4-[(5-methyl-2-phenyl-4-oxazolyl)methoxy]phenyl]sulfonyl]amino]-, ethyl ester (CA INDEX NAME)



RN 827018-22-4 HCAPLUS
CN 1H-Pyrazole-4-carboxamide, 1-ethyl-N-methyl-3-[[[4-[(5-methyl-2-phenyl-4-oxazolyl)methoxy]phenyl]sulfonyl]amino]- (CA INDEX NAME)



RN 827018-23-5 HCAPLUS
CN 1H-Pyrazole-4-carboxamide, 1-ethyl-N,N-dimethyl-3-[[[4-[(5-methyl-2-phenyl-4-oxazolyl)methoxy]phenyl]sulfonyl]amino]- (CA INDEX NAME)



RN 827018-24-6 HCAPLUS
CN 1H-Pyrazole-4-carboxamide, N-(cyclopropylmethyl)-1-ethyl-3-[[[4-[(5-methyl-2-phenyl-4-oxazolyl)methoxy]phenyl]sulfonyl]amino]- (CA INDEX NAME)



RN 827018-25-7 HCAPLUS
CN 1H-Pyrazole-4-carboxamide, 1-ethyl-3-[[[4-[(5-methyl-2-phenyl-4-oxazolyl)methoxy]phenyl]sulfonyl]amino]-N-(phenylmethyl)- (CA INDEX NAME)



RN 827018-26-8 HCAPLUS
CN Benzenesulfonamide, N-[1-ethyl-4-(1-piperidinylcarbonyl)-1H-pyrazol-3-yl]-4-[(5-methyl-2-phenyl-4-oxazolyl)methoxy]- (CA INDEX NAME)



RN 827018-27-9 HCAPLUS
CN 1H-Pyrazole-4-carboxylic acid, 1-ethyl-3-[methyl[[4-[(5-methyl-2-phenyl-4-oxazolyl)methoxy]phenyl]sulfonyl]amino]-, ethyl ester (CA INDEX NAME)



IT 827018-07-5P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of N-pyrazolylbenzenesulfonylamide derivs. as activators of PPARs)
RN 827018-07-5 HCAPLUS
CN 1H-Pyrazole-4-carboxylic acid, 1-ethyl-3-[[[4-[[5-methyl-2-[4-(trifluoromethyl)phenyl]-4-oxazolyl]methoxy]phenyl]sulfonyl]amino]-, ethyl ester (CA INDEX NAME)



REFERENCE COUNT: 9 THERE ARE 9 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> d ibib abs hitstr 2

L63 ANSWER 2 OF 3 USPATFULL on STN

ACCESSION NUMBER:	2007:49194 USPATFULL Full-text		
TITLE:	Benzenesulfonylamino compounds and pharmaceutical compositions containing these compounds		
INVENTOR(S):	Vedananda, Thalaththani Palalage, Shrewsbury, MA, UNITED STATES		

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 20070043020	A1	20070222	
APPLICATION INFO.:	US 2004-563708	A1	20040707	(10)
	WO 2004-EP7442		20040707	
			20060619	PCT 371 date

	NUMBER	DATE
PRIORITY INFORMATION:	US 2003-485870P	20030708 (60)

DOCUMENT TYPE:	Utility
FILE SEGMENT:	APPLICATION
LEGAL REPRESENTATIVE:	NOVARTIS, CORPORATE INTELLECTUAL PROPERTY, ONE HEALTH PLAZA 104/3, EAST HANOVER, NJ, 07936-1080, US

NUMBER OF CLAIMS: 31
EXEMPLARY CLAIM: 1
LINE COUNT: 1586
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Compounds of the formula ##STR1## provide pharmacological agents which bind to Peroxisome Proliferator-Activated Receptors (PPARs). Accordingly, the compounds of the instant invention are useful for the treatment of conditions mediated by the PPAR receptor activity in mammals. Such conditions include dyslipidemia, hyperlipidemia, hypercholesteremia, atherosclerosis, hypertriglyceridemia, heart failure, myocardial infarction, vascular diseases, cardiovascular diseases, hypertension, obesity, inflammation, arthritis, cancer, Alzheimer's disease, skin disorders, respiratory diseases, ophthalmic disorders, inflammatory bowel diseases (IBDs), ulcerative colitis and Crohn's disease, and conditions in which impaired glucose tolerance, hyperglycemia and insulin resistance are implicated, such as type-1 and type-2 diabetes, and Syndrome X.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
IT 827018-08-6P 827018-09-7P
(preparation of N-pyrazolylbenzenesulfonylamide derivs. as activators of PPAR receptors)
RN 827018-08-6 USPATFULL
CN 1H-Pyrazole-4-carboxylic acid, 1-ethyl-3-[[[4-[(5-methyl-2-phenyl-4-oxazolyl)methoxy]phenyl]sulfonyl]amino]-, ethyl ester (CA INDEX NAME)



RN 827018-09-7 USPATFULL
CN 1H-Pyrazole-4-carboxylic acid, 1-ethyl-3-[[[4-[(5-methyl-2-phenyl-4-oxazolyl)methoxy]phenyl]sulfonyl]amino]- (CA INDEX NAME)



IT 827018-10-0P 827018-11-1P 827018-12-2P
827018-13-3P 827018-14-4P 827018-15-5P
827018-16-6P 827018-17-7P 827018-18-8P
827018-19-9P 827018-20-2P 827018-21-3P
827018-22-4P 827018-23-5P 827018-24-6P
827018-25-7P 827018-26-8P 827018-27-9P
(preparation of N-pyrazolylbenzenesulfonylamide derivs. as activators of PPAR receptors)

RN 827018-10-0 USPATFULL
CN 1H-Pyrazole-4-carboxamide, 1-ethyl-3-[[[4-[(5-methyl-2-phenyl-4-oxazolyl)methoxy]phenyl]sulfonyl]amino]- (CA INDEX NAME)



RN 827018-11-1 USPATFULL
CN 1H-Pyrazole-4-carboxamide, N,1-diethyl-3-[[[4-[(5-methyl-2-phenyl-4-oxazolyl)methoxy]phenyl]sulfonyl]amino]- (CA INDEX NAME)



RN 827018-12-2 USPATFULL
CN Benzenesulfonamide, N-(4-benzoyl-1-ethyl-1H-pyrazol-3-yl)-4-[(5-methyl-2-phenyl-4-oxazolyl)methoxy]- (CA INDEX NAME)



RN 827018-13-3 USPATFULL
CN 1H-Pyrazole-4-carboxylic acid, 3-[[[4-[(5-methyl-2-phenyl-4-oxazolyl)methoxy]phenyl]sulfonyl]amino]- (CA INDEX NAME)



RN 827018-14-4 USPATFULL
CN 1H-Pyrazole-4-carboxylic acid, 3-[[[4-[(5-methyl-2-phenyl-4-oxazolyl)methoxy]phenyl]sulfonyl]amino]-1-(phenylmethyl)-, ethyl ester (CA INDEX NAME)



RN 827018-15-5 USPATFULL
CN 1H-Pyrazole-4-carboxylic acid, 3-[[[4-[(5-methyl-2-phenyl-4-oxazolyl)methoxy]phenyl]sulfonyl]amino]-1-(phenylmethyl)- (CA INDEX NAME)



RN 827018-16-6 USPATFULL
CN 1H-Pyrazole-4-carboxylic acid, 1-methyl-3-[[[4-[(5-methyl-2-phenyl-4-oxazolyl)methoxy]phenyl]sulfonyl]amino]-, ethyl ester (CA INDEX NAME)



RN 827018-17-7 USPATFULL
CN 1H-Pyrazole-4-carboxylic acid, 1-methyl-3-[[[4-[(5-methyl-2-phenyl-4-oxazolyl)methoxy]phenyl]sulfonyl]amino]- (CA INDEX NAME)



RN 827018-18-8 USPATFULL
CN 1H-Pyrazole-4-carboxylic acid, 3-[[[4-[(5-methyl-2-phenyl-4-oxazolyl)methoxy]phenyl]sulfonyl]amino]-1-(2-propen-1-yl)-, ethyl ester (CA INDEX NAME)



RN 827018-19-9 USPATFULL
CN 1H-Pyrazole-4-carboxylic acid, 3-[[[4-[(5-methyl-2-phenyl-4-oxazolyl)methoxy]phenyl]sulfonyl]amino]-1-(2-propen-1-yl)- (CA INDEX NAME)



RN 827018-20-2 USPATFULL
CN 1H-Pyrazole-4-carboxylic acid, 3-[[[4-[[5-methyl-2-[4-(trifluoromethyl)phenyl]-4-oxazolyl]methoxy]phenyl]sulfonyl]amino]-1-phenyl-, ethyl ester (CA INDEX NAME)



RN 827018-21-3 USPATFULL
CN 1H-Pyrazole-4-carboxylic acid, 1-(1-methylethyl)-3-[[[4-[(5-methyl-2-phenyl-4-oxazolyl)methoxy]phenyl]sulfonyl]amino]-, ethyl ester (CA INDEX NAME)



RN 827018-22-4 USPATFULL
CN 1H-Pyrazole-4-carboxamide, 1-ethyl-N-methyl-3-[[[4-[(5-methyl-2-phenyl-4-oxazolyl)methoxy]phenyl]sulfonyl]amino]- (CA INDEX NAME)



RN 827018-23-5 USPATFULL
CN 1H-Pyrazole-4-carboxamide, 1-ethyl-N,N-dimethyl-3-[[[4-[(5-methyl-2-phenyl-4-oxazolyl)methoxy]phenyl]sulfonyl]amino]- (CA INDEX NAME)



RN 827018-24-6 USPATFULL
CN 1H-Pyrazole-4-carboxamide, N-(cyclopropylmethyl)-1-ethyl-3-[[[4-[(5-methyl-2-phenyl-4-oxazolyl)methoxy]phenyl]sulfonyl]amino]- (CA INDEX NAME)



RN 827018-25-7 USPATFULL
CN 1H-Pyrazole-4-carboxamide, 1-ethyl-3-[[[4-[(5-methyl-2-phenyl-4-oxazolyl)methoxy]phenyl]sulfonyl]amino]-N-(phenylmethyl)- (CA INDEX NAME)



RN 827018-26-8 USPATFULL
CN Benzenesulfonamide, N-[1-ethyl-4-(1-piperidinylcarbonyl)-1H-pyrazol-3-yl]-4-[(5-methyl-2-phenyl-4-oxazolyl)methoxy]- (CA INDEX NAME)



RN 827018-27-9 USPATFULL
CN 1H-Pyrazole-4-carboxylic acid, 1-ethyl-3-[methyl[[4-[(5-methyl-2-phenyl-4-oxazolyl)methoxy]phenyl]sulfonyl]amino]-, ethyl ester (CA INDEX NAME)



IT 827018-07-5P
(preparation of N-pyrazolylbenzenesulfonylamide derivs. as activators of PPARs)
RN 827018-07-5 USPATFULL
CN 1H-Pyrazole-4-carboxylic acid, 1-ethyl-3-[[[4-[[5-methyl-2-[4-(trifluoromethyl)phenyl]-4-oxazolyl]methoxy]phenyl]sulfonyl]amino]-, ethyl ester (CA INDEX NAME)



=> d ibib ed ab 3

L63 ANSWER 3 OF 3 PASCAL COPYRIGHT 2008 INIST-CNRS. ALL RIGHTS RESERVED. on STN

ACCESSION NUMBER: 2004-0340839 PASCAL Full-text

COPYRIGHT NOTICE: Copyright .COPYRGT. 2004 INIST-CNRS. All rights reserved.

TITLE (IN ENGLISH): A novel Pd-catalyzed cyclization reaction of ureas for the synthesis of dihydroquinazolinone p38 kinase inhibitors

AUTHOR: SCHLAPBACH Achim; HENG Richard; DI PADOVA Franco

CORPORATE SOURCE: Novartis Institute for Biomedical Research, Arthritis and Bone Metabolism, Lichtstrasse, 4002 Basel, Switzerland

SOURCE: Bioorganic & medicinal chemistry letters : (Print), (2004), 14(2), 357-360
ISSN: 0960-894X

DOCUMENT TYPE: Journal

BIBLIOGRAPHIC LEVEL: Analytic

COUNTRY: United Kingdom

LANGUAGE: English

NOTE: 3/4 p. ref. et notes

AVAILABILITY: INIST-22446, 354000116251010120

UP 20040723

AB A series of potent p38 inhibitors based on the dihydroquinazoline scaffold was synthesized using a novel Pd-catalyzed cyclization reaction of aryl-benzyl ureas. Optimization of this compound class led to compound 20, which inhibits p38α in vitro with IC.sub.5.sub.0 = 14 nM and is active in the mouse TNFα-release model.

=> file stnguide
FILE 'STNGUIDE' ENTERED AT 13:35:13 ON 02 OCT 2008
USE IS SUBJECT TO THE TERMS OF YOUR CUSTOMER AGREEMENT
COPYRIGHT (C) 2008 AMERICAN CHEMICAL SOCIETY (ACS)

FILE CONTAINS CURRENT INFORMATION.
LAST RELOADED: Sep 26, 2008 (20080926/UP).

```
=> d his ful

     (FILE 'HOME' ENTERED AT 12:15:54 ON 02 OCT 2008)

     FILE 'STNGUIDE' ENTERED AT 12:15:56 ON 02 OCT 2008

     FILE 'STNGUIDE' ENTERED AT 12:16:18 ON 02 OCT 2008

     FILE 'ZCAPLUS' ENTERED AT 12:16:27 ON 02 OCT 2008
                E US2006-563708/APPS

     FILE 'HCAPLUS' ENTERED AT 12:16:54 ON 02 OCT 2008
L1             2 SEA ABB=ON  PLU=ON  US2006-563708/APPS
                 D SCAN
                 D BIB 2
                 D BIB 1
L2             1 SEA ABB=ON  PLU=ON  L1 NOT PIXEL/TI

     FILE 'WPIX' ENTERED AT 12:17:54 ON 02 OCT 2008
L3             2 SEA ABB=ON  PLU=ON  US2006-563708/APPS
L4             1 SEA ABB=ON  PLU=ON  L3 NOT PIXEL/TI

     FILE 'STNGUIDE' ENTERED AT 12:18:13 ON 02 OCT 2008
                D QUE L2

     FILE 'HCAPLUS' ENTERED AT 12:18:41 ON 02 OCT 2008
                D IBIB ED ABS IND L2

     FILE 'STNGUIDE' ENTERED AT 12:18:42 ON 02 OCT 2008
                D QUE L4

     FILE 'WPIX' ENTERED AT 12:18:58 ON 02 OCT 2008
                D IALL CODE L4

     FILE 'STNGUIDE' ENTERED AT 12:18:59 ON 02 OCT 2008

     FILE 'REGISTRY' ENTERED AT 12:19:07 ON 02 OCT 2008

     FILE 'HCAPLUS' ENTERED AT 12:19:10 ON 02 OCT 2008
L5             TRA PLU=ON  L2 1- RN :      37 TERMS

     FILE 'REGISTRY' ENTERED AT 12:19:14 ON 02 OCT 2008
L6            37 SEA ABB=ON  PLU=ON  L5

     FILE 'LREGISTRY' ENTERED AT 12:19:53 ON 02 OCT 2008
L7             STR

     FILE 'REGISTRY' ENTERED AT 12:22:51 ON 02 OCT 2008
L8             0 SEA SSS SAM L7

     FILE 'STNGUIDE' ENTERED AT 12:23:01 ON 02 OCT 2008

     FILE 'REGISTRY' ENTERED AT 12:24:35 ON 02 OCT 2008
L9             SCREEN 1786
L10            0 SEA SSS SAM (L9 AND L7)
L11              SCREEN 1788
L12            0 SEA SSS SAM (L11 AND L7)
L13              STR L7
```

```
     FILE 'REGISTRY' ENTERED AT 12:26:54 ON 02 OCT 2008
L14             0 SEA SSS SAM L13
L15             0 SEA SSS SAM (L9 AND L11 AND L13)

     FILE 'STNGUIDE' ENTERED AT 12:27:31 ON 02 OCT 2008

     FILE 'LREGISTRY' ENTERED AT 12:32:51 ON 02 OCT 2008
L16               STR L7

     FILE 'REGISTRY' ENTERED AT 12:34:12 ON 02 OCT 2008
L17             0 SEA SSS SAM (L11 AND L16)

     FILE 'LREGISTRY' ENTERED AT 12:35:12 ON 02 OCT 2008
L*** DEL          STR L13

     FILE 'STNGUIDE' ENTERED AT 12:36:52 ON 02 OCT 2008

     FILE 'REGISTRY' ENTERED AT 12:39:45 ON 02 OCT 2008
L*** DEL7390643 S N2C3/ES OR NCNC2/ES OR N2CNC/CS OR NCOC2/ES OR NCSC2/ES OR NC

     FILE 'STNGUIDE' ENTERED AT 12:41:36 ON 02 OCT 2008

     FILE 'REGISTRY' ENTERED AT 12:42:10 ON 02 OCT 2008
L18        1320380 SEA ABB=ON  PLU=ON  N2C3/ES OR NCOC2/ES
L19              2 SEA SUB=L18 SSS SAM L13
                   D QUE STAT

     FILE 'STNGUIDE' ENTERED AT 12:42:57 ON 02 OCT 2008

     FILE 'REGISTRY' ENTERED AT 12:46:51 ON 02 OCT 2008
                   D QUE STAT
                   D SCAN
                   D QUE STAT
L20             41 SEA SUB=L18 SSS FUL L13
                   SAVE TEMP L20 GAR708PSET1/A
L21             21 SEA ABB=ON  PLU=ON  L6 AND L20
                   D SCAN
L22              1 SEA ABB=ON  PLU=ON  L21 AND "C26 H25 F3 N4 O6 S"/MF
                   SAVE TEMP L22 GAR708ES/A
                   D SCAN
L23             16 SEA ABB=ON  PLU=ON  L6 NOT L20
                   D SCAN

     FILE 'STNGUIDE' ENTERED AT 12:50:43 ON 02 OCT 2008
                   D QUE STAT L20
                   D QUE STAT L22

     FILE 'REGISTRY' ENTERED AT 12:51:45 ON 02 OCT 2008
                   D IDE L22

     FILE 'STNGUIDE' ENTERED AT 12:51:45 ON 02 OCT 2008

     FILE 'STNGUIDE' ENTERED AT 12:51:59 ON 02 OCT 2008

     FILE 'ZCAPLUS' ENTERED AT 12:52:55 ON 02 OCT 2008
L24               QUE ABB=ON  PLU=ON  VEDANANDA, T?/AU
L25               QUE ABB=ON  PLU=ON  NOVARTIS/CS,SO,PA

     FILE 'HCAPLUS' ENTERED AT 12:54:07 ON 02 OCT 2008
L26             2 SEA ABB=ON  PLU=ON  L20
```

```
L27           1 SEA ABB=ON  PLU=ON  L22
L28           2 SEA ABB=ON  PLU=ON  (L26 OR L27)
L29           1 SEA ABB=ON  PLU=ON  L28 AND (L24 OR L25)
L30           1 SEA ABB=ON  PLU=ON  L28 NOT L29
                D BIB

     FILE 'STNGUIDE' ENTERED AT 12:56:01 ON 02 OCT 2008

     FILE 'WPIX' ENTERED AT 12:56:10 ON 02 OCT 2008
                D QUE L20
L31           3 SEA SSS SAM L13
L32          47 SEA SSS FUL L13
                SAVE TEMP L32 GAR708WPIS/A
                SELECT L32 1- SDCN
L33           6 SEA ABB=ON  PLU=ON  (RAC2TR/DCN OR RAC2TS/DCN OR RAC2TZ/DCN OR
                RAGQML/DCN OR RAGQMM/DCN OR RAGQMN/DCN OR RAGQMO/DCN OR
                RAGQMP/DCN OR RAGQMQ/DCN OR RAGQMS/DCN OR RAGQMT/DCN OR
                RAGQMU/DCN OR RAGQMV/DCN OR RAGQMW/DCN OR RAGQMX/DCN OR
                RAGQMY/DCN OR RAGQMZ/DCN OR RAGQN0/DCN OR RAGQN1/DCN OR
                RAGQN2/DCN OR RAGQN3/DCN OR RAGQN4/DCN OR RAGQN5/DCN OR
                RAHXNT/DCN OR RAQKGB/DCN OR RAQKGC/DCN OR RAQKGD/DCN OR
                RAQKGG/DCN OR RAQKGH/DCN OR RAQKGI/DCN OR RAQKGJ/DCN OR
                RAQKGK/DCN OR RAQKGL/DCN OR RAQKGM/DCN OR RAQKGN/DCN OR
                RAQKGO/DCN OR RAQKGP/DCN OR RAQKGQ/DCN OR RAQKGR/DCN OR
                RAQKGS/DCN OR RAQKGT/DCN OR RARI2C/DCN OR RARI2G/DCN OR
                RARI2H/DCN OR RARI27/DCN OR RA9ISR/DCN OR RA9ITM/DCN) OR
                L32/DCR
L34           1 SEA ABB=ON  PLU=ON  L33 AND (L24 OR L25)
L35           5 SEA ABB=ON  PLU=ON  L33 NOT L34
                D BIB HITSTR 1-5

     FILE 'STNGUIDE' ENTERED AT 13:00:50 ON 02 OCT 2008

     FILE 'REGISTRY' ENTERED AT 13:02:25 ON 02 OCT 2008
L36     3910521 SEA ABB=ON  PLU=ON  NCNC2/ES OR N2CNC/ES OR NCSC2/ES OR SC4/ES

L37           0 SEA SUB=L36 SSS SAM L13
                D QUE STAT
L38          31 SEA SUB=L36 SSS FUL L13
                SAVE TEMP L38 GAR708PSET2/A

     FILE 'LREGISTRY' ENTERED AT 13:05:12 ON 02 OCT 2008
L39             STR L16

     FILE 'REGISTRY' ENTERED AT 13:05:49 ON 02 OCT 2008
L40           2 SEA SUB=L38 SSS SAM L39
                D SCAN
L41          23 SEA SUB=L38 SSS FUL L39
                SAVE TEMP L41 GAR708RSET2/A

     FILE 'STNGUIDE' ENTERED AT 13:07:55 ON 02 OCT 2008

     FILE 'HCAPLUS' ENTERED AT 13:08:07 ON 02 OCT 2008
L42           3 SEA ABB=ON  PLU=ON  L41
L43           0 SEA ABB=ON  PLU=ON  L42 AND (L24 OR L25)
L44           1 SEA ABB=ON  PLU=ON  L29 OR L43
L45           3 SEA ABB=ON  PLU=ON  L42 NOT L44
L46           3 SEA ABB=ON  PLU=ON  L45 OR L30
                D BIB 1-3
```

```
     FILE 'STNGUIDE' ENTERED AT 13:09:11 ON 02 OCT 2008

     FILE 'USPATFULL, USPATOLD, USPAT2' ENTERED AT 13:10:42 ON 02 OCT 2008
L47            2 SEA ABB=ON  PLU=ON  L20 OR L22 OR L41
L48            1 SEA ABB=ON  PLU=ON  L47 AND (L24 OR L25)
L49            1 SEA ABB=ON  PLU=ON  L47 NOT L48

     FILE 'STNGUIDE' ENTERED AT 13:11:26 ON 02 OCT 2008

     FILE 'TOXCENTER' ENTERED AT 13:11:38 ON 02 OCT 2008
L50            1 SEA ABB=ON  PLU=ON  L20 OR L22 OR L41
L51            1 SEA ABB=ON  PLU=ON  L50 AND (L24 OR L25)
L52            0 SEA ABB=ON  PLU=ON  L50 NOT L51

     FILE 'STNGUIDE' ENTERED AT 13:12:25 ON 02 OCT 2008

     FILE 'MEDLINE, BIOSIS, EMBASE, BIOTECHNO, CABA, DRUGU, VETU' ENTERED AT
     13:12:48 ON 02 OCT 2008
L53            0 SEA ABB=ON  PLU=ON  L20 OR L22 OR L41

     FILE 'STNGUIDE' ENTERED AT 13:13:13 ON 02 OCT 2008
                D QUE L41

     FILE 'BEILSTEIN' ENTERED AT 13:13:30 ON 02 OCT 2008
L54            1 SEA SSS SAM L39
                 D QUE STAT
L55            5 SEA SSS FUL L39
                 SAVE TEMP L55 GAR708BEIP/A
L56            1 SEA SUB=L55 SSS SAM L13
L57            5 SEA SUB=L55 SSS FUL L13
                 SAVE TEMP L57 GAR708BEIR/A

     FILE 'STNGUIDE' ENTERED AT 13:15:39 ON 02 OCT 2008
                D QUE L55

     FILE 'CHEMINFORMRX' ENTERED AT 13:16:02 ON 02 OCT 2008
L58            0 SEA SSS SAM L39 (     0 REACTIONS)
L59            0 SEA SSS FUL L39 (     0 REACTIONS)

     FILE 'STNGUIDE' ENTERED AT 13:16:35 ON 02 OCT 2008

     FILE 'MEDLINE, BIOSIS, EMBASE, PASCAL, CABA, CEABA-VTB, LIFESCI, BIOENG,
     BIOTECHNO, BIOTECHDS, DRUGU, DRUGB, VETU, VETB, SCISEARCH, CONFSCI,
     DISSABS, RDISCLOSURE' ENTERED AT 13:17:35 ON 02 OCT 2008
L60          794 SEA ABB=ON  PLU=ON  ?BENZENESULFONYLAMIN? OR ?BENZENESULPHONYLA
                 MIN? OR (?BENZENE?(1T)(?SULFONYL? OR ?SULPHONYL?)(1T)(?AMINO
                 OR ?AMINE))
L61            1 SEA ABB=ON  PLU=ON  L60 AND (L24 OR L25)

     FILE 'STNGUIDE' ENTERED AT 13:22:22 ON 02 OCT 2008
                D QUE STAT L20
                D QUE STAT L22
                D QUE STAT L38
                D QUE STAT L41
                D QUE STAT L32
                D QUE L35
                D QUE NOS L49
                D QUE NOS L52
                D QUE L53
                D QUE STAT L55
```

```
                D QUE STAT L57
                D QUE STAT L59
                D QUE L46

      FILE 'HCAPLUS, WPIX, USPATFULL, BEILSTEIN' ENTERED AT 13:27:49 ON 02 OCT
      2008
L62             13 DUP REM L46 L35 L49 L52 L57 L59 (1 DUPLICATE REMOVED)
                       ANSWERS '1-3' FROM FILE HCAPLUS
                       ANSWERS '4-7' FROM FILE WPIX
                       ANSWER '8' FROM FILE USPATFULL
                       ANSWERS '9-13' FROM FILE BEILSTEIN
                SAVE TEMP L62 GAR708MAIN/A

      FILE 'STNGUIDE' ENTERED AT 13:28:02 ON 02 OCT 2008

      FILE 'WPIX, HCAPLUS, USPATFULL, BEILSTEIN' ENTERED AT 13:29:35 ON 02 OCT
      2008
                D IBIB ED ABS HITSTR 1-3

      FILE 'STNGUIDE' ENTERED AT 13:29:37 ON 02 OCT 2008

      FILE 'WPIX, HCAPLUS, USPATFULL, BEILSTEIN' ENTERED AT 13:30:37 ON 02 OCT
      2008
                D IALL ABEQ TECH ABEX HITSTR 4-7

      FILE 'STNGUIDE' ENTERED AT 13:30:44 ON 02 OCT 2008

      FILE 'WPIX, HCAPLUS, USPATFULL, BEILSTEIN' ENTERED AT 13:31:01 ON 02 OCT
      2008
                D IBIB AB HITSTR 8

      FILE 'STNGUIDE' ENTERED AT 13:31:02 ON 02 OCT 2008

      FILE 'WPIX, HCAPLUS, USPATFULL, BEILSTEIN' ENTERED AT 13:31:12 ON 02 OCT
      2008
                D IDE 9

      FILE 'STNGUIDE' ENTERED AT 13:31:13 ON 02 OCT 2008

      FILE 'WPIX, HCAPLUS, USPATFULL, BEILSTEIN' ENTERED AT 13:31:28 ON 02 OCT
      2008
                D RX 9

      FILE 'STNGUIDE' ENTERED AT 13:31:28 ON 02 OCT 2008

      FILE 'WPIX, HCAPLUS, USPATFULL, BEILSTEIN' ENTERED AT 13:31:35 ON 02 OCT
      2008
                D IDE 10

      FILE 'STNGUIDE' ENTERED AT 13:31:35 ON 02 OCT 2008

      FILE 'WPIX, HCAPLUS, USPATFULL, BEILSTEIN' ENTERED AT 13:31:42 ON 02 OCT
      2008
                D RX 10

      FILE 'STNGUIDE' ENTERED AT 13:31:43 ON 02 OCT 2008

      FILE 'WPIX, HCAPLUS, USPATFULL, BEILSTEIN' ENTERED AT 13:31:50 ON 02 OCT
      2008
                D IDE 11
```

```
     FILE 'STNGUIDE' ENTERED AT 13:31:51 ON 02 OCT 2008

     FILE 'WPIX, HCAPLUS, USPATFULL, BEILSTEIN' ENTERED AT 13:31:56 ON 02 OCT
     2008
               D RX 11

     FILE 'STNGUIDE' ENTERED AT 13:31:57 ON 02 OCT 2008

     FILE 'WPIX, HCAPLUS, USPATFULL, BEILSTEIN' ENTERED AT 13:32:03 ON 02 OCT
     2008
               D IDE 12

     FILE 'STNGUIDE' ENTERED AT 13:32:04 ON 02 OCT 2008

     FILE 'WPIX, HCAPLUS, USPATFULL, BEILSTEIN' ENTERED AT 13:32:09 ON 02 OCT
     2008
               D RX 12

     FILE 'STNGUIDE' ENTERED AT 13:32:09 ON 02 OCT 2008

     FILE 'WPIX, HCAPLUS, USPATFULL, BEILSTEIN' ENTERED AT 13:32:16 ON 02 OCT
     2008
               D IDE 13

     FILE 'STNGUIDE' ENTERED AT 13:32:17 ON 02 OCT 2008

     FILE 'WPIX, HCAPLUS, USPATFULL, BEILSTEIN' ENTERED AT 13:32:23 ON 02 OCT
     2008
               D RX 13

     FILE 'STNGUIDE' ENTERED AT 13:32:23 ON 02 OCT 2008
               D QUE NOS L44
               D QUE NOS L34
               D QUE NOS L48
               D QUE NOS L51
               D QUE L53
               D QUE L61

     FILE 'HCAPLUS, WPIX, USPATFULL, TOXCENTER, PASCAL' ENTERED AT 13:33:35 ON
     02 OCT 2008
L63            3 DUP REM L44 L34 L48 L51 L61 (2 DUPLICATES REMOVED)
                     ANSWER '1' FROM FILE HCAPLUS
                     ANSWER '2' FROM FILE USPATFULL
                     ANSWER '3' FROM FILE PASCAL
               SAVE TEMP L63 GAR708INV/A
               D IBIB ED ABS HITSTR
               D IBIB ABS HITSTR 2
               D IBIB ED AB 3

     FILE 'STNGUIDE' ENTERED AT 13:35:13 ON 02 OCT 2008


     FILE HOME

     FILE STNGUIDE
     FILE CONTAINS CURRENT INFORMATION.
     LAST RELOADED: Sep 26, 2008 (20080926/UP).

     FILE ZCAPLUS
```

FILE COVERS 1907 - 2 Oct 2008 VOL 149 ISS 14
FILE LAST UPDATED: 1 Oct 2008 (20081001/ED)

ZCAplus now includes complete International Patent Classification (IPC)
reclassification data for the second quarter of 2008.

New CAS Information Use Policies, enter HELP USAGETERMS for details.

This file contains CAS Registry Numbers for easy and accurate
substance identification.

FILE HCAPLUS

FILE COVERS 1907 - 2 Oct 2008 VOL 149 ISS 14
FILE LAST UPDATED: 1 Oct 2008 (20081001/ED)

HCAplus now includes complete International Patent Classification (IPC)
reclassification data for the second quarter of 2008.

New CAS Information Use Policies, enter HELP USAGETERMS for details.

This file contains CAS Registry Numbers for easy and accurate
substance identification.

FILE WPIX
FILE LAST UPDATED: 30 SEP 2008 <20080930/UP>
MOST RECENT UPDATE: 200862 <200862/DW>
DERWENT WORLD PATENTS INDEX SUBSCRIBER FILE, COVERS 1963 TO DATE
>>> Now containing more than 1.1 million chemical structures in DCR <<<

>>> IPC Reform backfile reclassifications have been loaded to the end of
June 2008. No update date (UP) has been created for the
reclassified documents, but they can be identified by
20060101/UPIC and 20061231/UPIC, 20070601/UPIC, 20071001/UPIC,
20071130/UPIC, 20080401/UPIC and 20080701/UPIC.
ECLA reclassifications to June and US national classifications to
the end of April 2008 have also been loaded. Update dates
20080401 and 20080701/UPEC and /UPNC have been assigned to these. <<<

FOR A COPY OF THE DERWENT WORLD PATENTS INDEX STN USER GUIDE,
PLEASE VISIT:
http://www.stn-international.de/training_center/patents/stn_guide.pdf

FOR DETAILS OF THE PATENTS COVERED IN CURRENT UPDATES, SEE
http://scientific.thomsonreuters.com/support/patents/coverage/latestupdate

EXPLORE DERWENT WORLD PATENTS INDEX IN STN ANAVIST, VERSION 2.0:
http://www.stn-international.com/archive/presentations/DWPIAnaVist2_0608.p

>>> HELP for European Patent Classifications see HELP ECLA, HELP ICO <<<

FILE REGISTRY
Property values tagged with IC are from the ZIC/VINITI data file
provided by InfoChem.

STRUCTURE FILE UPDATES: 1 OCT 2008 HIGHEST RN 1056151-32-6
DICTIONARY FILE UPDATES: 1 OCT 2008 HIGHEST RN 1056151-32-6

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH July 5, 2008.

Please note that search-term pricing does apply when
conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and
predicted properties as well as tags indicating availability of
experimental property data in the original document. For information
on property searching in REGISTRY, refer to:

http://www.cas.org/support/stngen/stndoc/properties.html

FILE LREGISTRY
LREGISTRY IS A STATIC LEARNING FILE

NEW CAS INFORMATION USE POLICIES, ENTER HELP USAGETERMS FOR DETAILS.

FILE USPATFULL
FILE COVERS 1971 TO PATENT PUBLICATION DATE: 2 Oct 2008 (20081002/PD)
FILE LAST UPDATED: 2 Oct 2008 (20081002/ED)
HIGHEST GRANTED PATENT NUMBER: US7430762
HIGHEST APPLICATION PUBLICATION NUMBER: US20080244796
CA INDEXING IS CURRENT THROUGH 2 Oct 2008 (20081002/UPCA)
ISSUE CLASS FIELDS (/INCL) CURRENT THROUGH: 2 Oct 2008 (20081002/PD)
REVISED CLASS FIELDS (/NCL) LAST RELOADED: Aug 2008
USPTO MANUAL OF CLASSIFICATIONS THESAURUS ISSUE DATE: Aug 2008

USPATFULL now includes complete International Patent Classification (IPC)
reclassification data for the second quarter of 2008.

FILE USPATOLD

FILE COVERS U.S. PATENTS 1790-1975
Produced using data provided by Univentio.

This database was created using Optical Character Recognition (OCR)
technology. For this reason, some characters may be missing or

mistranslated. In order to improve searchability and retrieval, CA indexing information has been added to the Title, Inventor, and Patent Assignee fields where possible. Please see HELP CASDATA for more information on the availability of CAS indexing in this database.

USPATOLD now includes complete International Patent Classification (IPC) reclassification data for the second quarter of 2008.

FILE USPAT2

FILE COVERS 2001 TO PUBLICATION DATE: 2 Oct 2008 (20081002/PD)
FILE LAST UPDATED: 2 Oct 2008 (20081002/ED)
HIGHEST GRANTED PATENT NUMBER: US20070164820
HIGHEST APPLICATION PUBLICATION NUMBER: US20080243521
CA INDEXING IS CURRENT THROUGH 2 Oct 2008 (20081002/UPCA)
ISSUE CLASS FIELDS (/INCL) CURRENT THROUGH: 2 Oct 2008 (20081002/PD)
REVISED CLASS FIELDS (/NCL) LAST RELOADED: Jun 2008
USPTO MANUAL OF CLASSIFICATIONS THESAURUS ISSUE DATE: Jun 2008

USPAT2 now includes complete International Patent Classification (IPC) reclassification data for the second quarter of 2008.

FILE TOXCENTER

FILE COVERS 1907 TO 30 Sep 2008 (20080930/ED)

The MEDLINE file segment has been updated with the National Library of Medicine's revised 2008 MeSH terms. See HELP RLOAD for details.

This file contains CAS Registry Numbers for easy and accurate substance identification.

The BIOSIS segment of TOXCENTER has been augmented with 13,000 records from 1946 through 1968.

FILE MEDLINE
FILE LAST UPDATED: 1 Oct 2008 (20081001/UP). FILE COVERS 1949 TO DATE.

MEDLINE has been updated with the National Library of Medicine's revised 2008 MeSH terms. See HELP RLOAD for details.

This file contains CAS Registry Numbers for easy and accurate substance identification.

See HELP RANGE before carrying out any RANGE search.

MEDLINE Accession Numbers (ANs) for records from 1950-1977 have been converted from 8 to 10 digits. Searches using an 8 or 10 digit AN will retrieve the same record. The 10-digit ANs can be expanded, searched, and displayed in all records from 1949 to the present.

FILE BIOSIS
FILE COVERS 1926 TO DATE.
CAS REGISTRY NUMBERS AND CHEMICAL NAMES (CNs) PRESENT
FROM JANUARY 1926 TO DATE.

RECORDS LAST ADDED: 1 October 2008 (20081001/ED)

BIOSIS has been augmented with 1.8 million archival records from 1926 through 1968. These records have been re-indexed to match current

BIOSIS indexing.

FILE EMBASE
FILE COVERS 1974 TO 1 Oct 2008 (20081001/ED)

EMBASE was reloaded on March 30, 2008.

EMBASE is now updated daily. SDI frequency remains weekly (default) and biweekly.

This file contains CAS Registry Numbers for easy and accurate substance identification.

Beginning January 2008, Elsevier will no longer provide EMTREE codes as part of the EMTREE thesaurus in EMBASE. Please update your current-awareness alerts (SDIs) if they contain EMTREE codes.

For further assistance, please contact your local helpdesk.

FILE BIOTECHNO
FILE LAST UPDATED: 7 JAN 2004 <20040107/UP>
FILE COVERS 1980 TO 2003.
THIS FILE IS A STATIC FILE WITH NO UPDATES

>>> SIMULTANEOUS LEFT AND RIGHT TRUNCATION AVAILABLE IN /CT AND BASIC INDEX <<<

FILE CABA
FILE COVERS 1973 TO 2 Oct 2008 (20081002/ED)

This file contains CAS Registry Numbers for easy and accurate substance identification.

The CABA file was reloaded 7 December 2003. Enter HELP RLOAD for details.

FILE DRUGU
FILE LAST UPDATED: 2 OCT 2008 <20081002/UP>
>>> DERWENT DRUG FILE (SUBSCRIBER) <<<

>>> FILE COVERS 1983 TO DATE <<<
>>> THESAURUS AVAILABLE IN /CT <<<

FILE VETU
FILE LAST UPDATED: 2 JAN 2002 <20020102/UP>
FILE COVERS 1983-2001

FILE BEILSTEIN
FILE LAST UPDATED ON April 1, 2008

FILE COVERS 1771 TO 2008.
FILE CONTAINS 10,322,808 SUBSTANCES

>>>PLEASE NOTE: Reaction Data and substance data are stored in separate documents and can not be searched together in one query. Reaction data for BEILSTEIN compounds may be displayed immediately with the display codes PRE (preparations) and REA (reactions). A substance answer set retrieved after the search

```
   for a chemical name, a compounds with available reaction
   information by combining with PRE/FA, REA/FA or more generally
   with RX/FA. The BEILSTEIN Registry Number (BRN) is the link
   between a BEILSTEIN compound and belonging reactions. For mo
   detailed reaction searches BRNs can be searched as reaction
   partner BRNs Reactant BRN (RX.RBRN) or Product BRN (RX.PBRN).<<<

>>> FOR SEARCHING PREPARATIONS SEE HELP PRE  <<<

**********************************************************************
* PLEASE NOTE THAT THERE ARE NO FORMATS FREE OF COST.                *
* SET NOTICE FEATURE: THE COST ESTIMATES CALCULATED FOR SET NOTICE   *
* ARE BASED ON THE HIGHEST PRICE CATEGORY. THEREFORE; THESE          *
* ESTIMATES MAY NOT REFLECT THE ACTUAL COSTS.                        *
* FOR PRICE INFORMATION SEE HELP COST                                *
**********************************************************************

>>> Price change as of January 1st, 2008: Connect Time and Structure
    Search fees re-introduced. See NEWS and HELP COST <<<

FILE CHEMINFORMRX
FILE LAST UPDATED: 9 JUN 2008       <20080609/UP>

>>> CAS Registry Numbers are available for
    substances prior to 1995   <<<

FILE PASCAL
FILE LAST UPDATED: 29 SEP 2008       <20080929/UP>
FILE COVERS 1977 TO DATE.

>>> SIMULTANEOUS LEFT AND RIGHT TRUNCATION IS AVAILABLE
    IN THE BASIC INDEX (/BI) FIELD  <<<

FILE CEABA-VTB
FILE LAST UPDATED: 23 SEP 2008       <20080923/UP>
FILE COVERS 1966 TO DATE

>>> DECHEMA, the producer of CEABA-VTB is using a new classification
    scheme.
    The new classification schemes are available as a PDF file
    and may be downloaded free-of-charge from:
    http://www.stn-international.de/news/cc-de.pdf
    and
    http://www.stn-international.de/news/cc-en.pdf <<<

FILE LIFESCI
FILE COVERS 1978 TO 10 Sep 2008 (20080910/ED)

FILE BIOENG
FILE LAST UPDATED: 13 AUG 2008       <20080813/UP>
FILE COVERS 1982 TO DATE

>>> SIMULTANEOUS LEFT AND RIGHT TRUNCATION AVAILABLE IN
    THE BASIC INDEX <<<

FILE BIOTECHDS
FILE LAST UPDATED: 30 SEP 2008       <20080930/UP>
FILE COVERS 1982 TO DATE

>>> USE OF THIS FILE IS LIMITED TO BIOTECH SUBSCRIBERS <<<
```

```
      FILE DRUGB
       >>>  FILE COVERS 1964 TO 1982 - CLOSED FILE  <<<


      FILE VETB
      FILE LAST UPDATED: 25 SEP 94      <940925/UP>
      FILE COVERS 1968-1982


      FILE SCISEARCH

      FILE COVERS 1974 TO 26 Sep 2008 (20080926/ED)

      SCISEARCH has been reloaded, see HELP RLOAD for details.

      FILE CONFSCI
      FILE COVERS 1973 TO 12 Sep 2008 (20080912/ED)

      CSA has resumed updates, see NEWS FILE

      FILE DISSABS
      FILE COVERS 1861 TO 25 SEP 2008 (20080925/ED)

      Only fair use as provided by the United States copyright law is
      permitted.  PROQUEST INFORMATION AND LEARNING COMPANY MAKES NO
      WARRANTY REGARDING THE ACCURACY, COMPLETENESS OR TIMELINESS OF
      THE LICENSED MATERIALS OR ANY WARRANTY, EXPRESS OR IMPLIED,
      INCLUDING ANY WARRANTY OF MERCHANTABILITY OR FITNESS FOR A
      PARTICULAR PURPOSE, AND SHALL NOT BE LIABLE FOR DAMAGES OF ANY
      KIND OR LOST PROFITS OR OTHER CLAIMS RELATED TO THE LICENSED
      MATERIALS OR THEIR USE.

      FILE RDISCLOSURE
      FILE LAST UPDATED: 11 SEP 2008       <20080911/UP>
      FILE COVERS 1960 TO DATE

      >>> SIMULTANEOUS LEFT AND RIGHT TRUNCATION IS AVAILABLE IN THE
          BASIC INDEX (/BI) AND TITLE (/TI) FIELDS <<<

      >>> IMAGES ARE AVAILABLE ONLINE AND FOR EMAIL-PRINTS <<<

=>
```